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ABSTRACT 
Muamvatin (30) is a polypropionate natural product isolated from Siphonaria 
normalis by Ireland et al. in 1986. Muamvatin (30) is made from eight propionate units 
and contains an extraordinary trioxaadamantane ring system. This ring system exists in 
only one other naturally occurring polypropionate known as caloundrin B. Regarding the 
rare muamvatin trioxaadamantane ring system, it was hypothesized this ring system may 
not be formed via an enzymatic process and the actual natural product could be the linear 
precursor ent-71 which cyclizes to muamvatin (30) during isolation. The first total 
synthesis of muamvatin (30) by Paterson et al. confirmed its absolute and relative 
configuration, but the ambiguity regarding the origin of the trioxaadamantane ring system 
in this molecule remains unresolved.  
This work describes two approaches to make the linear precursor ent-71 from triol 
ketone 153. The carbon skeleton of muamvatin was synthesized through two iterative 
diastereoselective aldol reactions. In the first approach, “the thiopyran route”, the diene 
moiety of aldehyde 73 required protection to avoid reduction during desulfurization. 
Although use of the tircarbonyliron complex was successful, the trihydroxy ketone 
revealed upon desulfurization was unstable and spontaneously cyclized to bicyclic acetal 
156. Molecular mechanics revealed that the relative configurations embedded in C3, C7, 
and C8 dramatically effected the stability of the corresponding bicyclic acetal. With that 
lesson learned, the fully assembled linear precursor 197 was made in our second 
approach “the acyclic route”. The oxidation state of the backbone oxygens were 
manipulated via an unusual chemoselective double Swern oxidation. Finally, revealing 
the sensitive 5-hydroxy-3,7,9-trione functionality formed the precursor 202. Efficient 
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cyclization of precursor 202 and removal of the protecting group at C11-OH produced 
the desired natural product 30. The cyclization conditions tested on the linear precursor 
202, suggested that although the cyclization to the trioxaadamantane is strongly favored 
thermodynamically, the process is very slow and unlikely to occur during the isolation 
process. Thus, formation of the trioxaadamantane ring system could be an enzyme-
mediated process as was concluded for caloundrin B. 
 vi
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1. INTRODUCTION 
1.1 The thiopyran route to polypropionates 
The thiopyran route to polypropionates has been one of the research themes in the 
Ward group for several years.1 This strategy featured by simple, scalable, and cost-
efficient procedures for preparation starting materials.2,3 Easy desulfurization of the final 
products and flexible chemistry make the thiopyran templates quite popular. During the 
last decade, the essential elements of this strategy were explored extensively in the Ward 
group (Scheme 1.1). Different approaches such as the iterative aldol reaction of 
tetrahydro-4H-thiopyran-4-one 7 with carboxaldehyde 64,5 or a simultaneous aldol 
reaction of dialdehyde 8 with tetrahydro-4H-thiopyran-4-one 7 were developed.6 All 
these efforts provided rapid access to tetra and hexapropionate synthons. 
 The difficulty in selectively accessing hexapropionate 12 is revealed when 
considering the 512 possible diastereomers (Scheme 1.1). This number decreased to 20 
diastereomers in 10 by disconnecting the carboxyl group and adjusting oxidation states of 
oxygen atoms. Previous results demonstrated that all 20 possible diastereomers could be 
obtained through iterative two-directional aldol reactions or simultaneous aldol reaction 
of tetrahydro-4H-thiopyran-4-one 7 and dialdehyde 8 (Scheme 1.1).4,6,7 Controlling the 
stereoselectivity of these aldol couplings is an ongoing objective in the Ward group. To 
date, the thiopyran route has been used successfully in total syntheses of several 
polypropionate natural products such as serricornin,8 membrenone B9, baconipyrone C10 
(44), baconipyrone A10 (43), siphonarin B10 (28) and ent-caloundrin B.11  
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Scheme 1.1 The thiopyran route to polypropionates 
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a) NaHCO3; b) Na, MeOH; c) (HOCH2)2, PTSA (cat.); d) LDA, ClCO2Me; e) 
10% H2SO4; f) (TMSOCH2)2, TMSOTf; g) LiAlH4; h) (COCl)2, DMSO, Et3N; i) 
IBX; j) refs. 12, 13 k) ref. 6 l) refs. 4, 5. 
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1.1.1 Preparation of the tetrapropionate synthons 9 
The preliminary building blocks in the thiopyran route to polypropionates are the 
four tetrapropionate synthons 9. The aldol reaction between easily accessible silyl enol 
ether 132 and aldehyde 6 can form four possible diastereomers 9 (Scheme 1.2). Three out 
of four possible diastereomer can be produced with high selectivity by using different 
mediators such as MgBr2·OEt2, MeLi and TiCl4.12 The least accessible diastereomer 9c, 
was obtained via imidazole mediated isomerization of 9d.13  
Synthesis of enantiomerically pure polypropionate natural products typically 
requires starting from enantiomerically enriched building blocks. In the thiopyran route to 
polypropionates, each of the four tetrapropionate synthons (9a-9d) can be prepared in 
enantiopure form by following the same procedures but starting from enantiopure 
aldehyde 6 (Scheme 1.2).14 Alternatively, recent investigations established a new method 
for enantioselective preparation of tetrapropionate synthons 9a via enantiotopic group 
selective direct aldol reaction of racemic aldehyde 6 with ketone 7, mediated by (S)-
proline as the desired organocatalyst.15,16 
Although this reaction provided 9a with high enantioselectivity (>98%ee), the 
yield still needed to be improved. Meticulous optimization showed that a large excess of 
ketone 7 (i.e. 8 equiv) was needed to obtain a yield 56%. Applying the tetrazole catalyst 
14, which has higher solubility, and increasing the concentration considerably reduced 
the amount of required ketone (2 equiv vs. 9 equiv) and improved the yield to 75% on 
multi-gram scale without need for chromatography while maintain high enantioselectivity 
(>98%ee).3 Isomerization of enantiomerically enriched aldol adduct 9a via methods 
mentioned previously, provides 9b the thermodynamically more stable diastereomer 
without loss of enantioenrichment. Thus two out of the four diastereomers of the aldol 
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adduct 9 can be efficiently prepared in enantiopure form from racemic and achiral 
reactants (Scheme 1.2).  
Scheme 1.2 Preparation of the first aldol adducts 
 
 
a) MeLi; b) MgBr2·Et2O; c) TiCl4; d) Imidazole, CHCl3; e) SiO2, Et3N; f) 14 (20 
mol%) 14, wet DMSO; g) (S)-proline, wet DMSO. 
1.1.2 Preparation of hexapropionate synthons 10 
An aldol reaction of any of the four tetrapropionate synthons 9 with aldehyde 6 
results in formation of hexapropionate synthons 10 (Scheme 1.1). As mentioned 
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previously, all twenty possible diastereomeric forms of hexapropionates 10 are known 
and methodology studies established access to all possible diastereomers.4,5,7,13,17 
In order to understand the diastereoselectivity in the aldol reaction of ketones 9a-
d and aldehyde 6, some terms should be identified. Seebach and Prelog proposed the 
terms like and unlike to differentiate the reactions of two chiral reactants,18 in this case 
ketones 9a-d and aldehyde 6. The term like is used when the fiducial stereogenic centers 
of the aldehyde and the ketone reactants have the same absolute configuration and the 
term unlike is used when the fiducial stereogenic centers of the reactants have different 
absolute configurations. 
At least three stereochemical control elements dictate the diastereoselectivity in an 
aldol reaction between chiral reactants. These are the enolate and aldehyde diastereoface 
selectivity, and the aldol relative topicity. When these three stereochemical controlling 
elements reinforce each other the aldol reaction is highly diastereoselective and is called 
a “matched”19,20 reaction. On the other, hand, if they do not reinforce each other, the 
reaction is called “mismatched”19,20 and will proceed with diminished 
diastereoselectivity. Another important concept for reactions of chiral reactants in 
racemic form is mutual kinetic enantioselection (MKE).21 This term refers to the relative 
facility (rate constants) of the like versus unlike reactions.  
Previous results of aldol reactions between ketone 9a-d and aldehyde 6 were 
based on Ti(IV) enolates formed by reaction of the ketones with TiCl4 or Ti(OiPr)Cl3 and 
an amine base (Figure 1.1).4 Analysis of the product distributions of these reactions 
illustrates both the diastereoselectivities and the relative rates of the like and unlike 
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reactions. It was also observed that the condition of the ß-hydroxyl group (protected or 
unprotected) strongly influences diastereoselectivity in the aldol reactions. 
Each reaction (i.e., 15 or 17 with racemic aldehyde 6) can form eight possible 
diastereomers, four each from the like and unlike combinations of reactant enantiomers. 
In this investigation, like refers to the same absolute configurations at C3 of the ketone 
and C3” of the aldehyde, while unlike refers to the opposite absolute configurations at C3 
of the ketone and C3” of the aldehyde. Ward et al. demonstrated that the reactions of ß-
hydroxy ketones occur with high diastereoselectivity and high MKE, while the reactions 
of the related ß-alkoxy ketones occur with high diastereoselectivity but low MKE. The 
reactions that occurred with high MKE using racemic reactants proceed with the expected 
kinetic resolution using enantiomerically enriched ketone and racemic aldehyde thereby, 
allowing access to enantiomerically enriched hexapropionate synthons. 
The aldol reaction of the enolate 15 (formed directly from ß-hydroxy ketones 9) 
with racemic aldehyde 6 selectively formed one of the eight possible diastereomers. 
Analysis of the product from this reaction shows that the stereoselectivity of the unlike 
combination of the starting materials reinforce each other and produce one product 
specifically. Because no product from the like combination of starting materials was 
observed, the reaction must have occurred with a high level of MKE (Figure 1.1, section 
i). Consequently, for each of the four diastereomers 15 the reactions were repeated using 
enantiomerically enriched ketones and racemic aldehyde 6. These reactions proceeded 
with kinetic resolution to form enantiomerically enriched aldol adducts 16.    
In contrast the aldol reaction of the related ß-alkoxy enolate 17 with the same 
aldehyde 6 under the similar conditions proceeded with completely different 
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diastereoselectivity (Figure 1.1, section ii). Analysis of the reactions for each 
diastereomer of 17 showed approximately 1:1 ratio of two aldol products, one from each 
possible combinations (like and unlike). Analysis of the results for each diastereomer of 
17 showed one of the stereocontrol elements (aldol relative topicity) was not biased. 
Consequently, both like and unlike combinations of aldol partners (enolates 17 and 
aldehyde 6) were matched and each reaction selectively gave one of the four possible 
products. Because the like and unlike occurred with a similar facility, (low MKE) two 
products were produced in near equal amounts.  
In conclusion, having access to enantiomerically enriched bis-aldol adducts from 
the ß-alkoxy ketone series requires enantiomerically enriched aldehyde and ketone while 
the enantiomerically enriched bis-aldol adducts from the ß-hydroxy ketone series require 
only one of the partners to be enantiomerically enriched (the reactions proceed with KR). 
 8
 
 
Figure 1.1 Stereoselectivity in the synthesis of hexapropionate synthons 
My contribution to this area of research concerned the development of aldol 
reactions of the protected ß-hydroxy enolates 20 with racemic aldehyde 6 that proceed 
via kinetic resolution with tunable enantioselectivity.5 In this project applying different 
enolates such as boron and titanium “ate” complex strongly enhanced the aldol relative 
topicity (the stereocontrol element that was not biased in the previous approach to 
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hexapropionate synthons). Hence, enantiomerically enriched aldol adducts (21 and 22) 
were formed selectively by starting from enantiomerically enriched ß-hydroxy enolates 
20 and racemic aldehyde (±)-6 via kinetic resolution (Figure 1.2). Having access to 
enantiomerically enriched hexapropionates 10 or tetrapropionates 9 provided an avenue 
for applying these templates in the total synthesis of polypropionates. 
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Figure 1.2 Tunable enantioselectivity in the hexapropionate synthesis  
1.2 Introduction to siphonariid mollusks and their polypropionates 
 Siphonariid mollusks (genus Siphonaria) are small air breathing sea snails known 
as the most ancient pulmonates. These species can be found either in tropical or 
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temperate coast lines at intertidal zones around the globe.22 Regarding their unique 
respiratory system (transformed lung sacs instead of gills), they may represent an 
evolutionary link between the marine and land mollusks. Although these mollusks feed 
on algae at low tides, there is no evidence to support their assimilation of algal 
metabolites from their food. Instead, it has been shown that their polypropionate-based 
metabolites originate from  de novo biosynthesis.23  
Although, siphonariid mollusks are primitive in evolutionary terms, they are 
extraordinary architects of a variety of polypropionate natural products and regardless of 
their geographical locations, they produce similar polypropionate metabolites.24 These 
polypropionates have been categorized into two classes.22  Class І includes acyclic 
systems (e.g., siphonarienone (23), and isosiphonarienolone (25)), and compounds with 
2-pyrone and furanone ring systems (e.g., diemenensin A (24), and 
deoxysiphonarienfuranone (26)). An (S) absolute configuration at all methyl bearing 
stereogenic centers in the linear chain is characteristic of this class. While Class I 
represents structurally mundane polypropionates, Class II comprises much more complex 
and heavily oxygenated networks that commonly are cyclized to either γ-pyrone and/or 
spiroacetal ring systems (e.g., siphonarin A (27) and B (28), caloudrin B (29), and 
muamvatin (30)) (Figure 1.3).  
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Figure 1.3 Examples of polypropionates from siphonariid pulmonates 
Class II siphonariid polypropionates show much more complexity in comparison 
to Class I. This complexity can be attributed to the polyoxygenated backbone of the 
molecule as well as various cyclization modes that create different ring systems in this 
class. For instance, formation of trioxaadamantanes from 3-hydroxy-1,5,7- triones, γ-
pyrones from 1,3,5-triones, and tetrahydro-2-hydroxy pyrones from 5-hydroxy-1,3-
diones. It is also reasonable to consider that the same polyoxygenated backbone can be 
cyclized into various architectures. Such considerations suggest that seemingly different 
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polypropionates might originate from a common linear or thermodynamically unstable 
precursor.10,11,23 
Extensive experimentation has shown that polyketides are synthesized in nature 
by multifunctional enzymes called polyketide synthases (PKSs).25 Such enzymes are 
capable of condensing a malonic acid derivative with an activated thioester and 
simultaneous decarboxylation of the malonic acid. The product ß-ketoester can be further 
modified (e.g., keto-reduction, dehydration, enoyl-reduction) prior to the next cycle. In a 
different approach, methylation of a preformed polyacetate chain by S-adenosyl 
methionine is the second pathway known in polpropionate synthesis (Figure 1.4).26 
S-KS
O
S-ACP
O O
HO+ S-ACP
O O
condensation
CO2
KS-SH
PKS polypropionate
PKS
+
SAM
S-KS
O
S-ACP
O O
HO+ S-ACP
O O
condensation
CO2
KS-SH
S-ACP
O O
SAM
31 32 33
34 35 36 37
 
Figure 1.4 Biosynthesis pathways 
One of the first studies in biosynthesis of polypropionates from siphonariid 
mollusks was done by Garson et al.27 Injection of sodium [1-14C] propionate to the foot 
muscle of S. denticulate resulted in incorporation of 14C propionate units in the harvested 
denticulatin A (39) (Figure 1.5) demonstrating de novo biosynthesis.27  
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Figure 1.5 Biosynthetic studies on denticulatin A (39) 
 Decarboxylation of the terminal propionate unit after condensation results in 
ambiguity with respect to the direction of polypropionate chain extension. Garson et al. 
were able to answer this question by using the method described previously.27 Siphonarin 
A (27), isolated from S. zelandica, consists of nine propionate units and one acetate unit. 
Feeding sodium [1-14C] propionate to S. zelandica via injection in the foot pad showed 
incorporation of 14C in the biosynthesized siphonarin A (27) chain (Scheme 1.3). 
Analysis of the acetate containing degradation product from the natural product did not 
show any incorporation of 14C. This result indicated that the chain growth is starting from 
C20 to C1 direction and not the other way (Scheme 1.3).  
Although polypropionate biosynthetic pathways have been extensively studied, it 
is still not clearly defined whether the cyclized products isolated are formed via 
enzymatic or non-enzymatic processes. The isolation of polypropionates from siphonariid 
mollusks usually involves multiple extraction and chromatography steps. Of the many 
siphonariid polypropionates known, it is not uncommon to find a hemiacetal, a pyrone 
ring system, or both structural motifs present in the natural product. Unraveling such ring 
systems by hypothetical ring-chain tautomerism (after hydration in case of pyrone) leads 
to heavily oxygenated linear precursors with several stereogenic centers.28,29 Considering 
 15
such a linear precursor as the “starting material” and exposing it to the isolation 
conditions may result in spontaneous, thermodynamically controlled cyclization to one or 
more products. As the result, several different polypropionate “natural products” may 
form from a similar precursor. For instance, hypothetical ring opening/rearranging of four 
polypropionates from S. zelandica: siphonarin B (28), caloundrin B (29), baconipyrone A 
(43), and baconipyrone C (44) results in the same linear precursor (42). Recently Beye 
and Ward successfully synthesized the putative precursor 42 as a kinetically stable 
compound.10 Interestingly, siphonarin B (28), baconipyrone A (43), and baconipyrone C 
(44) were obtained from 42 under different reaction conditions. Such observations 
suggested that the isolated natural products: siphonarin B (28), baconipyrone A (43), 
baconipyrone C (44) could be artifacts of isolation rather than the result of an enzymatic 
process (Figure 1.6).10,27,30 By contrast, caloundrin B (29) could not be detected in 
various attempts to isomerize 42. Beccerril-Jiménez and Ward prepared caloundrin B 
(29) by a different route and showed that it was much less thermodynamically stable than 
siphonarin B (28) and 42.11 Consequently, caloundrin B (29) can not be an artifact 
formed from 42 or siphonarin B (28) but might be the actual natural product from which 
28, 43, and 44 can be derived.  
 
 16
Scheme 1.3 Biosynthetic studies on siphonarin A (27) 
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a) O3,CH2Cl2, -78ºC; b) H2O, then p-Br-C6H4COCH2Br. 
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Figure 1.6 Siphonariid decapropionates rearrangement pathways 
1.3 Isolation and structure determination of muamvatin 
In 1986, Ireland et al. isolated an extraordinary polypropionate metabolite from 
Siphonaria normalis. These mollusks were collected intertidally from a region called 
Muamvatu in Fiji. The carbon tetrachloride extract of S. normalis contained the major 
portion of an unusual polypropionate. Extensive chromatography of this extract yielded 
65.2 mg of a polypropionate natural product named muamvatin. Unlike other 
polypropionates isolated from pulmonate mollusks, muamvatin showed highly unusual 
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structural features such as a trioxaadamantane ring system as well as an unsaturated diene 
moiety.30 The chemical ionization mass spectrum (CIMS) of muamvatin showed a small 
M+H ion at m/z 395. Fragment ions at m/z 377 and m/z 359 represented loss of two water 
molecules. Based on mass spectral data, the molecular formula C23H38O5 was deduced. A 
strong absorption at 236 nm in UV spectrum suggested the presence of a 1,3-diene. The 
polypropionate nature of muamvatin was clearly indicated in its 1H NMR spectrum 
showing six methyl groups, two ethyl groups, two exchangeable hydroxyl protons, and 
the two spin systems 45 and 46 illustrated in Figure 1.7. The 1H-1H spin decoupling and 
COSY experiments, defined two ethyl groups, one at each terminus, with one connected 
to a vinylic carbon and the other one attached to a carbon bonded to oxygen (C1-C2 and 
C17-C18). Correlations between the protons at C5 to those at C4 and C6 were clear in the 
COSY spectrum. A 1H-13C NMR correlation experiment allowed assignment of all 
protonated carbons. The five remaining quaternary carbons were assigned to two fully 
substituted sp2 carbons and three ketal carbons. The above data supported the partial 
structure 47 because of no clear differentiation among ketal carbons (Figure 1.7). A 
NMR 1H-13C polarization transfer experiment completed the structure assignment by 
correlating the proton at C5 to both the C7 and C3 ketal carbons. 
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Figure 1.7 Proposed fragments of muamvatin defined by NMR experiments  
The relative configuration of the substituents on the trioxaadamantane ring system 
was defined based on proton-proton coupling constants and two dimensional NOE 
experiments. The small 3JHH couplings between H-C5 and H-C4, and H-C5 and H-C6 are 
due to axial-equatorial-axial orientation made clear from COSY and NOE between H-C4 
and H-C6. Comparative NMR studies as well as the rigidity of the trioxaadamantane ring 
system forced the ethyl group at C3, hydroxyl group at C7, and the diene side chain to 
have equatorial orientation. Clear NOE correlation between H-C8 and the C6 methyl 
group indicated that the C8 methyl group was axial. The E geometry of the two 
trisubstituted olefinic carbons was assigned based on the 13C NMR shifts of the vinylic 
methyls at δ 12.3 and 16.7 ppm but the relative configuration at C10 and C11 remained 
undefined (Figure 1.8). The PCC oxidation of 49 produced aldehyde 50.30 High 
resolution FABMS of 50 secured the molecular formula as C15H24O5 which was in 
agreement with the 1H and 13C NMR and confirmed the structure of 50 with the 
exception of C10 relative configuration (Scheme 1.4). 
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Figure 1.8 NMR based correlation of substituents on muamvatin backbone structure 
  The above NMR studies defined clearly the three-dimensional structure of 
muamvatin (except for the relative configuration of the two stereogenic centers at C10 
and C11); however, the absolute configuration of the natural product remained unknown. 
In contrast with its unique structural features, muamvatin did not show any antibiotic 
activity against any common test organisms. 
Scheme 1.4 Oxidative degradation of muamvatin (49) 
 
1.4 Synthetic studies on muamvatin 
From a synthetic point of view, the key structural features of muamvatin (30) 
include the densely oxygenated octapropionate backbone that contains several contiguous 
stereogenic centers as well as the unprecedented trioxaadamantane ring system. This ring 
system has subsequently been found in only one other naturally occurring 
polypropionate, caloudrin B (29).24  
To date, there has been a single total synthesis of muamvatin which confirmed the 
relative configuration of the trioxaadamantane and established its absolute 
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configuration.31 On the other hand, the formation of the unique trioxaadamantane ring 
system has also been studied.29,32,33 The details of each will be discussed in following 
sections.  
1.4.1 Hoffmann’s studies on muamvatin 
Hoffmann’s approach to muamvatin started with extensive studies on the 
trioxaadamantane portion of muamvatin and its formation under different conditions. 
Their first approach was to make hydroxytrione 52 from triol ketone 53. Because 
compound 53 predominantly existed as the hemiacetal 54, the free hydroxyl group at C5 
and ketone at C9 were internally protected. Thus, 54 selectively exposed the hydroxyl 
groups at C3 and C7 for further oxidation (Figure 1.9).  
 
Figure 1.9 Synthetic strategy for making compound 27  
The aldehyde (±)-57 was obtained in 7 steps from methacrolein 56 in a racemic 
form.34 Boron mediated aldol reaction of (±)-57 with 3-pentanone (58) formed 59 as a 
single compound in 85% yield establishing all stereogenic centers required on the carbon 
skeleton. Liberating the hydroxy groups at C3 and C5 produced the hemiacetal 62 in 92% 
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yield. Because several attempted methods to convert 62 to 55 were not effective, a new 
approach to the same target was devised. Direct Swern oxidation of 59 gave trione 60 in 
68% yield as a mixture of epimers at C8 (Scheme 1.5). Hydrolysis of the C5 silyl ether in 
60 under acidic conditions quantitatively formed dihydropyrone 61. Using less acidic 
HF·pyridine to remove the silyl ether formed 60% of the desired trioxaadamantane 51 
and 37% of 61. Optimized reaction conditions gave the trioxaadamantane ring 51 in 72% 
yield with no elimination product. Exposing 51 to acidic conditions also gave 
dihydropyrone 61. This approach showed that both epimers of 60 can form the desired 
trioxaadamantane 27.34 The cyclization conditions found in this study were used in a 
separate investigation to establish the absolute configuration of muamvatin. 
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Scheme 1.5 Hoffmann’s approach to the trioxaadamantane ring system 51 
 
a) 9-BBNOTf, iPr2EtN; b) Bu4N+F-; C) (COCl)2, DMSO, Et3N; d) HF, CH3CN; e) 
HF·Py, 65 ºC; f) HF·Py, THF, H2O, 20 ºC; g) 1N aq. HCl, CH3CN. 
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Hoffmann et al. successfully synthesized both C10 epimers of aldehyde 50, the 
degradation product from PCC oxidation of 49.35 Coupling of (R)-α-chlorocrotylboronate 
64 with methacrolein (56) formed alcohol (+)-65 that after stereoselective chain 
elongation and oxidation state adjustments, provided aldehyde 66 in 6 steps and 80% 
overall yield (Scheme 1.6).34  
Scheme 1.6 Enantioselective synthesis of aldehyde 66 
 
 
Boron mediated aldol couplings of aldehyde 66 with each enantiomer of 67 
formed aldol adducts 68a and 68b (Scheme 1.7). Swern oxidation of the aldol adducts 
according to the previously developed method (Scheme 1.5), gave triones 69a and 69b, 
respectively. Subjecting the triones to HF·pyridine followed by hydrogenolysis of the 
benzyl protecting group and oxidation of the liberated alcohol groups gave aldehydes 70a 
and 70b.  
 The spectroscopic data for 70a perfectly matched those for aldehyde 50, the 
degradation product from muamvatin. In addition, the single crystal X-ray structure for 
70a established the relative configuration for all stereogenic centers. Finally, the optical 
rotations for aldehydes 70a and 50 had opposite signs establishing the absolute 
configuration of 50 as ent-70a.  
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Scheme 1.7 Preparation of both C10 epimers of aldehyde 70  
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a) (COCl)2, DMSO, Et3N; b) HF·Py, THF, H2O, 20 ºC; c) H2, Pd(OH)2; d) 
PCC/aluminum oxide.  
Hoffmann proposed the relative configuration of the hydroxy group at C11 of 
muamvatin based on the available NMR data of the natural product and knowing the 
relative configuration at C10. The torsion angle around the C9-C10 bond is dictated by 
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minimizing the g+g- interactions between the methyl groups at C10 and C8. On the other 
hand the C10-C11 torsion angel in muamvatin should have a conformation that 
minimizes g+g- interactions as well as allows hydrogen bonding between the hydroxyl 
group at C11 and one of the oxygens at C9 ketal moiety. Therefore, among the possible 
C10-C11 syn and anti diastereomers of muamvatin only one can explain the large 3JH- C10/ 
H-C11 coupling constant (J = 9 Hz). Thus, Hoffmann et al. proposed 30 as the structure for 
muamvatin (Figure 1.10 ).35 
 
Figure 1.10 Absolute configuration of muamvatin  
Extending the above study, Hoffmann et al. attempted the total synthesis of ent-
muamvatin.32 The approach was based on the previous studies focused on preparation of 
the trioxaadamantane ring system of ent-muamvatin. Unraveling the full carbon skeleton 
of ent-muamvatin revealed the linear octapropionate chain 71 that was envisioned to arise 
from ketone 72 and known34 aldehyde 66. Ketone 72 was planned to be obtained from 
aldehyde 73 (Figure 1.11).  
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Figure 1.11 Hoffmann’s retrosynthetic analysis of ent-muamvatin 
Aldehyde 73 was prepared in three steps from 74 via Wittig reaction with 75 
followed by a sequential redox process. Ketone 80 was obtained from 73 via Evans aldol 
reaction that set the two required stereogenic centers to give 78 which then was followed 
by insertion of an ethyl group (Scheme 1.8).  
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Scheme 1.8 Preparation of ketone 80 
 
a) THF, reflux; b) LiAlH4; C) nPr4NRuO4, NMO; d) Bu2BOTf, iPr2EtN; e) LiBH4, 
MeOH; f) α,α,4-trimethoxytoluene, PPTS; g) DIBAL-H; h) (COCl)2, DMSO, 
Et3N; i) EtMgBr;  j) (COCl)2, DMSO, Et3N. 
Boron mediated aldol reaction of ketone 80 with aldehyde 66 followed by 
oxidation of the newly formed hydroxy group gave 81, as a protected derivative of the 
acyclic tautomer of ent-muamvatin. Treatment of 81 with HF·pyridine affected removal 
of the silyl protecting group of the C5 hydroxy group and catalyzed formation of the 
trioxaadamantane ring generating 82 in 10% yield along with hemiacetal 83. Further 
efforts to form 82 from 83 were unsuccessful and at best resulted in dehydration to 
dihydropyrone 84 (Scheme 1.9). On the other hand, attempts at oxidative removal of the 
PMB group in 82 failed to produce the desired ent-30. Because the goal of this work was 
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to establish the structure of muamvatin, additional research to solve the above problem 
was not pursued after Paterson’s report of the total synthesis of muamvatin 30.31 
Scheme 1.9 Assembly of the full carbon skeleton  
 
 
a) 9-BBNOTf, iPr2EtN; b) (COCl)2, DMSO, Et3N; c) HF·Py, THF, H2O, 20 ºC, 8 
days; d) PTSA. 
Although Hoffmann’s approach to muamvatin was not successful, his approach 
successfully established the absolute and relative configuration of all stereogenic centers 
on the carbon backbone of muamvatin. 
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1.4.2 Paterson’s total synthesis of muamvatin 
Paterson et al. reported the only total synthesis of muamvatin.31 Because the 
absolute and relative configuration of muamvatin was not known at the time, the initial 
goal was to prepare aldehyde 5030 (ent-70a), obtained by Ireland et al. as a degradation 
product from muamvatin. According to their retrosynthetic analysis (Figure 1.12), 
aldehyde ent-70a would be obtained by sequential aldol coupling of propanal (87) with 
the dipropionate reagent (R)-86. Oxidation state manipulation of the resulting 
pentapropionate 85 would set the stage for cyclization of the trioxaadamantane ring 
system.  
 
Figure 1.12 Paterson’s retrosynthesis of muamvatin 30 
Diastereoselective aldol reaction of the Sn(II) enolate of (R)-86  with propanal 
formed 88 (Scheme 1.10). Stereoselective reduction of ketone 88 followed by protection 
of the diol, debenzylation, and oxidation of the resulting primary alcohol produced 
aldehyde 90. Diastereoselective boron mediated aldol reaction of ketone (R)-86 with 
aldehyde 90 formed the desired pentapropionate 91. Deprotection of the silyl group 
formed hemiacetal 92 as the only product. Due to internal protection of the hydroxyl 
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group at C5 in the hemiacetal 92, selective oxidation of hydroxyl groups at C3 and C7 
was successfully achieved by Swern oxidation. Diketone 93 was sensitive to acidic and 
basic conditions but eventually was successfully cyclized to the trioxaadamantane 98 by 
overnight exposure to silica gel (Scheme 1.11).  
Scheme 1.10 Synthesis of diketone 93 
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a) Sn(OTf)2, Et3N; b) Me4NBH(OAc)3; c)tBu2Si(OTf)2, 2,6-Lutidine; d)H2, 10% 
Pd/C; e) (COCl)2, DMSO, Et3N; f) (Chx)2BCl, Et3N; g) HF·Py, THF.  
Rearrangement of hemiacetal 93 to the desired ring system 98 required ring 
opening of the hemiacetal ring system to the hydroxyl triketone 94 followed by a series 
of acetal ring forming steps (Scheme 1.11). Because this rearrangement was successfully 
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catalyzed by silica gel, the possibility that muamvatin was an artifact of isolation was 
suggested.  
Scheme 1.11 Formation of the trioxaadamantane 98  
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a) SiO2 
Trioxaadamantane 98 was readily converted to aldehyde ent-70a by 
hydrogenalysis of the benzyl ether followed by PDC oxidation of the resulting alcohol 
(Scheme 1.12). Coupling aldehyde ent-70a with the vinyl lithium reagent formed by 
treatment of 99 with tBuLi gave 11-epi-muamvatin in 85% yield. The C11 configuration 
was inverted via an oxidation, stereoselective reduction sequence to give muamvatin (30) 
(Scheme 1.12). This synthesis successfully established the absolute and relative 
configuration of muamvatin however the overall yield was not reported.  
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Scheme 1.12 Completion of the total synthesis of muamvatin (30) 
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a) H2, 10% Pd/C; b) Pd/C, 4-Å molecular sieve; c) catecholborane, 
chloroamine-T, NaI; d) nBuLi; e) nPr4NRuO4, NMO; f) DIBAL-H. 
1.4.3 Studies on formation of the trioxaadamantane ring system under 
thermodynamic control 
The unusual trioxaadamantane ring has been observed in only two natural 
products: muamvatin (30) and caloundrin B (29). The difference between these 
trioxaadamantane ring systems is the relative configuration at C4 (i.e., (4R) in muamvatin 
(30) and (4S) in caloundrin B (29)). Formation of each ring system requires a specific 
cyclization mode of its linear putative precursor among all other possible modes of 
cyclization (see Figure 1.13 and Figure 1.14). In this regard, theoretical ground state 
energies of the possible hemiacetal, spiroacetal, and trioxaadamantane ring systems that 
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might be formed from the putative acyclic precursor of siphonarine B (28), muamvatin 
(30), and caloundrin B (29) were calculated by Garson et al.29 They proposed that 
thermodynamic factors control the formation of muamvatin and the siphonarins, where 
the preferred acetal ring systems are correlated to the configuration of the hydroxyl and 
methyl groups and the oxidation state of the carbons in the acyclic precursor.  
The acyclic tautomer of muamvatin is shown in two C8-epimeric forms in Figure 
1.13. Two different cyclization modes result in trioxaadamantanes (30 and 8-epi-30) or 
spiroketals (101a and 101b). Molecular mechanics calculations indicated the 
trioxaadamantane ring system 30 is significantly more stable than the other possible 
structural isomers (i.e., 8-epi-30, hemiacetal 102, 101a, and 101b). These results 
supported the idea that muamvatin could be formed in a thermodynamically controlled 
non-enzymatic process and was a possible artifact of isolation. In other words, the actual 
biosynthetic product might be the less stable hemiacetals 101a, 101b, or 102 or one of the 
acyclic epimers ent-71 which then formed the trioxaadamantane 30 via exposure to silica 
gel chromatography during isolation.  
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Figure 1.13 Various cyclization modes of the acyclic tautomer of muamvatin 
Similar calculations were performed to compare the relative energies of the 
possible spiroacetal and trioxaadamantane resulting from cyclization of the common ring-
chain tautomer of caloundrin B (29) and siphonarin B (28) (Figure 1.14). These results 
suggested a much higher relative stability of the spiroacetal structures (28 and (8S)-28) 
over the trioxaadamantane ring systems (29 and (8R)-29) the same as what was shown by 
Ward et al.10,11 experimentally. Spiroacetal 28 (siphonarin B) was calculated to be 
slightly more stable than its epimer (8S)-28 (destabilized by a g+g- interactions between 
the methyl group at C6 and C8). Similarly, comparing the relative stability of 29 and 8-
epi-29 showed that 29 is 5.33 kJ mol-1 more stable than 8-epi-29 due to the 1,3-diaxial 
interaction between methyl groups at C6 and C8 in 8-epi-29.  
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Figure 1.14 Siphonarin B (28) vs. caloundrin B (29) cyclization 
Recently, Beye and Ward were able to synthesize a mixture of the putative 
precursors (8R)-42 and (8S)-42 (Figure 1.6).10 Interestingly, they successfully isomerized 
this epimeric mixture into siphonarin B (28), baconipyrone A (43), and baconipyrone C 
(44); however, no sign of caloundrin B (29) was observed in these experiments. In a 
separate study, Becerril-Jimènez and Ward prepared ent-caloundrin B by total 
synthesis.11 They showed that ent-caloundrin B was thermodynamically unstable relative 
to ent-siphonarin B (28).11 It was proposed that the actual biosynthetic product might be 
caloundrin B (29) and that the other isomeric products (28, 43, and 44) are possible 
artifacts formed in the isolation process.  
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Beye and Ward also successfully synthesized truncated models of the 
trioxaadamantane ring systems of muamvatin (30) and caloundrin B (29)  and studied 
their thermodynamic behaviors (Scheme 3.11).73 The model trioxaadamantane ring 
systems of muamvatin (30) and caloundrin B (29), 51a and 51b, respectively, are ring-
chain tautomers of the hydroxytriones 103a and 103b (Figure 1.15). Although the 
trioxaadamantane ring systems are the thermodynamically most stable tautomers, their 
formation proceeds through the less stable hemiacetal intermediates 105a and 105b. Any 
harsh acidic or basic conditions can turn these hemiacetals to dihydropyrones (61a and 
61b) by dehydration or induce retro-Claisen fragmentation to give esters (106a and 
106b).  
 
Figure 1.15 Trioxaadamantanes from 3-hydroxy-1,5,7-triones 
The dithiatrioxa pentacyclic ring systems 109 and 110 were prepared via the 
thiopyran route to polypropionates (Scheme 1.13). Subsequent desulfurization formed 
the two trioxaadamantanes 111 and 112 that are destabilized by a syn pentane interaction 
between the methyl groups at C6 and C8. The isomerizations of 111 and 112 to the more 
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stable epimers 51a and 51b respectively were achieved by treatment with imidazole. This 
isomerization required ring opening, epimerization of C8 methyl group (to form acyclic 
precursors 103a and 103b) and refolding as indicated in Figure 1.15. Interestingly, the 
isomerizations of 111 and 112 showed quite different behaviors. The trioxaadamantane 
ring system 111 quantitatively formed the thermodynamically more stable 
trioxaadamantane 51 on exposure to imidazole. Isomerization of 112 under the same 
condition formed trioxaadamantane 51b along with the hemiacetal 113 and ester 106b 
(the result of retro-Claisen fragmentation of a hemiacetal forms; e.g. 113) (Scheme 1.13).  
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Scheme 1.13 Synthetic studies on model trioxaadamantanes from muamvatin (30) and 
caloundrin B (29)  
 
a) IBX, DMSO b) FeCl3·SiO2 c) Me3SiOTf d) Raney Ni e) HF·Py f) Imidazole, 
CDCl3, rt 
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1.5 Conclusions 
The unusual trioxaadamantane ring system of muamvatin has been studied in 
several research groups. Successful synthesis of 50 and 51 established the absolute and 
relative configuration of the trioxaadamantane ring system of muamvatin (30) and 
provided strategies and conditions to form the unusual trioxaadamantane ring system. 
The only total synthesis of muamvatin disclosed by Paterson et al. proved the structure. 
However, because the synthesis proceeded via a pre-formed trioxaadamantane 
intermediate, there was no opportunity to study the behavior of acyclic tautomer 42 and 
its cyclization to 30. The synthesis of 42 and study of its cyclization behavior would help 
to answer questions regarding the origin of the unusual ring system in muamvatin (30) 
(whether it is formed via an enzymatic process or is an artifact of isolation). In this 
regard, Ward et al. developed methodologies for fast, easy, and selective preparation of 
propionate synthons via the thiopyran route to polypropionates and successfully disclosed 
total synthesis of several polypropionate natural products.8-11 With these examples in 
hand, research was directed towards the synthesis of putative linear precursor of 
muamvatin and studying its cyclization modes. 
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2. RESULTS AND DISCUSSION 
2.1 Research objectives 
The objective of this research was focused on the synthesis of the putative acyclic 
precursor of muamvatin (30 = 116a); i.e., 114a or its 11-O-protected analogue 114b 
(Figure 2.1). With the acyclic precursor in hand, conditions could be investigated to 
determine possible cyclization pathways (e.g., formation of the retro-Claisen product 118 
or dihydropyrone 117) and/or facilitate the pathway that leads to the trioxaadamantane 
116. Ideally, such studies should shed light on the possible origin of the unique 
trioxaadamantane ring system; whether it is formed through an enzyme-mediated process 
or under thermodynamic control as an artifact of isolation. The previous total synthesis of 
muamvatin by Paterson et al.31 (Section 1.4.2) established its relative and absolute 
configuration. Their synthetic approach was based on coupling of a preformed 
trioxaadamantane fragment ent-70a with the diene component of the molecule. Although 
they were able to form the truncated trioxaadamantane ring system 98 successfully, it did 
not address the origin of the unique ring system present in muamvatin.  
The secondary research objective was to demonstrate the synthetic potential of the 
thiopyran route to polypropionates (see Section 1.1) for rapid and stereoselective 
assembly of the polypropionate motifs.  
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Figure 2.1 Research objectives 
2.2 Synthesis of muamvatin, part 1: the thiopyran route  
The trioxaadamantane ring system present in muamvatin (30 = 116a) is a ring-
chain tautomer of the 5,11-dihydroxy-3,7,9-trione (8R)-114a (Figure 2.2). Retrosynthetic 
disconnections of the C3-C4 and C10-C11 carbon-carbon bonds produce three fragments 
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that in the synthetic direction were envisioned to be coupled together by substrate-
controlled stereoselective aldol couplings. A significant advantage of this synthetic 
approach is that the aldehyde fragments 87 and 73 are achiral with the triketone 119 as 
the sole chiral fragment. Thus, either enantiomeric or racemic muamvatin (116a = 30) 
would be accessible via the same strategy by starting with the appropriate enantiomer or 
racemic ketone 119. Of course, trione 119 is expected to be configurationally unstable 
and a suitable synthetic equivalent would be required. Ketone 9a, readily available via 
the thiopyran route to polypropionates, was selected as the reagent to represent 119. 
ketones (+)-9a, (-)-9a, and (±)-9a are readily prepared on large scale (40 g) without 
chromatography via an organocatalytic aldol reaction of ketone 7 with aldehyde (±)-6.3 
 
Figure 2.2 Retrosynthetic analysis of muamvatin 
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Based on the above strategy, a synthetic plan was devised beginning with a 
stereoselective aldol reaction between propanal (87) and ketone (+)-9a to set the desired 
relative configuration at C4 (Scheme 2.1). Stereoselective reduction of the C5 ketone 
moiety of the resulting aldol adduct 120 would result in formation of triol 121. The 
second stereoselective aldol reaction of the derived ketone 123 with the known32 diene 
aldehyde 73 would form the fully assembled carbon skeleton 124. Deprotection and 
desulfurization of 124 would give 125 that was expected to exist in its hemiacetal form 
126. Finally, correction of the oxidation states at C3 and C7 of hemiacetal 126 would 
furnish the desired target 114 in its hemiacetal form 127. Successful protecting group 
manipulation would be critical to the success of this strategy. Not only must protecting 
group P1 be orthogonal to protecting group P2, it must also survive the deprotection of the 
ketal moiety at C9 in compound 122 and be removable under mild conditions. 
Desulfurization and removal of P1 should reveal all methyl groups as well as the triol 
portion present in compound 125. It was expected that triol 125 would exist in the 
hemiacetal form 126 where the C5 hydroxyl group would be internally protected thereby 
allowing for chemoselective oxidation of C3 and C7 alcohols. Thus, the formation of 126 
as the thermodynamically more stable tautomer would provide successful differentiation 
among the three hydroxyl groups in compound 125.  
The hemiacetal 127 is a ring-chain tautomer of the acyclic form (8R)-114b. At 
this stage, removal of the P2 protecting group would form the muamvatin acyclic 
precursor (8R)-114a in its hemiacetal form which would serve the primary objective of 
this research project (see Section 2.1). Thus, P2 should be robust enough to survive 
through the synthesis of the fully assembled carbon skeleton 124, and be removed under 
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sufficiently mild conditions so as not to interfere with the sensitive functionalities 
contained in 127. If this could not be achieved, removal of P2 after trioxaadamantane 
formation would be required. Although this would result in a total synthesis of 
muamvatin, it would preclude studying the origin of this “natural product” (Scheme 2.1).  
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Scheme 2.1 Synthetic strategy towards muamvatin  
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2.2.1 Synthesis of tris-benzyl ketone 129 
The above synthetic strategy towards muamvatin is based on assembly of the full 
carbon skeleton followed by the oxidation state manipulation of the polyoxygenated 
carbon chain. In this approach, racemic ketone 9a3 was initially used (readily available 
and easily could be obtained in enantiomerically pure form) in order to establish the 
chemistry involved along this synthetic route.  
Stereoselective aldol coupling of propanal (86) with the Ti(IV) enolate formed 
from ketone 9a produced aldol adduct 120 as the predominant product (>20:1 dr) in good 
yield (Scheme 2.2). The relative configuration of the newly formed stereogenic centers 
was assigned by analogy to the previous work in Ward group9 (see Figure 1.1). Previous 
studies had shown that Ti(IV) mediated aldol reactions of β-hydroxy ketones (such as 9a) 
have very high 1,3-syn enolate diastereoface selectivity and anti aldol relative topicity. It 
was proposed that this high stereoselectivity results from the cyclic Ti(IV) enolate 15a 
which makes one face of the enolate much more accessible than the other (Scheme 2.3).  
Stereoselective reduction of aldol adduct 120 with NaBH4 formed triol 121 (12:1 
dr). In the 1H NMR spectrum of 121, the large J couplings between HC4 and HC5 and 
between HC5 and HC6 clearly indicated that these protons were axial and thus 
established the 4,5-anti and 5,6-anti relative configuration (Figure 2.3).  
 
Figure 2.3 Structure elucidation of 121 
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Scheme 2.2 Preparation of the tris-benzyl ketone 129 
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a) TiCl3(OiPr), DIPEA, -78 ºC; b) NaBH4; c) KH, BnBr; d) Amberlyst®, acetone. 
Hydrolysis of the ketal moiety at C9 in 120 would reveal a carbonyl group 
providing a handle to install the rest of the carbon chain (Scheme 2.2). Before that 
operation, protection of the three hydroxyl groups in triol 121 with a group orthogonal to 
the ketal was necessary to avoid any unwanted hemiacetal formation by cyclization of the 
C5-OH onto the C9 ketone moiety. Benzyl (Bn) ethers were chosen due to their 
robustness to conditions for ketal hydrolysis and having the potential for removal 
concomitant with the desulfurization process. Alkylation of the triol 121 with benzyl 
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bromide in the presence of KH formed the tris-benzyl ketal 128 in a good yield. Reaction 
of 128 with Amberlyst® in acetone gave the desired ketone 129.  
2.2.2 Synthesis of the diene aldehyde 73 and assembly of the full carbon 
skeleton 
As shown previously (Scheme 2.1), the planned assembly of the full carbon 
skeleton of muamvatin required stereoselective aldol reaction between tris-benzyl ketone 
129 and diene aldehyde 73. Aldehyde 73 was prepared as reported previously by 
Hoffmann et al.32 except IBX (instead of Pr4NRuO4/NMO) was used in the final 
oxidation step. This modification simplified the procedure and gave comparable yield and 
purity on larger scale (Scheme 2.3). 
Scheme 2.3 Preparation of aldehyde 73 
 
a) THF, reflux; b) LiAlH4, Et2O; c) IBX, DMSO, rt. 
Stereoselective aldol reaction of aldehyde 73 with the enol dicyclohexylborinate 
derived from ketone 129 gave the adduct 131a (>20:1 dr) (Scheme 2.4). Unfortunately, 
131a could not be separated from unreacted 129. Reaction of this mixture with Ac2O and 
DMAP gave 131b in good overall yield. The relative configuration of the newly formed 
stereogenic centers in 131b was assigned by analogy with the results obtained in the 
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previously discussed boron mediated aldol reactions of thiopyran ketone similar to 129 
(see Figure 1.2).5 
Desulfurization and debenzylation of 131b should form the acyclic backbone of 
muamvatin, presumably in its hemiacetal form 133 (Scheme 2.4). Not unexpectedly, the 
diene moiety of the molecule did not survive exposure to Raney Ni. Analysis of the 1H 
NMR spectrum of the crude products indicated the absence of diene even under 
conditions of incomplete desulfurization/debenzylation. Thus, either a more 
chemoselective desulfurization/debenzylation method needed to be developed or the 
diene portion of the molecule needed to be protected to survive the 
desulfurization/debenzylation step. 
Scheme 2.4 Assembly of the full carbon skeleton of muamvatin 
 
a) (Chx)2BCl, Et3N, then 73; b) Ac2O, DIPEA, DMAP; c) Raney Ni, EtOH. 
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2.2.3 Revised synthetic strategy 
Despite the failed attempt to form the desired hemiacetal 133, the described 
methods offered some insight for addressing the problems encountered. The conditions 
used for desulfurization/debenzylation were not chemoselective enough to avoid 
reduction of the diene moiety of compound 131. So, it was hypothesized that protection 
of the diene portion would enable successful desulfurization/debenzylation of compound 
131 without interference from the diene portion. 
Looking for a suitable protecting group for the diene portion of the molecule led 
to tricarbonyliron-diene complexes. Numerous applications of tricarbonyliron-diene 
complexes in organic synthesis were reported. In particular, tricarbonyl(η4-diene)iron 
complexes have found flexible applications especially to the regio-, diastereo-,32,36-38 and 
enantioselective synthesis of organic compounds39-42 including biologically active natural 
products.43-46 Easy preparation and simple removal of the ironcarbonyl moiety under mild 
oxidative conditions in the final stage of the synthesis make tricarbonyl(η4-diene)iron 
complexes versatile compounds.47,48 Although it was shown that a tricarbonyliron 
complex of an acyclic, labile diene can protect the diene against reduction and oxidation 
reactions48, there are few reports on diastereoselective aldol reactions of (tricarbonyl)iron 
complex of diene aldehydes.49,50 For example, the aldol reaction of aldehyde (±)-135 with 
lithium enolate 134 gave 71% of two adducts in low diastereoselectivity (1.4:1 dr) 
(Scheme 2.5).51 With this background, preparation of the tricarbonyl(η4-diene)iron 
complex of aldehyde 73 was targeted to study its efficiency for the desired purposes.  
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Scheme 2.5 Diastereoselective aldol reaction of aldehyde 135 with enolate 134 
 
2.2.3.1 Preparation and aldol reactions of the Fe(CO)3 protected diene aldehyde 
138b  
Known methods were adapted to prepare the desired aldehyde (±)-138b (Scheme 
2.6). Reaction of diene ester 76 with Fe2(CO)9 formed complex (±)-137 in moderate 
yield.46,48 Reduction of ester (±)-137 with DIBAL-H gave the corresponding alcohol (±)-
138a with minimal loss of the ironcarbonyl moiety.52,53 IBX oxidation of (±)-138a 
provided aldehyde (±)-138b in good yield. The choice of solvent was found to be crucial 
for the oxidation step. Standard solvents for the IBX mediated oxidation (such as 
acetonitrile or DMSO) resulted in either a very slow rate or partial removal of the 
Fe(CO)3 moiety. Using THF as a co-solvent with DMSO resulted in a reasonable rate of 
oxididation with minimal deprotection of the iron complex. The efficacy of this diene 
protection was tested by desulfurization of 140 in the presence of (±)-137 which gave 
desulfurized ketone 139 without any decomposition of (±)-137 (Scheme 2.6). 
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Scheme 2.6 Preparation of diene Iron complex (±)-138b  
 
a) Fe2(CO)9, Benzene, reflux; b) DIBAL-H, THF, -78 ºC; c) IBX, (THF:DMSO 
1:2); d) Raney Ni, EtOH, reflux. 
Complexation of the achiral diene aldehyde 73 with Fe(CO)3 results in the chiral 
aldehyde (±)-138b. Thus, the presence of the tricarbonyliron moiety generates a new 
stereogenic element. An aldol reaction of aldehyde (±)-138b with a chiral ketone (i.e., 
tris-benzyl ketone 129) can produce up to eight possible adduct diastereomers. According 
to the multiplicativity rule,20,54 the stereoselectivity of aldol reactions between chiral 
fragments can be factorized into three stereocontrol elements: i) enolate face selectivity, 
ii) aldehyde face selectivity, and iii) aldol relative topicity. A highly stereoselective aldol 
reaction has all three of these stereocontrol elements highly biased (see Section 1.1.2). 
Previous studies in the Ward group, have shown that the enolate diastereoface 
selectivity of closely related tetrapropionate synthons, such as 9, can be manipulated to 
favor 3,5-syn or 3,5-anti aldol adducts by having the C1′-OH free or protected, 
respectively.4 The aldol relative topicity can also be manipulated to be highly syn or anti 
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selective by using different enolates (i.e., boron or Ti(IV) “ate”) (see Section 1.1.2).5 
Lastly, numerous examples of nucleophilic addition to 2,4-dienals bearing 
tricarbonyl(η4-diene)iron complexes showed that the population of s-cis and s-trans 
conformers dictated the diastereoface selectivity (the addition of the nucleophile 
selectively occurred exo to the (tricarbonyl)iron moiety) (Figure 2.4).38 The distribution 
of the two conformers (s-cis vs. s-trans) depends on several features such as the diene 
substituents, the nature of the nucleophile, temperature, and presence or absence of a 
Lewis acid.  
 
Figure 2.4 The diastereo-face selectivity of aldehyde (±)-138b 
To test the reactivity and selectivity of aldehyde (±)-138b, a model aldol reaction 
with ketone 140 (a closely related analogue to tris-benzyl ketone 129) was conducted 
(Scheme 2.7). Surprisingly, none of the common enolates derived by reaction of 140 with 
(Chx)2BCl/Et3N, TiCl4/Et3N, TiCl3(OiPr)/Et3N or LDA produced any aldol adduct, under 
various conditions. The reactivity of aldehyde 73 was apparently diminished drastically 
in its complexed form with Fe(CO)3. However, using the ‘amine free’ Li enolate of 
ketone 140, generated via direct enolization by tBuLi, gave a 70% yield of two aldol 
adducts in a 7:1 ratio (based on 1H NMR of the crude reaction mixture). The relative 
configurations of the major and minor aldol adducts 141 and 142 were determined from 
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their X-ray crystal structures (Figure 2.5). Accordingly, both adducts were formed with 
the same aldehyde diastereoface selectivity, presumably by addition to the less hindered 
face of the s-trans conformer (see Figure 2.4). The major adduct had the desired 3’,5’-
trans-1,3’-anti relative configuration which is the out come of the favored transition state 
shown in Scheme 2.7. 
Scheme 2.7 Model study on aldol reaction of aldehyde (±)-138  
 
a) tBuLi, -78 ºC then (±)-138b 
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Figure 2.5 ORTEP representations for 141 and 142 
2.2.3.2 Preparation of the full carbon skeleton of muamvatin using aldehyde (±)-
138b and its deprotection studies 
Applying the above method to the aldol reaction of aldehyde (±)-138b with 
ketone 129 gave an inseparable 5:1 mixture of two diastereomeric aldol adducts 143 in 
good yield (Scheme 2.8). The configuration of the major product was assumed to be 8-
10-anti-10,11-anti in analogy to the major adduct 141 obtained in the model study 
(Scheme 2.7). Obtaining aldol adduct 143 in reasonable yield provided an avenue for 
further investigation because the diene moiety of the fully assembled carbon skeleton was 
protected from reduction under Raney Ni conditions needed for 
desulfurization/debenzylation. 
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Scheme 2.8 Assembly of the full carbon skeleton using aldehyde (±)-138b 
 
a) tBuLi, -78 ºC then (±)-138b 
In order to effectively utilize 143, the C11-OH needed to be orthogonally 
protected with respect to the benzyl groups at C3, C5 and C7 positions so as to allow 
chemoselective oxidation of the OH groups at C3 and C7. Fortuitously, the C11-OH 
showed very high resistance towards protection even with small protecting groups such 
as acetate. This observation implied that the iron carbonyl moiety acted as a protecting 
group for both the diene and the C11-OH. In the ideal case, debenzylation and 
desulfurization of 143 should form the desired hemiacetal 146 (Scheme 2.9), ready for 
further oxidation state manipulation with the C11-OH group protected by the adjacent 
Fe(CO)3 group. 
Treatment of 143 with Raney Ni successfully desulfurized the fully assembled 
carbon skeleton revealing all methyl groups at C4, C6, C8, and C10 (Scheme 2.9). 
Concomitantly, hydrogenolysis of benzyl ethers also occurred revealing the hydroxyl 
groups at C3, C5 and C7 positions without affecting the diene portion of the molecule. 
Unfortunately, instead of the desired hemiacetal 146, the only product isolated from the 
reaction mixture was the bicyclic acetal 145. 
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Scheme 2.9 Desulfurization and debenzylation of 143 
 
The undesired result of the reaction of 143 with Raney Ni required a careful 
analysis of the bicyclic ring system in product 145 to understand the problem in hand. 
Perhaps, conditions could be found to hydrolyze the bicyclic ring system 145 to the 
desired hemiacetal 146. In this regard, the model compound 151a was prepared by Raney 
Ni desulfurization of the triol ketal 121 followed by treatment with aqueous acid 
(Scheme 2.10). A plausible expectation from this reaction was to obtain the desired 
hemiacetal 149 that has a favorable anomeric effect at C9, a stabilizing hydrogen bond 
between the C3-OH and C9-OH, and most of the substituents on the six-membered ring 
in equatorial orientations. Instead, the reaction mixture showed only bicyclic ketal 151a. 
The chair conformation of ring A in bicyclic acetal 151a was established based on the 
large (10 Hz) 3JHH between HC-7 and HC-8 and the medium (5 Hz) 3JHH between HC-7 
and HC-6 observed in the 1H NMR spectrum. The boat conformation for ring B was 
suggested by the large (10 Hz) 3JHH between HC-3 and HC-4.  
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Scheme 2.10 Preparation of the bicyclic model system 151a 
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a) Raney Ni, EtOH, reflux; b) HCl, H2O/THF, rt. 
The stability of the bicyclic acetal 151a was tested by exposure to different acidic 
conditions (Scheme 2.11); however, only starting material was harvested from the 
reaction mixtures. In hope of destabilizing the bicyclic ketal 151a, the configuration of 
hydroxyl group at C7 was inverted by oxidation followed by reduction to give 151b. 
However, as with 151a, exposure of 151b to various acidic conditions failed to produce 
detectable amounts of hemiacetal 7-epi-149. Unfortunately, the synthetic strategy 
outlined in Scheme 2.1 failed.  
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Scheme 2.11 Preparation and stability of 7-epi-151a 
 
a) IBX, THF/DMSO; b) NaBH4, MeOH; c) H+, H2O/THF under various 
conditions. 
2.2.4  Summary and conclusion 
So far, the fully assembled carbon skeleton of muamvatin has been completed 
twice (having the diene portion protected and unprotected) via application of the 
thiopyran route to polypropionates. Although muamvatin was not synthesized by these 
routes, they do show the effectiveness of this strategy for achieving fast and 
stereoselective assembly of polypropionate motifs. It was also shown that the Fe(CO)3 
moiety can act as an efficient protecting group for diene systems during reductive 
desulfurization conditions (i.e., Raney Ni). However, the inherent tendency of the 
trihydroxy ketone moiety of 144 to spontaneously form bicyclic acetal 145 could not be 
suppressed and this route was abandoned. 
2.3 Synthesis of muamvatin, part 2: the ‘acyclic’ route 
As previously shown (Scheme 2.1), obtaining intermediate 126 is crucial to the 
planned total synthesis of muamvatin. Unfortunately, the tendency of ketone 144 to 
spontaneously form the bicyclic acetal 145 instead of the desired hemiacetal 146 resulted 
in a dead end for that route (Scheme 2.9). Although formation of the desired hemiacetal 
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150 from the bicyclic system 151a also failed (Scheme 2.10), modifications of the initial 
strategy (Scheme 2.1) offered some potential to solve the encountered problem. 
Considering the preparation of the linear precursor  (8R)-114a from ketone triol 
153, the configurations of the three stereogenic centers at C3, C7, and C8 are variable 
(Figure 2.6). This is because the C3 and C5 stereogenic centers are not present in 
muamvatin and the configuration at C8 is readily epimerizable and can be established 
under thermodynamic control. In the previous route, the tris-hydroxy ketone 155 had the 
substituents at C3, C5 and C8 with a syn relative configuration which ultimately led to 
spontaneous formation of the bicyclic compound 156. The configurations of these three 
stereogenic centers presumably play an important role in the facility of this cyclization of 
the starting triol ketone 155. Considering the triol ketone 154 as a simpler model of 153 
(Figure 2.6), eight diastereomers are possible by varying the relative configurations of 
the stereogenic centers at C3, C7, and C8.  
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Figure 2.6 Looking back to the previous strategy 
Simple molecular mechanics calculations, employing Spartan software,∗ on the 
eight bicyclic acetals 151a-h suggested that the ground state energies for the eight 
possible diastereomers are very different (Figure 2.7). Consistent with the experimental 
results, the (3R,7S,8R) diastereomer, 151a, was by far the most stable diastereomer. 
Hoffmann et al. observed formation of 151b33 (the second most stable bicyclic acetal) 
from (3S,7S,8R)-154 under acidic conditions. However, Paterson et al. did not observe 
any sign of closely related bicyclic acetal 151d in their approach to the total synthesis of 
muamvatin.31 Based on these observations, it was hypothesized that the higher the ground 
state energy of the bicyclic system, the lower the facility of its undesired formation. Out 
of eight diastereomeric forms, the two diastereomers 151f (3S,7R,8S) and 151h 
                                                 
∗
 All calculations were performed using the software Spartan ’08 V 1.2.0 for Microsoft Windows from 
Wave function, Inc. The calculations represent the ground state energy of the most stable conformer as 
determined using Molecular Mechanics/MMFF (Merck Molecular Force Field) model. 
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(3S,7S,8S) showed the highest ground state energies. Based on their relative ease of 
preparation, the linear precursor (3S,7R,8S)-154 was targeted for synthesis in a 
modification of the previous strategy. 
 
 
Figure 2.7 All possible diastereomeric forms of 151 in bicyclic form 
2.3.1 Revised synthetic analysis 
The assembly of the full carbon skeleton was envisioned through stereoselective 
aldol reactions of the two achiral aldehydes 86 and 73 with enantiomerically pure ketone 
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157 (Scheme 2.12). In this approach, using the acyclic ketone 157 avoids complication of 
chemoselectivity during the desulfurization process with respect to competitive reduction 
of the diene moiety as observed in the previous route (see Section 2.2.2). To form the 
triol ketone (3S,7R,8S)-154, stereoselective aldol reaction of ketone 157 with propanal 
(86) followed by stereoselective reduction of the C5 carbonyl in adduct 158 and 
protecting group manipulation would provide the ketone 161. Finally, a stereoselective 
aldol reaction of ketone 161 with diene aldehyde 73 would produce the complete 
muamvatin carbon skeleton.  
Proper manipulation of protecting groups is essential for the success of this 
synthetic plan.  Not only must the P1 and P2 protecting groups be orthogonal to each other 
but also they need to survive the conditions required for deprotection of the C9 ketal 
moiety. Selective removal of the P1 protecting groups in 162 followed by oxidation of the 
hydroxyl groups at C3 and C7 would provide the fully functionalized carbon backbone 
161. Finally, the P2 and P3 protecting groups in compound 161 must be removed under 
mild conditions so as not to affect the sensitive functionalities needed to form the 
trioxaadamantane ring system (Scheme 2.12). If necessary, the P3 protecting group could 
be removed after formation of the trioxaadamantane ring system to avoid any destructive 
interference from other functionalities on the molecule. 
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Scheme 2.12 Revised synthetic strategy 
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2.3.2 Model studies on diastereoselective aldol reaction of the acyclic 
ketone (-)-164 
As discussed in the previous section, the carbon skeleton 162 is envisioned to 
result from two stereoselective aldol reactions between the two achiral aldehydes 86 and 
73 with the masked hydroxydiketone 157 (Scheme 2.12). The aldol reaction of ketone 
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157 with propanal (86) must proceed with selective addition to the (Z)-enolate re face 
with syn aldol relative topicity to form the desired adduct 159. On the other hand, the 
aldol reaction of diene aldehyde 73 with ketone 161 must proceed by selective addition to 
the (E)-enolate re face with anti relative topicity to give the desired adduct 162. At this 
stage, it was considered prudent to establish the conditions needed to obtain the desired 
stereoselectivities in these aldol reactions using model compounds. 
2.3.2.1 The syn-syn aldol reaction of ketone (-)-164 with propanal (86)  
The readily available (+)-O-TES-9a5 (ref. Figure 2.2) was transformed to ketone 
(-)-164 (Scheme 2.13). With ketone (-)-164 in hand, the syn selective aldol reaction with 
propanal (86) could be attempted. Literature precedent suggests that the (Z)-boron 
enolates, prepared by reaction of a 2-alkyl ethyl ketones with 9-BBNOTf and iPr2EtN, 
react with aldehydes to give adducts with 1,3-syn methyl groups and syn aldol relative 
topicity.55,56 The (Z)-boron enolate of ketone (-)-164 was prepared by adapting the 
conditions used in previous research by Paterson et al.55 and treated with propanal (86) to 
give aldol adduct (+)-165 in 62% yield and high diastereoselectivity (>20:1 dr by 1H 
NMR of the crude product). In order to establish the relative configuration of newly 
formed stereogenic centers, the carbonyl group at C5 was reduced with LiAlH4 and the 
resulting diol was protected as the acetonide 167 (Scheme 2.13). The 13C NMR spectrum 
of 167 showed methyl signals at 20 and 30 ppm establishing the 3,5-syn relative 
configuration in 167.57 The key 3,4-syn relative configuration in compound 167 (i.e., 
from syn aldol relative topicity) was established based on the small coupling constants 
(3JHH= 2 Hz) observed between HC3-HC4 and HC4-HC5 in the 1H NMR spectrum of 
167. 
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In order to establish the relative configuration at C4 and C6 (i.e., from the enolate 
diastereoface selectivity in the aldol reaction), the regioisomeric acetonide 169 was 
prepared as outlined in Scheme 2.13. The 13C NMR spectrum of 169 showed the two 
acetonide methyl groups at ca. 20 and 30 ppm establishing a 5,7-syn relative 
configuration57 and, considering the already established 6,7-syn and 4,5-syn relative 
configurations, indicated the presence of a 4,6-syn relative configuration in 169. Thus, the 
adduct (+)-165 results from an aldol reaction with syn relative topicity to re diastereoface 
of the (Z)-enolate of (-)-164, as was required by the synthetic plan. 
Scheme 2.13 Stereoselective aldol reaction of (-)-164 with propanal (86) 
 
a) Raney Ni, EtOH, Reflux; b) 9-BBNOTf, Et3N, -78 ºC then 86; c) LiAlH4; d) 
3,3-dimethoxypropane, PTSA; e) TBAF; f) Et3SiOTf, 2,6-lutidine,0 ºC. 
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2.3.2.2 The model syn-anti aldol reaction of ketone (-)-164 with diene aldehyde 73 
As mentioned previously (Section 2.3.1), the carbon skeleton of muamvatin was 
envisioned to result from stereoselective aldol reaction of enantiomerically pure ketone 
161 with diene aldehyde 73. The desired aldol adduct 162 would result from addition to 
the re face of (E)-enolate of 162 with anti aldol relative topicity. It is known that (E)-
boron enolates prepared by reaction of 2-alkyl ethyl ketones with (Chx)2BCl and Et3N 
reacts with various aldehydes to give the desired selectivity.58-60 In order to test whether 
the above analysis was valid, ketone (-)-164 (a closely related analogue to ketone 161) 
was treated with (Chx)2BCl and Et3N followed by addition of diene aldehyde 73 to give 
the aldol adduct 170. Stereoselective reduction of 172 with DIBAL-H followed by 
acetonide protection of the resulting diol 171 (>20:1 dr) gave 172 (Scheme 2.14). The 
13C NMR spectrum of 172 showed acetonide methyl groups at ca. 20 and 30 ppm 
establishing a 7,9-syn relative configuration.57 The anti relative configuration between 
hydroxyl group at C7 and methyl group at C8 was established based on the magnitude of 
coupling constants for the vicinal hydrogens at C7 and C8 (3JHH= 10 Hz) observed in the 
1H NMR spectrum of 172. The relative configuration of the methyl groups at C8 and C10 
was determined to be syn based on NOE experiments on alcohol 173 prepared by 
treatment of 172 with TBAF. A positive NOE was detected on CH3-C8 upon irradiation 
of the C10 methine hydrogen (Scheme 2.14). Similarly, irradiation of the C10 methyl 
group gave a positive NOE on the C9 hydrogen. Together, these NMR studies confirmed 
the relative configuration of the model aldol adduct 170 as shown in Scheme 2.14. 
At this stage, with the viability of the two key stereoselective aldol reactions 
confirmed, a plausible path to form the carbon skeleton of muamvatin was in hand. 
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Scheme 2.14 Aldol reaction of 73 with the (E)-boron enolate of ketone (-)-164 
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a) (Chx)2BCl, Et3N; b) DIBAL-H, -78ºC; c) 3,3-dimethoxypropane, PTSA; c) 
TBAF, THF, RT. 
2.3.3 Stereoselective reduction of ketone (+)-165 and preparation of the 
tris-allyl ketone 188 
With the desired aldol adduct (+)-165 in hand, stereoselective reduction of the C5 
ketone was attempted. Despite numerous attempts using various known methods for 
directed hydride delivery, such as NaBH4, Zn(BH3)2, or NaBH(OAc)3,61-63no sign of 
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desired diol 174 was observed and the starting ketone (+)-165 was recovered from the 
reaction mixture (Scheme 2.15). 
Scheme 2.15 Attempts on stereoselective reduction of ketone (+)-165 
 
a) NaBH4, Zn(BH4)2, or NaBH(OAc)3 under various conditions. 
 In an alternative approach, the C3 hydroxy group of (+)-165 was protected as its 
triethylsilyl ether to form 175. Reaction of ketone 175 with super hydride (LiEt3BH) 
formed the desired alcohol 176 in good diastereoselectivity (7:1 dr) (Scheme 2.16). After 
hydrolysis of the silyl ethers, the major diastereomer was transformed into an inseparable 
3:1 mixture of acetonides 177 and 178. Analysis of the 13C NMR spectrum for this 
mixture showed a pair of acetonide methyl groups at ca. 25 ppm for both isomers 
strongly suggesting a 3,5-anti-5,7-anti relative configuration in the precursor 176.57 Thus, 
protecting the C3 hydroxyl group in aldol adduct (+)-165 not only facilitated the 
stereoselective reduction of ketone 175 but also provided an opportunity for orthogonal 
protection of the C5 hydroxy group in compound 176 as previously discussed (Section 
2.3.1, Scheme 2.12).  
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 Scheme 2.16 Stereoselective reduction of (+)-165 
 
a) Et3SiCl, imidazole, DMF; b) LiEt3BH, 0 ºC to RT; c) TBAF; d) 3,3-
dimethoxypropane, PTSA. 
Allyl ether was chosen as an appropriate protecting group. Reaction of 176 with 
KHMDS followed by addition of allylbromide gave the allyl protected compound 180 as 
the only product isolated instead of the desired 181 (Scheme 2.17). Presumably the 
presence of two triethylsilyl ether groups at C3 and C7 prevented the alkylation of the 
alkoxide group at C5 and a 1,5 silyl migration became the favored pathway. Failing to 
selectively protect the C5-OH group in compound 176, required a few changes in the 
synthetic plan to address this issue (Scheme 2.18).  
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Scheme 2.17 1,5-Silyl migration and allyl protection of 176 
 
a) KHMDS/DMPU then allyl bromide. 
The two silyl protecting groups in 176 can be removed to make triol 182 (Scheme 
2.17). Protection of the triol 182 with a group orthogonal to the ketal will allow formation 
of ketone 184. Stereoselective aldol reaction of 184 with aldehyde 73 will form aldol 
adduct 185 that can be protected with a group different from P1. The ability to remove the 
P1 protecting groups under mild condition is crucial in order to form the desired 
hemiacetal 186. Formation of the key hemiacetal 186 internally protects the C5-OH 
group and allows chemoselective oxidation of the hydroxyl groups at C3 and C7 thereby 
leading to the fully functionalized carbon skeleton of muamvatin. Finally, removal of the 
P2 protecting group under mild conditions would provide the desired precursor to study 
the formation of the trioxaadamantane ring system and complete the synthesis of 
muamvatin (Scheme 2.17). 
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Scheme 2.18 Alternative avenue in the synthetic strategy  
OH O
OO
O
3 5 7
TESTES
176
OH OH
OO
OH
3 5 7
182
OP1 OP1
OO
OP1
3 5 7
183
OP1 OP1OP1
3 5 7
184
a
protection
deprotection
O
1. stereoselective aldol with #
2. protection
O
OP1 OP1OP1
3 5 7
185
O OP2 73
O
H OH
OP2OH
186
OH
1. deprotection of P1
2. oxidation
1. oxidation
2. deprotection of P2
3. cyclization
muamvatin (30)
77%
3
5
7
 
a) TBAF, THF, RT. 
As mentioned previously, the choice of the P1 protecting group is essential to the 
success of this approach. Recently, a new catalyst was introduced by Kitamura et al. for 
efficient removal of allyl ethers under mild conditions.64 Very low loading (<1 mol%) of 
the Ru(IV) catalyst 190 in a protic solvent was sufficient to remove different types of 
allyl ethers at ambient temperature. More importantly, catalyst 190 showed high 
chemoselectivity towards allyl groups without any destructive affect on alkynes, alkenes, 
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or aromatic rings.65 To test the efficiency of this catalyst, tris-allyl ketal 187 was prepared 
which then upon exposure to FeCl3·6H2O formed ketone 188 quantitatively (Scheme 
2.19). Ketone 188 is the tris-allyl derivative of (3S,7R,8S)-154 (Figure 2.7). At this stage, 
it was worthwhile to examine the hypothesis discussed previously (Section 2.3) and test 
the susceptibility of (3S,7R,8S)-154 towards formation of the bicyclic compound 151f 
(Scheme 2.19). The allyl groups in ketone 188 were removed under very mild conditions 
(2 mol% of catalyst 190 at 30 ºC) and the product was immediately subjected to IBX 
oxidation to give diketone 189 in good yield. This experiment demonstrated that 
formation of a bicyclic acetal was not especially facile for (3S,7R,8S)-154 and that 
chemoselective oxidation via the hemiacetal was possible for this diastereomer. 
 
Scheme 2.19 Preparation of ketone 188 
    
a) KHMDS, DMPU then allyl bromide, -78 ºC to rt; b) FeCl3·6H2O; c) 190, 
(2mol%), MeOH, 30 ºC; d) IBX, DMSO/THF. 
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2.3.4 Assembly of the full carbon skeleton  
With ketone 188 and aldehyde 73 in hand, an aldol reaction to couple these 
reactants could be attempted. Treatment of ketone 188 with (Chx)2BCl and Et3N gave the 
putative (E)-enol borinate 191 that after addition of diene aldehyde 73 gratifyingly gave a 
81% yield of predominantly one aldol adduct 192 (>20:1 dr, judged by 1H NMR 
spectroscopy) (Scheme 2.20). It was assumed that 192 had the indicated relative 
configuration, based on the results obtained in the model reaction (Scheme 2.14).  
Scheme 2.20 Stereoselective aldol reaction of ketone 188 with aldehyde 73 
 
a) B(Chx)2Cl, Et3N then 73. 
2.3.5 Deallylation studies on the fully assembled carbon skeleton 192 
With aldol adduct 192 in hand, the oxidation of both hydroxyl groups at C3 and 
C7 could be tried. In order to manipulate the oxidation state of the fully assembled carbon 
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skeleton 192, protection of the hydroxyl group at C11 and deprotection of the hydroxyl 
groups at C3, C5, and C7 were attempted.  
 The C11-OH group was first protected as the triethylsilyl ether 193a (Scheme 
2.21). Exposure of ketone 193a to a catalytic amount of Ru(IV) complex 190 in methanol 
gave bicyclic compound 194a as the only product. Deprotection of triethylsilyl ether 
moiety as well as elimination of the allyl ether at C7 suggested that 193a was very 
sensitive to the deallylation conditions. Subsequently, the C11-OH group was protected 
as the acetate 193b. However, subjecting 193b to the deallylation conditions, gave 
bicyclic acetal 194b (Scheme 2.21). Despite extensive experimentation on the 
deallylation step, the only fully deprotected products obtained were the bicyclic acetals 
194a and 194b. It was uncertain whether the elimination reaction leading to 194a/194b 
occurred before the deallylation of the C7-OH (i.e., elimination of H-O-allyl) or after 
deallylation (i.e., elimination of H-OH). It was decided to conduct the deallylation-
cyclization process in a stepwise manner. Thus, protection of the C9 ketone moiety 
would prevent the formation of a hemiacetal and disfavor elimination without affecting 
the deallylation process. The desired protecting group must survive the deallylation 
process and should be removable under mild condition without affecting the resulting 
triol. The O-trimethylsilyl-cyanohydrin (O-TMS cyanohydrin) was chosen as a suitable 
protecting group (Scheme 2.22).  
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Scheme 2.21 Deallylation of the fully assembled carbon skeleton  
   
a) Et3SiOTf, 2,6-lutidine; b) AC2O, DMAP, DIPEA; c) 190, (2mol%), MeOH, 30 
ºC.  
A number of methodologies have been developed over the years to protect 
ketones as their O-trimethylsilyl-cyanohydrin. Some of these methods are based on using 
TMSCN with Lewis acids such as Yb(CN)3,66 Yb(OTf)3,67 Eu(fod)3,68 MgAlCO3,69 while 
others rely on nucleophilic addition of cyanide to carbonyl moieties such as KCN, 18-
crown-6/Me3SiCN,70 and Me3SiCN/KCN/ZnI271. Of these methods, nucleophilic addition 
of cyanide ion using the 18-crown-6·KCN catalyst developed by Evans et al.70 followed 
by in situ protection of the resulting cyanohydrin as its trimethylsilyl ether was promising 
and with optimization gave a reasonable yield of 196 as a 1.4:1 mixture of diastereomers 
(Scheme 2.22). 
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Scheme 2.22 Protection of the ketone moiety in 193b 
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a) TMSCN, 18-crown-6·KCN, rt. 
Successful deallylation of 196 formed a diastereomeric mixture of triol 198 with 
no sign of formation of 194b (Scheme 2.23). Removal of the O-trimethylsilyl-
cyanohydrin under mild conditions revealed the ketone 198a. Surprisingly, the desired 
hemiacetal 198b was not thermodynamically favored (198a:198b, 3:1). Thus, the 
resulting mixture was not synthetically useful for chemoselective oxidation. 
Not being able to get the hemiacetal 198b as the more thermodynamically stable 
tautomer was very disappointing at this stage. Conformational analysis of the desired 
hemiacetal 198b revealed a strong steric interaction between the dienyl group and the 
oxygen atom of the hemiacetal ring system. This interaction presumably favors triol 
ketone 198a (opened form) over 198b (closed form) despite the latter having all possible 
substituents in equatorial orientation (Scheme 2.23).  
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Scheme 2.23 Formation of the ketone triol 198  
 
a) 190, (2mol%), MeOH, 30 ºC; b) HF·Py/Py, H2O (cat.); c) H2O/MeOH, reflux. 
2.3.6 Chemoselective oxidation and the end game 
Comparison of the triol ketone 198a with compound 114b (see Figure 2.1) 
revealed the only difference between the two structures was the oxidation state of 
hydroxyl groups at C3 and C7. Unfortunately, achieving that transformation was 
complicated because the internal protection of C5-OH via hemiacetal ring formation was 
not favored (Scheme 2.23). Experiments aimed at assessing possible protection schemes, 
showed a very clear differential reactivity among the three hydroxyl groups in the 
diastereomeric mixture of triol 197 (Scheme 2.24). Stepwise triethylsilyl ether protection 
of 197 gave alcohol 199 indicating highly selective reaction of the C3 and then the C7 
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hydroxyl groups in preference to the C5 hydroxyl. This remarkable result suggested a 
possible direct solution to the desired transformation (chemoselective oxidation of C3, 
and C7 over C5).  
Scheme 2.24 Chemoselective oxidation/protection of triol 197 
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a) Et3SiOTf, 2,6-lutidine; b) (COCl)2, DMSO, Et3N. 
Swern oxidation of triol 197 resulted in a diastereomeric mixture of hydroxy 
diketone 200 (1.2:1 dr) in excellent yield considering the situations (Scheme 2.24). 
Taking into account the selective formation of 199 and the mechanism of Swern 
oxidation,72 this result is rationalized by the formation of intermediate 201 as the 
kinetically favored species which upon addition of the base gives the desired hydroxy 
diketone 200 (Scheme 2.25).  
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Scheme 2.25 Proposed mechanism for the chemoselective oxidation of 197 
  
According to the synthetic plan (Scheme 2.12), removal of both O-trimethylsilyl-
cyanohydrin and acetate ester protecting groups from the diastereomeric mixture of 200 
should form the desired linear precursor 114a that can be used in further cyclization 
studies. Unfortunately, all efforts to remove acetate ester at C11-OH led to decomposition 
of the starting material. Since the removal of the acetate group was not successful, 
removal of the O-trimethylsilyl-cyanohydrin moiety should lead to O-acetate-C11-114b 
(R = Ac) that has all the necessary functionalities to form the desired trioxaadamantane 
ring system. Subsequent removal of the acetate moiety after formation of the 
trioxaadamantane should give the desired natural product muamvatin (30).  
Hydrolysis of the trimethylsilyl group with HF·pyridine gave a diastereomeric 
mixture of compounds that was not characterized, but was immediately subjected to a 
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slurry of chromatography silica gel in ethyl acetate to remove the cyanohydrin moiety 
(Scheme 2.26). Interestingly, a mixture of two C8-epimeric forms of the 114b (R = Ac) 
was produced (ca. 65% of the mixture; identified by two quartets at ca. δH 4.02 and 4.00 
ppm and signals at δC 59.9 and 61.8) with small amounts of enol (ca. 14% of the mixture; 
identified by the signal at ca. δH 16.97 ppm) and hemiacetal (ca. 10% of the mixture; 
identified by the signal at ca. δH 4.99 ppm and acetal carbon at δC at 105.0 ppm) (Figure 
2.8). The diastereomeric mixture 202 was remarkably stable to silica gel chromatography 
and remained intact while stored in CDCl3 at room temperature for several days. 
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Scheme 2.26 Preparation of the precursor 202  
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a) HF·Py/Py, H2O (cat.); b) SiO2, EtOAc; c) HF·Py/Py, H2O (cat.); d) DIBAL-H, 
THF, -78 ºC. 
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Figure 2.8 1H NMR spectrum of 202 
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Figure 2.9 13C NMR spectrum of 202 
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Looking back to the earlier studies in formation of the trioxaadamantane ring 
system (Section 1.4) suggested several different mild conditions. Based on the previous 
work by Paterson et al.31, subjecting the diastereomeric mixture 202 to chromatography 
silica gel (Merck kieselgel 60 F254) for 18 hours did not form the desired 
trioxaadamantane ring system and resulted in full recovery of the starting material. 
However, exposing the diastereomeric mixture 202 to imidazole in CDCl3 as suggested 
by Ward et al.73 changed the ratio between tautomers (ca. the hemiacetal ratio increased 
to 40% of the reaction mixture after 5 days), it did not result in formation of the desired 
trioxaadamantane ring system 203. Subsequently, treatment of 202 with HF·pyridine as 
reported by Hoffmann et al.33 for 10 days at ambient temperature resulted in formation of 
the desired trioxaadamantane ring system 203 (46%) as the predominant component in 
the reaction mixture (ca, 50% conversion by 1H NMR of the crude reaction mixture). Re-
treatment of the recovered starting material under the same reaction conditions provided 
an additional amount of 203 (69% after two cycles) along with recovered 202 (21%) 
(Scheme 2.26). Finally, removal of the acetate protecting group with DIBAL-H, cleanly 
produced muamvatin (30) ([α]D +60; c 0.13, CH2Cl2), that gave spectroscopic data (MS, 
IR, 1H and 13C NMR) (Tables 2.1 and 2.2) that matched perfectly with those reported30 
for isolated ([α]D +61.1; c 0.175 CH2Cl2) and synthetic31 ([α]D +62; c 0.08 CH2Cl2) 
muamvatin (30). 
Interestingly, exposure of muamvatin (30) to reaction conditions such as 
HF·pyridine (conditions used to form the trioxaadamantane ring system) for twenty days 
at ambient temperature or to imidazole for ten days at 40 ºC in CDCl3 did not show 
equilibration to any other possible tautomers of precursors 114a (114a = (8R/S)-ent-71) 
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(see Figure 1.13). Such observations suggest that muamvatin is the most 
thermodynamically stable tautomer from 114a consistent with the calculations.29 Thus, 
the formation of the trioxaadamantane ring system is likely to be governed by an enzyme-
mediated process rather than an artifact of isolation.  
Table 2.1 13C NMR (CDCl3) comparison of natural and synthetic muamvatin 
  
Naturala 
δC (ppm)b Assignment 
Synthetic 
δC (ppm) 
5.8 
29.9 
102.1 
37.7 
78.7 
43.0 
97.5 
35.0 
105.2 
40.7 
79.4 
134.6 
132.7 
131.6 
132.1 
21.4 
14.1 
16.7 
12.3 
10.4 
6.6 
13.2 
C-1 
C-2 
C-3 
C-4 
C-5 
C-6 
C-7 
C-8 
C-9 
C-10 
C-11 
C-12 
C-13 
C-14 
C-15 
C-16 
C-17 
CH3C-14 
CH3C-12 
CH3C10 
CH3C-8 
CH3-C4 or CH3C-6 
6.1 
30.1 
103.2 
37.8 
78.8 
43.1 
97.7 
35.2 
105.4 
40.9 
79.6 
134.7 
132.9 
131.7 
132.3 
21.6 
14.4 
16.9 
12.5 
10.6 
6.9 
13.41 aData from Ireland et al.(ref. 45), bChemical shifts for synthetic material are 
consistently 0.2-0.3 ppm higher than those reported for the natural product 
presumably due to a different reference standard; we used δc CDCl3 = 77.23. 
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Table 2.2 1H NMR (CDCl3) comparison of natural and synthetic muamvatin 
  
aData and assignment according to ref. 45 
 
Naturala 
 
  
Synthetic 
 
δH (ppm) Multiplicity J (Hz) Assignment δH (ppm) Multiplicity J (Hz) 
0.96 
1.69-1.56 
1.18 
1.69 
1.69 
3.88 
1.15 
1.97 
1.97 
 
2.10 
2.10 
1.03 
0.73 
4.40 
 
1.76 
5.87 
1.72 
5.32 
0.98 
t 
dq 
d 
dq 
q 
br s 
d 
q 
dq 
 
dq 
q 
d 
d 
d 
 
s 
br s 
s 
br t 
t 
7.46 
14.34, 7.46 
7.93 
14.34, 7.46 
6.93 
 
7.03 
7.03 
9.02, 7.18 
 
7.19, 7.52 
6.74 
6.74 
7.18 
9.02 
 
 
 
 
7.19 
7.52 
H3C-1 
HC-2 
H3CC-4 
HC-4, HC-2 
 
HC-5 
H3CC-6 
HC-6, HC-10 
 
HOC-7 
HC-8, H2C-16 
 
H3CC-8 
H3CC-10 
HC-11 
HOC-11 
H3CC-12 
HC-13 
H3CC-14 
HC-15 
H3C-17 
0.95 
1.59-1.51 
1.18 
1.70-1.65 
 
3.88 
1.14 
2.00-1.92 
 
2.59 
2.13-2.05 
 
1.03 
0.72 
4.40 
4.38 
1.76 
5.87 
1.72 
5.31 
0.98 
t 
m 
d 
m 
 
br s 
d 
m 
 
br s 
m 
 
d 
t 
d 
br s 
br s 
s 
br s 
br dd 
t 
7.5 
 
7 
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7 
7 
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7,7 
7.5 
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2.4 Summary and conclusion  
In summary, muamvatin was synthesized in 14 linear steps starting from readily 
available (-)-164 in 5.3% overall yield (Figure 2.9). This is the first successful synthesis 
of muamvatin via cyclization of the fully assembled carbon skeleton of the linear 
precursor to the desired trioxaadamantane ring system. In this approach, two substrate-
controlled stereoselective aldol couplings of ketone (-)-164 and two achiral aldehydes 86 
and 73 produced three of the six stereogenic centers existing in muamvatin backbone 
114b (C3, 10, 11; >20:1 dr). The crucial stereogenic center at C5 resulted from an 
unusual diastereoselective reduction of 175 using super hydride (7:1 dr). The C6 
stereogenic center existed in the starting ketone (-)-164, that was prepared form ketone (-
)-9a in three steps and 67% yield. Moreover, this synthesis is the first example of the use 
of allyl ethers as viable protecting groups with mild removal using a ruthenium based 
catalyst 190 in the presence of other sensitive functionalities. The chemoselective double 
Swern oxidation reaction to overcome the oxidation state manipulation problem on the 
fully assembled carbon skeleton of muamvatin precursor is noteworthy.  
Despite the failure encountered in the attempted formation of acyclic precursor 
114a and studying its cyclization modes, precursor 202 was successfully cyclized to the 
desired trioxaadamantane 203. Regarding the conditions used to form the desired 
trioxaadamantane ring system (exposure to HF·pyridine for 10 days) suggested that the 
formation of such trioxaadamantane ring system is not a facile process that could readily 
happen under the conditions used for isolation, such as exposure to silica gel or different 
solvent systems; but, it might be the result of an enzymatic process.  
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Figure 2.10 Summary of the synthetic route 
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3. EXPERIMENTAL 
3.1 General methods 
Anhydrous solvents were distilled under argon atmosphere as follows: 
Terahydrofuran (THF) and diethyl ether from benzophenone sodium ketyl; CH2Cl2 from 
CaH2; MeOH from Mg(OMe)2; dimethyl sulfoxide (DMSO) from CaH2. All experiments 
involving air and/or moisture sensitive compounds were conducted either in an oven 
dried round-bottle flask capped with a rubber septum, and attached via a needle and 
connecting tubing to an argon manifold equipped with mercury bubbler (ca. 5 mm 
positive pressure of argon) or in a Schlenk flask capped with a rubber stopper, and 
attached via connecting tubing to an argon manifold equipped with mercury bubbler (ca. 
5 mm positive pressure of argon). Low temperature baths were: ice/water (0 ºC), 
CO2/CH3CN (-50 ºC), and CO2(s)/acetone (-78 ºC). Unless otherwise noted, reaction 
temperatures refer to that of the bath. 
Preparative TLC (PTLC) was carried out on glass plates (20×20 cm) pre-coated 
(0.25 mm) with silica gel 60 F254. Materials were detected by visualization under an 
ultraviolet lamp (254 nm) and/or by treating a 1 cm vertical strip removed from the plate 
with a solution of phosphomolybdic acid (5%) containing a trace of ceric sulfate in aq 
sulfuric acid (5% v/v), followed by charring on a hot plate. TLC was carried out on glass 
plates (1×3 cm) pre-coated (0.25 mm) with silica gel 60 F254 and was visualized in the 
same manner as that described for PTLC.  
Concentration refers to removal of volatiles with a rotary evaporator under 
vacuum supplied by a water aspirator. Evacuation at ca. 0.5 torr with a vacuum pump 
generally followed rotary evaporation. 
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Flash column chromatography (FCC) was performed according to Still et al.74 
with Merck silica gel 60 (40-63 µm). All mixed solvent eluents are reported as v/v 
solutions. Unless otherwise noted, all reported compounds were homogeneous by thin 
layer chromatography (TLC) and by 1H NMR spectroscopy.  
Spectral data 
High resolution mass spectra (HRMS) and low resolution mass spectra (LRMS) 
were obtained on a VG 70E double focusing high resolution spectrometer; only partial 
data are reported. Alternatively, HRMS was obtained on a LC-MS/MS time-of-flight 
high resolution spectrometer with electrospray ionization (ESI) from acetonitrile solution. 
IR spectra were recorded on a Fourier transform interferometer using a diffuse 
reflectance cell (DRITF) or by casting a thin film from CDCl3 solution onto a KBr disc; 
only diagnostic and/or intense peaks are reported. Unless otherwise noted all experiments 
used DRITF.  
Unless otherwise noted, NMR spectra were measured in CDCl3 solution at 500 
MHz for 1H and 125 MHz for 13C. Signals due to the solvent (13C NMR spectroscopy) or 
residual protonated solvent (1H NMR spectroscopy) served as the internal standard: 
CDCl3 (7.26 δH, 77.23 δC); C6D6 (7.16 δH, 128.39 δC). The 1H NMR chemical shifts and 
coupling constants were determined assuming first-order behavior. Multiplicity is 
indicated by one or more of the following: s (singlet), d (doublet), t (triplet), q (quartet), 
m (multiplet), br (broad), ap (apparent); the list of coupling constants (J) corresponds to 
the order of the multiplicity assignment. Coupling constants (J) are reported to the nearest 
0.5 Hz (digital resolution ca. 0.2 Hz/pt) or the nearest 0.1 Hz (digital resolution ca. 0.03 
Hz/pt). The 1H NMR assignments were made based on chemical shift and multiplicity 
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and were confirmed, where necessary, by homonuclear decoupling and/or two-
dimensional correlation experiments (gCOSY, gHSQC, gHMBC). The 13C NMR 
assignments were made on the basis of chemical shift and multiplicity (as determined by 
13C-DEPT or gHSQC) and were confirmed, where necessary, by two-dimensional 1H/13C 
correlation experiments (gHSQC and/or gHMBC). The multiplicity of 13C NMR signals 
refers to the number of attached H’s (i.e., s = C, d = CH, t = CH2, q = CH3).  
Specific rotation ([α]D) are the average of 5 determinations at ambient 
temperature using a 1 mL, 10 cm cell; the units are 10-1 deg cm2 g-1, the concentration (c) 
are reported in g/100 mL, and the values are rounded to reflect the accuracy of the 
measured concentrations (the major source of error). 
Materials 
The following compounds and reagents were prepared as described previously: 
7;2 6,(±)-9a,3 and (+)-O-TES-9a (.98% ee);5 73;32 190;64 140;13 W-2 Raney nickel;75 
IBX;76 TiCl3(OiPr);77 KCN·18-crown-6;70 2,6-lutidine was distilled from CaH2 under 
argon and stored over 4Å molecular sieves; Et3N and iPr2NEt were distilled from CaH2 
under argon atmosphere and stored over KOH; All other reagents were commercially 
available and unless otherwise noted, were used as received.  
Experimental procedures and characterization data 
Spectral data and experimental procedures are presented in order, by compound 
number with the exception of muamvatin (30) that appears at the end. 
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(3R,5S)-rel-3-((S)-Hydroxy((R)-1,4-dioxa-8-thiaspiro[4.5]decan-6-yl)methyl)-5-((S)-
1-hydroxypropyl)tetrahydro-4H-thiopyran-4-one (120) 
 
120 
This procedure was adapted from Ward et al.4 A solution of TiCl3(OiPr) (0.5 M in 
CH2Cl2; 35 mL, 18 mmol) was added over 10 minutes to a stirred solution of (±)-9a (4.90 
g, 16 mmol) in CH2Cl2 (100 mL) at –78 °C. After 10 min, iPr2EtN (2.8 mL, 2.1 g, 16 
mmol) was added slowly to the reaction mixture. After 1 h, propanal (1.2 mL, 0.97 g, 17 
mmol) was added, and after 1 h, iPr2EtN (4.2 mL, 3.1 g, 24 mmol) was added. After 2 h, 
the reaction was quenched by addition of saturated aq NH4Cl (50 mL) with vigorous 
stirring. The cooling bath was removed and the reaction mixture was allowed to warm to 
ambient temperature over 20 min. Celite® (30 g) followed by Et2O (150 mL) were added 
to the mixture (this process cleared the emulsion). After 5 min, the organic (top) layer 
was decanted and filtered through a sintered glass funnel containing a pad of Na2SO4 (20 
g, 2 cm) on top of a pad of Celite® (20 g, 2 cm). The remaining lower layer in the 
reaction vessel was extracted twice with Et2O and twice with ethyl acetate by addition of 
the solvent with stirring followed after 5 min by decanting and filtering as above. The 
combined filtrates were concentrated to give a crude product whose 1H NMR spectrum 
suggested the presence of a 1.5:1 mixture of 120 (>20:1 dr) and (±)-9a, respectively. 
Fractionation of the crude by FCC (40% ethyl acetate in hexane) gave recovered (±)-9a 
(1.5 g, 30%) and the titled compound (3.1 g, 53%). 
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IR (DRITF) νmax: 3521, 1693 cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 4.27 (1H, ddd, J = 6, 6, 7 Hz, HC-1'), 3.99-3.87 (4H, m, 
H2C-2', H2C-3'), 3.71-3.65 (1H, m, HC-1"), 3.24 (1H, ddd, J = 4.5,4.5, 11.5 Hz, HC-3), 
3.10 (1H, dd, J = 11.5, 14 Hz, HC-2), 2.98-2.86 (8H, m, HC-2, HC-5, H2C-6, H2C-7', HO 
×2), 2.74 (1H, ddd, J = 3, 8, 12.5 Hz, HC-9'), 2.63 (1H, ddd, J = 3, 8, 12.5 Hz, HC-9'), 
2.11 (1H, ddd, J = 5, 5.5, 6 Hz, HC-6'), 1.88 (1H, ddd, J = 3, 8, 13 Hz, HC-10'), 1.72 (1H, 
ddd, J = 3, 8, 13 Hz, HC-10'), 1.58 (1H, ddq, J = 4, 14, 7.5 Hz, HC-2"), 1.50 (1H, ddq, J 
= 7, 14, 7.5 Hz, HC-2"), 0.98 (3H, t, J = 7.5 Hz, H3C-3"). 
13C NMR (125 MHz, CDCl3): δ 217.0 (s, C-4), 109.1 (s, C-5'), 72.8 (d, C-1"), 70.1 (d, C-
1'), 64.9 (t, C-2'), 64.3 (t, C-3'), 59.6 (d, C-5), 57.2 (d, C-3), 47.4 (d, C-6'), 36.2 (t, C-2), 
35.5 (t, C-6), 35.1 (t, C-10'), 28.6 (t, C-7'), 27.0 (t, C-2"), 26.8 (t, C-9'), 10.0 (q, C-3"). 
LRMS (EI), m/z (relative intensity): 362 ([M]+, 4), 276 (16), 159 (24), 195 (29), 132 
(71), 116 (10), 99 (100), 86 (18), 54 (30). 
HRMS (EI), m/z calcd for C16H26O5S2: 362.1222; found: 362.1211. 
(3S,4S,5S)-rel-3-((S)-Hydroxy((R)-1,4-dioxa-8-thiaspiro[4.5]decan-6-yl)methyl)-5-
((S)-1-hydroxypropyl)tetrahydro-2H-thiopyran-4-ol (121) 
 
121 
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NaBH4 (611 mg, 16.2 mmol) was added to a stirred solution of 120 (2.93 g, 8.08 
mmol, 0.08M) in THF (85 mL) and methanol (15 mL) at –78 °C. After 1 h, aq NaOH 
(0.4 M; 50 mL) was added and the mixture was allowed to warm to ambient temperature. 
After 1.5 h, the mixture was extracted with CH2Cl2. The combined organic layers were 
dried over Na2SO4, and concentrated to give a crude product (3 g) whose 1H NMR 
spectrum indicated the presence of a 12:1 mixture of alcohols. Fractionation of the crude 
by FCC (20% ether in CH2Cl2) gave the titled compound (2.58 g, 88%). 
IR (DRIFT) νmax: 3467, 3342 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 4.23 (1H, d, J = 9 Hz, HC-1'), 4.15-3.96 (4H, m, H2C-2', 
H2C-3'), 3.68 (1H, ddd, J = 3, 7, 7.5 Hz, HC-1"), 3.67 (1H, dd, J = 9, 9.5 Hz, HC-4), 3.04 
(1H, dd, J = 12, 14 Hz, HC-7'), 2.82 (1H, ddd, J = 2.5, 12.5, 13.5 Hz, HC-9'), 2.68 (1H, 
ddd, J = 2.5, 3.5, 14 Hz, HC-7'), 2.58 (1H, ddd, J = 2.5, 3.5, 13.5 Hz, HC-6), 2.52 (1H, 
dddd, J = 2.5, 3.5, 4, 13.5 Hz, HC-9'), 2.42 (1H, ddd, J = 2.5, 3.5, 14 Hz, HC-2), 2.30 
(1H, dd, J = 12, 13.5 Hz, HC-6), 2.30 (1H, dd, J = 11.5, 14 Hz, HC-2), 2.17 (1H, ddd, J = 
2.5, 4, 14 Hz, HC-10'), 2.08 (1H, br dd, J = 3.5, 12 Hz, HC-6'), 1.96 (1H, dddd, J = 3.5, 
9, 9, 11.5 Hz, HC-3), 1.89 (1H, dddd, J = 3.5, 7, 9.5, 12 Hz, HC-5), 1.72 (1H, ddd, J = 
3.5, 12.5, 14 Hz, HC-10'), 1.61 (1H, ddq, J = 3, 14, 7.5 Hz, HC-2"), 1.43 (1H, ddq, J = 
7.5, 14, 7.5 Hz, HC-2"), 0.98 (3H, t, J = 7.5 Hz, H3C-3"). 
13C NMR (125 MHz, CDCl3) δ 110.7 (s, C-5'), 79.3 (d, C-4), 76.3 (d, C-1'), 74.7 (d, C-
1"), 64.9 (t, C-2'), 64.3 (t, C-3'), 50.1 (d, C-5), 46.7 (d ×2, C-3, C-6'), 36.3 (t, C-10'), 29.5 
(t, C-2), 29.0 (t, C-6), 27.0 (t, C-2"), 26.7 (t, C-9'), 25.7 (t, C-7'), 9.5 (q, C-3"). 
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LRMS (EI), m/z (relative intensity): 364 ([M]+, 25), 346 (22), 302 (27), 195 (29), 284 
(20), 159 (40), 132 (100), 117 (31). 
HRMS (EI), m/z calcd for C16H28O5S2: 364.1378; found: 364.1376. 
 (R)-rel-6-((S)-(Benzyloxy)((3S,4S,5S)-4-(benzyloxy)-5-((S)-1-
(benzyloxy)propyl)tetrahydro-2H-thiopyran-3-yl)methyl)-1,4-dioxa-8-
thiaspiro[4.5]decane (128). 
 
128 
 
A solution of triol 121 (420 mg, 1.15 mmol) in THF (7 mL) was added slowly via 
syringe to a suspension of KH (oil removed by washing with hexane; 150 mg, 3.7 mmol) 
in THF (7 ml) at 0 °C. After 5 min, BnBr (0.68 mL, 5.7 mmol) was added slowly to the 
reaction mixture. The mixture was stirred at 0 °C for 10 min and then allowed to warm to 
ambient temperature. After 1 h (reaction complete by TLC analysis), the reaction mixture 
was cooled to 0 °C and quenched by slow addition of MeOH (1 mL) (Caution: H2 
evolution). The mixture diluted with CH2Cl2 and washed sequentially with water and 
brine. The aqueous layers were back extracted with CH2Cl2 and the combined organic 
layers were dried over Na2SO4, concentrated, and fractionated by FCC (10% ethy lacetate 
in hexane) to give the titled compound (720 mg, 98%). 
IR (neat) νmax: 3029 cm
-1
.  
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1
H NMR (500 MHz, CDCl3) δ 7.37-7.24 (15H, m, Ph), 4.74 and 4.32 (2H, d ×2, J = 11.5 
Hz, H2CPh), 4.62 and 4.38 (2H, d ×2, J = 11.5 Hz, H2CPh), 4.59 and 4.56 (2H, d ×2, J = 
11.5 Hz, H2CPh), 3.98 (1H, br dd, J = 2, 3 Hz, HC-1'), 3.88-3.79 (3H, m, H2C-2, HC-3), 
3.67 (1H, ddd, J = 2, 3, 10.5 Hz, HC-1"), 3.52-3.48 (1H, m, HC-3), 3.36 (1H, dd, J = 9.5, 
9.5 Hz, HC-4), 3.03 (1H, dd, J = 11, 14 Hz, HC-7), 2.88-2.82 (2H, m, HC-2', HC-9), 2.78 
(1H, ddd, J = 2, 2.5,13 Hz, HC-6'), 2.72 (1H, ddd, J = 2, 3, 14 Hz, HC-7), 2.58 (1H, dd, J 
= 11.5, 13 Hz, HC-6'), 2.54-2.46 (3H, m, HC-3', HC-5', HC-9), 2.42 (1H, dd, J = 11.5, 13 
Hz, HC-2'), 2.37 (1H, ddd, J = 3, 4.5, 11 Hz, HC-6), 2.10 (1H, ddd, J = 3, 4, 13.5 Hz, 
HC-10), 1.71 (1H, ddd, J = 3.5, 12.5, 13,5 Hz, HC-10), 1.63-1.52 (1H, m, HC-2"), 1.51-
1.41 (1H, m, HC-2"), 0.95 (3H, t, J = 7.5 Hz, H3C-3"). 
13C NMR (125 MHz, CDCl3) δ 139.10 (s, Ph), 139.06 (s, Ph), 138.9 (s, Ph), 128.53 (d 
×2, Ph), 128.52 (d ×2, Ph), 128.49 (d ×2, Ph), 128.2 (d ×2, Ph), 127.8 (d ×2, Ph), 127.73 
(d, Ph), 127.70 (d, Ph), 127.4 (d, Ph), 127.0 (d ×2, Ph), 109.4 (s, C-5), 80.2 (d, C-1"), 
78.0 (d, C-4), 77.4 (d, C-1'; confirmed by DEPT), 73.4 (t, CH2Ph), 71.8 (t, CH2Ph), 70.7 
(t, CH2Ph), 64.6 (t, C-2), 64.5 (t, C-3), 50.4 (d, C-3'), 49.1 (d, C-6), 48.0 (d, C-5'), 36.6 (t, 
C-10), 30.2 (br) (t, C-6'), 29.2 (t, C-7), 27.3 (t, C-2'), 26.9 (t, C-9), 23.1 (t, C-2"), 11.3 (q, 
C-3"). 
LRMS (EI), m/z (relative intensity): 634 ([M]+, 1), 543 (3), 435 (5), 279 (11), 132 (11), 
99 (25), 91 (100). 
HRMS (EI), m/z calcd for C37H46O5S2: 634.2786; found: 634.2778. 
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 (R)-rel-3-((S)-(Benzyloxy)((3S,4S,5S)-4-(benzyloxy)-5-((S)-1-
(benzyloxy)propyl)tetrahydro-2H-thiopyran-3-yl)methyl)dihydro-2H-thiopyran-
4(3H)-one (129). 
 
129 
 
A suspension of Amberlyst®-15 (2.24 g) and 128 (560 mg, 0.883 mmol) in 
acetone (40 mL) was heated under reflux. After 2 h (reaction complete by TLC analysis), 
the cooled mixture was decanted and the Amberlyst®-15 washed with CH2Cl2. The 
combined organic layers were washed with saturated aq NaHCO3, dried over Na2SO4, 
concentrated, and fractionated by FCC (20% ethyl acetate in hexane) to give the titled 
compound (520 mg, 95%). 
IR (DRIFT) νmax: 3030, 1696 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 7.36-7.27 (15H, m, Ph), 4.66 and 4.56 (2H, d ×2, J = 11 
Hz, H2CPh), 4.62 and 4.38 (2H, d ×2, J = 11.5 Hz, H2CPh), 4.54 and 4.30 (2H, d ×2, J = 
10.5 Hz, H2CPh), 4.24 (1H, br d, J = 7 Hz, HC-1'), 3.67 (1H, br d, J = 10 Hz, HC-1"), 
3.35 (1H, dd, J = 9.5, 10 Hz, HC-4'), 3.26 (1H, ddd, J = 4, 7, 10.5 Hz, HC-3), 3.13 (1H, 
br dd, J = 3.5,13.5 Hz, HC-2), 2.93-2.79 (5H, m, HC-2, HC-2', H2C-6, HC-6'), 2.74 (1H, 
ap ddd, J = 4.5, 5, 13 Hz, HC-5), 2.65-2.57 (2H, m, HC-2', HC-5), 2.49-2.38 (2H, m, HC-
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5', HC-6'), 2.30 (1H, br dd, J = 10, 11.5 Hz, HC-3'), 1.55-1.40 (2H, m, H2C-2"), 0.96 (3H, 
t, J = 7 Hz, H3C-3"). 
13
C NMR (125 MHz, CDCl3) δ 210.3 (s, C-4), 138.8 (s, Ph), 138.2 (s, Ph), 138.0 (s, Ph), 
128.68 (d ×2, Ph), 128.65 (d ×2, Ph), 128.5 (d ×2, Ph), 128.1 (d, Ph), 128.0 (d ×4, Ph), 
127.9 (d, Ph), 127.8 (d ×2, Ph), 127.7 (d, Ph), 80.0 (d, C-1"), 78.5 (d, C-4'), 78.4 (d, C-1'), 
74.5 (t, CH2Ph), 71.6 (t, CH2Ph), 70.8 (t, CH2Ph), 56.9 (d, C-3), 48.9 (d, C-3'), 47.7 (d, 
C-5'), 44.7 (t, C-5), 33.7 (t, C-2), 31.4 (t, C-6), 31.0 (t, C-2'), 27.5 (t, C-6'), 23.0 (t, C-2"), 
11.4 (q, C-3"). 
LRMS (CI, NH3), m/z (relative intensity): 608 ([M+18]+, 2), 483 (33), 375 (20), 285 (6), 
269 (5), 108 (18), 105 (17), 91 (100), 77 (5). 
HRMS (ESI), m/z calcd for C35H42O4S2+Na: 613.2416; found: 613.2404. 
(2E,4E)-2,4-dimethylhepta-2,4-dienal (73). 
1
3 5
8
O
 
73 
IBX (1.22 g, 4.36 mmol) was added to a stirred solution of 130 (510 mg, 3.63 
mmol) in DMSO (5 mL) in ambient temperature. The reaction was done by TLC after 3h. 
The reaction mixture was diluted by ethyl acetate (150 mL) and extracted twice by 
NaHCO3 solution. The organic layer were dried over Na2SO4, concentrated, and 
fractionated by FCC (15% ethyl acetate in hexane) to give the titled compound in (381 
mg, 88%). 
 101
The spectral data were matched perfectly with what is reported by Hoffmann et al.32 
 (S,2E,4E)-rel-1-((3R,5R)-5-((S)-Benzyloxy((3S,4S,5S)-4-(benzyloxy)-5-((S)-1-
(benzyloxy)propyl)tetrahydro-2H-thiopyran-3-yl)methyl)-4-oxotetrahydro-2H-
thiopyran-3-yl)-2,4-dimethylhepta-2,4-dienyl Acetate (131b).  
  
131b 
A solution of 129 (190 mg, 0.32 mmol) in CH2Cl2 (2.5 ml) was added dropwise 
via syringe to a stirred solution of (c-Hex)2BCl (1 M in hexane; 0.70 ml, 0.70 mmol), and 
Et3N (0.140 mL, 0.96 mmol) in CH2Cl2 (2 mL) at 0 °C. After 30 min, the reaction 
mixture was cooled to –78 °C and a solution of the 73 (88 mg, 0.64 mmol) in CH2Cl2 (1 
mL) was added to the reaction mixture. After 2 h, MeOH (3 mL), phosphate buffer (pH 
7; 6 mL), and 30% aq H2O2 (1.2 mL) were sequentially added with vigorous stirring. The 
reaction mixture was transferred to a 0 °C bath and after 15 min, the excess H2O2 was 
quenched by slow addition of saturated aq Na2SO3 (2 mL). The mixture was extracted 
with CH2Cl2 and the combined organic layers were dried over Na2SO4, and concentrated 
to give the crude product (310 mg) whose 1H NMR spectrum indicted the presence of a 
single adduct (>20:1 dr) along with 129 (ca. 75% conversion). The crude was 
fractionated by FCC (10% ethyl acetate in hexane) to give an inseparable mixture of 
aldol-adduct-131a and 129 (214 mg). Acetic anhydride (0.66 mL, 6.4 mmol), iPr2EtN 
(1.2 mL, 6.9 mmol), and DMAP (8 mg, 0.06 mmol) were added sequentially to a stirred 
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solution of the above mixture in CH2Cl2 (5 mL) at 0 °C. After 2 h, the mixture was 
diluted with CH2Cl2 (20 mL) and washed with saturated aq NaHCO3, dried over Na2SO4, 
concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to give recovered 
129 (40 mg, 21%) and the titled compound (170 mg, 69%). 
IR (DRIFT) νmax: 3031, 1741, 1706 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 7.36-7.22 (15H, m, Ph ×3), 6.08 (1H, s, HC-3), 5.88 (1H, 
d, J = 11 Hz, HC-1), 5.36 (1H, ap t, J = 7 Hz, HC-5), 4.64 and 4.418 (2H, d ×2, J = 11.5 
Hz, H2CPh), 4.61 and 4.51 (2H, d ×2, J = 11.5 Hz, H2CPh), 4.420 and 4.30 (2H, d ×2, J = 
10.5 Hz, H2CPh), 4.31 (1H, br d, J = 5 Hz, HC-1''), 3.64 (1H, br d, J = 10.5 Hz, HC-1'''), 
3.43 (1H, ddd, J = 5, 6, 10.5 Hz, HC-5'), 3.32 (1H, ap dd, J = 9.5, 10 Hz, HC-4''), 3.04-
2.92 (3H, m, HC-2', HC-3', HC-6'), 2.87-2.78 (3H, m, HC-2'', HC-6', HC-6''), 2.61-2.54 
(2H, m, HC-2', HC-2''), 2.49-2.40 (2H, m, HC-5'', HC-6''), 2.16 (1H, br dd, J = 10.5, 11 
Hz, HC-3''), 2.13-2.05 (2H, m, H2C-6), 1.82 (3H, s, H3CCO), 1.73 (3H, s, H3CC-2), 1.68 
(3H, s, H3CC-4), 1.62 (1H, br dq, J = 14, 7 Hz, HC-2'''), 1.42 (1H, ddq, J = 10.5, 14, 7 
Hz, HC-2'''), 0.98 (3H, t, J = 7.5 Hz, H3C-7), 0.92 (3H, t, J = 7 Hz, H3C-3'''). 
13C NMR (125 MHz, CDCl3) δ 209.9 (s, C-4'), 169.7 (s, COO), 138.8 (s, Ph), 138.4 (s, 
Ph), 138.2 (s, Ph), 136.4 (d, C-3), 134.5 (d, C-5), 131.2 (s, C-2 or C-4), 128.66 (d ×4, Ph), 
128.56 (d ×2, Ph), 128.3 (d, C-2 or C-4), 128.16 (d ×2, Ph), 128.13 (d ×2, Ph), 128.03 (d, 
Ph), 128.00 (d ×2, Ph), 127.82 (d, Ph), 127.78 (d, Ph), 80.1 (d, C-1'''), 79.4 (d, C-1), 78.6 
(d, C-4''), 77.2 (d, C-1''), 74.2 (t, CH2Ph), 71.6 (t, CH2Ph), 70.6 (t, CH2Ph), 53.9 (d, C-3'), 
53.4 (d, C-5'), 49.6 (d, C-3''), 47.8 (d, C-5''), 34.0 (t, C-6'), 33.3 (t, C-2'), 31.3 (t, C-2''), 
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27.8 (t, C-6''), 22.8 (t, C-2'''), 21.6 (t, C-6), 21.3 (t, CH3CO), 16.8 (t, CH2C-2), 14.2 (t, C-
7), 12.7 (t, CH3C-4), 11.6 (t, C-3'''). 
LRMS (EI), m/z (relative intensity): 770 ([M]+, 0.04), 710 (0.4), 519 (6), 403 (4), 345 
(5), 274 (11), 248 (7), 191 (7), 108 (20), 91 (100). 
HRMS (ESI), m/z calcd for C46H58O6S2+Na: 793.3567; found: 793.3570. 
Tricarbonyl[(2,3,4,5-η)-ethyl (2E,4E)-2,4-dimethyl-2,4-heptadienoate]iron (137).  
  
(±)-137 
A stirred solution of Fe2(CO)9 (3.00 g, 8.24 mmol) and 76 (1.00 g, 5.48 mmol) in 
benzene (40 mL) was heated under reflux. After 2 h, additional Fe2(CO)9 (1.50 g, 4.12 
mmol) was added. After 1 h, the mixture was allowed to cool to ambient temperature and 
was filtered through a pad of Celite®. The combined filtrate and washings were 
concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to give the titled 
compound (0.96 g, 54%). 
IR (DRIFT) νmax: 2044, 1985, 1970, 1691 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.86 (1H, s, HC-3), 4.18 (1H, dq, J = 10.5, 7.5 Hz, HCO), 
4.05 (1H, dq, J = 10.5, 7.5 Hz, HCO), 2.47 (1H, dd, J = 6, 7.5 Hz, HC-5), 2.17 (3H, s, 
H3CC-4), 1.99-1.90 (1H, ddq, J = 6, 14, 7 Hz, HC-6), 1.70-1.61 (1H, ddq, J = 7.5, 14, 7 
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Hz, HC-6), 1.26 (3H, t, J = 7 Hz, H3CCO), 1.12 (3H, t, J = 7 Hz, H3C-7), 1.12 (3H, s, 
H3CC-2). 
13
C NMR (125 MHz, CDCl3) δ 176.1 (s, C-1), 105.7 (s, C-4), 88.1 (d, C-3), 66.8 (d, C-
5), 60.7 (t, CH2O), 52.7 (s, C-2), 24.7 (t, C-6), 19.3 (q, CH3C-4), 15.6 (q, CH3C-2), 15.1 
(q, C-7), 14.4 (q, CH3CO). 
LRMS (EI), m/z (relative intensity): 322 ([M]+, 2), 294 (14), 266 (33), 238 (100), 222 
(39), 192 (14), 178 (15), 138 (21), 95 (12). 
HRMS (EI), m/z calcd for C14H18FeO5: 322.0504; found: 322.0507. 
Tricarbonyl[(2,3,4,5-η)-(2E,4E)-2,4-dimethyl-2,4-heptadien-1-ol]iron (138a). 
  
(±)-138a 
DIBAL-H (1 M in toluene; 3.1 mL, 3.1 mmol) was added slowly via syringe to a 
stirred solution of (±)-137 (503 mg, 1.56 mmol) in THF (20 mL) at –78 °C under argon. 
After 1 h, the reaction mixture was allowed to warm to ambient temperature over 1 h. 
The mixture was cooled to 0 °C and the reaction was quenched by sequential addition of 
ethanol (1 mL) and water (1 mL). The mixture was diluted with ethyl acetate (100 ml), 
washed with brine (20 ml), dried over Na2SO4, concentrated, and fractionated by FCC 
(15% ethyl acetate in hexane) to give the titled compound (401 mg, 92%). 
IR (DRIFT) νmax: 3250, 2035, 1956 cm
-1
.  
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1
H NMR (500 MHz, CDCl3) δ 5.08 (1H, s, HC-3), 3.56 (2H, br s, H2C-1), 2.40 (1H, br s, 
HO), 2.26 (1H, br t, J = 7 Hz, HC-5), 2.13 (3H, s, H3CC-4), 1.96-1.88 (1H, m, HC-6), 
1.68-1.59 (1H, m, HC-6), 1.21 (3H, s, H3CC-2), 1.08 (3H, t, J = 7.5 Hz, H3C-7). 
13
C NMR (125 MHz, CDCl3) δ 212.1 (s, CO ×3), 104.1 (s, C-4), 88.8 (d, C-3), 74.2 (t, C-
1), 67.9 (s, C-2), 66.7 (d, C-5), 24.7 (t, C-6), 19.2 (q, CH3C-4), 16.5 (br) (q, CH3C-2), 
15.6 (q, C-7). 
LRMS (EI), m/z (relative intensity): 280 ([M]+, 3), 252 (37), 224 (53), 178 (100), 175 
(39), 162 (50), 123 (39), 107 (38), 81 (44), 67 (38). 
HRMS (EI), m/z calcd for C12H16FeO4: 280.0398; found: 280.0400. 
Tricarbonyl[(2,3,4,5-η)-(2E,4E)-2,4-dimethyl-2,4-heptadienal]iron (138b).  
  
(±)-138b 
IBX (260 mg, 0.928 mmol) was added to a stirred solution of (±)-138a (200 mg, 
0.714 mmol) in THF (7 mL) and DMSO (7 mL) at ambient temperature. After 1.5 h, the 
reaction mixture was diluted with ethyl acetate, washed sequentially with saturated aq 
NaHCO3 solution, water and brine, dried over Na2SO4, concentrated, and fractionated by 
FCC (20% ethyl acetate in hexane) to give the titled compound (178 mg, 90%). 
IR (DRIFT) νmax: 2045, 2875, 1975, 1685 cm
-1
.  
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1
H NMR (500 MHz, CDCl3) δ 8.90 (1H, s, HC-1), 5.41 (1H, s, HC-2), 2.75 (1H, br dd, J 
= 6, 7 Hz, HC-5), 2.18 (3H, s, H3CC-4), 2.06-1.98 (1H, m, HC-6), 1.78-1.69 (1H, m, HC-
6), 1.17 (3H, t, J = 7 Hz, H3C-7), 1.17 (3H, s, H3C-2). 
13
C NMR (125 MHz, CDCl3) δ 198.9 (s, C-1), 107.9 (s, C-4), 89.8 (d, C-3), 69.1 (d, C-
5), 62.3 (s, C-2), 24.7 (t, C-6), 19.2 (q, CH3C-4), 15.6 (q, CH3C-2), 12.7 (q, C-7). 
LRMS (EI), m/z (relative intensity): 278 ([M]+, 3), 250 (21), 222 (58), 178 (40), 124 
(29), 109 (100), 95 (16), 67 (16). 
HRMS (EI), m/z calcd for C12H14FeO4: 278.0241; found: 278.0244. 
Tricarbonyl[(2,3,4,5-η)-(S,2E,4E)-rel-1-((3R,5R)-tetrahydro-5-((R)-
(methoxymethoxy)((R)-1,4-dioxa-8-thiaspiro[4.5]decan-6-yl)methyl)-3-oxo-2H-
thiopyran-3-yl)-2,4-dimethylhepta-2,4-dien-1-ol)]iron (141).  
 
141 
 
tBuLi (1.7 M in hexane; 0.25 mL, 0.42 mmol) was slowly added to a solution of 
140 (100 mg, 0.29 mmol) in THF (7 mL) at –78 °C. After 30 minutes, a solution of (±)-
138b (160 mg, 0.57 mmol) in THF (1 mL) was added slowly to the reaction mixture. 
After 1 h, the reaction was quenched by addition of phosphate buffer (pH 7; 25 mL). The 
mixture was transferred to an ice bath and vigorously stirred. After 15 min, the mixture 
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was diluted with CH2Cl2, washed with saturated aq NH4Cl, dried over Na2SO4, 
concentrated, and fractionated by FCC (20% ethylacetate in hexane) to give 142 (18 mg, 
10%) and 141 (102 mg, 56%). For each diastereomer, a crystal suitable for X-ray 
crystallography was obtained on standing from a solution in a 95:5 mixture of hexane and 
ethyl acetate, respectively. 
IR (DRIFT) νmax: 3488, 2033, 1965, 1706 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.40 (1H, s, HC-3), 4.77 (1H, d, J = 6.5 Hz, OCHO), 4.75 
(1H, dd, J = 2.5, 3 Hz, HC-1"), 4.68 (1H, d, J = 6.5 Hz, OCHO), 3.99 (1H, dd, J = 3.5, 10 
Hz, HC-1), 3.99-3.95 (2H, m, HC-2'', HC-3''), 3.80-3.74 (2H, m, HC-2'', HC-3''), 3.54 
(1H, ddd, J = 2.5, 6, 10 Hz, HC-5'), 3.38 (3H, s, H3CO), 3.12-3.05 (3H, m, HC-2', H2C-
6'), 2.99 (1H, dd, J = 11.5, 13 Hz, HC-7''), 2.91 (1H, ddd, J = 3.5, 4, 10 Hz, HC-3'), 2.88-
2.80 (3H, m, HC-2', HC-7'', HC-9''), 2.52-2.46 (1H, m, HC-9''), 2.46 (1H, ddd, J = 2.5, 3, 
11.5 Hz, HC-6''), 2.23 (3H, s, H3CC-4), 2.22 (1H, dd, J = 5.5, 8 Hz, HC-5"), 2.06 (1H, 
ddd, J = 2.5, 4, 13.5 Hz, HC-10''), 1.95 (1H, ddq, J = 5.5, 14.5, 7.5 Hz, HC-6), 1.91 (1H, 
d, J = 3.5 Hz, HO), 1.76-1.66 (2H, m, HC-6'', HC-10''), 1.12 (3H, t, J = 7 Hz, H3C-7), 
1.11 (3H, s, H3CC-2). 
13C NMR (125 MHz, CDCl3) δ 210.1 (s, C-4'), 108.7 (s, C-5''), 104 (s, C-4), 97.9 (t, 
OCH2O), 88.9 (d, C-3), 81.4 (d, C-1), 73.0 (d, C-1''), 70.5 (s, C-2), 68.5 (d, C-5), 64.8 (t, 
C-2''), 64.3 (t, C-3''), 56.3 (q, CH3O), 55.5 (d, C-3'), 53.5 (d, C-5'), 51.0 (d, C-6''), 37.3 (t, 
C-10''), 32.0 (t, C-6''), 31.7 (t, C-2''), 28.7 (t, C-7''), 27 (t, C-9''), 24.7 (t, C-6), 19.7 (q, 
CH3C-4), 15.7 (q, CH3C-2), 13.7 (q, C-7). 
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LRMS (ESI), m/z (relative intensity): 649 ([M+23]+, 7), 579 (6), 468 (10), 371 (97), 301 
(100), 279 (7), 206 (5). 
HRMS (ESI), m/z calcd for C27H38FeO9S2+Na: 649.1204; found: 649.1225. 
Tricarbonyl[(2,3,4,5-η)-(R,2E,4E)-rel-1-((3S,5R)-tetrahydro-5-((R)-
(methoxymethoxy)((R)-1,4-dioxa-8-thiaspiro[4.5]decan-6-yl)methyl)-3-oxo-2H-
thiopyran-3-yl)-2,4-dimethylhepta-2,4-dien-1-ol)]iron (142). 
 
142 
pale yellow crystalline solid. 
1
H NMR (500 MHz, CDCl3) δ 4.92 (1H, s), 4.81 (1H, t, J = 2.5 Hz), 4.70 (1H, d, J = 6.5 
Hz), 4.63 (1H, d, J = 6.5 Hz), 3.95 (1H, ddd), 3.82 (2H, ap t, J = 7 Hz), 3.75-3.70 (1H, 
m), 3.53-3.49 (2H, m), 3.36 (3H, s), 3.01-2.74 (10H, m), 2.49 (1H, ddd, J = 2, 3, 13 Hz), 
2.40 (1H, ddd, J = 3, 3, 12 Hz), 2.16 (3H, s), 2.04 (1H, ddd, J = 3, 4, 13 Hz), 1.95-1.89 
(1H, m), 1.74-1.61 (2H, m), 1.13 (3H, s), 1.09 (3H, t, J = 7.5 Hz). 
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Tricarbonyl[(2,3,4,5-η)-(S,2E,4E)-rel-1-((3R,5R)-5-((S)-benzyloxy((3S,4S,5S)-4-
(benzyloxy)-5-((S)-1-(benzyloxy)propyl)tetrahydro-2H-thiopyran-3-yl)methyl)-4-
oxotetrahydro-2H-thiopyran-3-yl)-2,4-dimethylhepta-2,4-dien-1-ol)]iron (143).  
 
143 
tBuLi (1.7 M in hexane; 80 µL, 0.14 mmol) in hexane was added slowly to a 
solution of 129 (53 mg, 0.09 mmol, 0.02 M) in THF (4.5 mL) at –78 °C. After 30 min, a 
solution of (±)-138b (49 mg, 0.18 mmol) in THF (1 mL) was added to the reaction 
mixture. After 3 h, the reaction was quenched by addition of phosphate buffer (pH 7; 2 
mL). The mixture was transferred to an ice bath and vigorously stirred. After 15 min, the 
mixture was diluted with CH2Cl2, washed with saturated aq NH4Cl, dried over Na2SO4, 
concentrated, and fractionated by FCC (10% acetone in pentane) to give the titled 
compound as an inseparable 5:1 mixture of two diastereomers (64 mg, 82%) as a plae 
yellow oil. 
IR (DRIFT) νmax: 3541, 2037, 1968, 1703 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 7.37-7.27 (15H, m, Ph), 5.14 (1H, s, HC-3'), 4.71 and 
4.55 (2H, d ×2, J = 11.5 Hz, H2CPh), 4.65 and 4.41 (2H, d ×2, J = 11.5 Hz, H2CPh), 4.50 
and 4.38 (2H, d ×2, J = 10.5 Hz, H2CPh), 4.57 (1H, br d, J = 7 Hz, HC-1''), 3.76 (1H, dd, 
J = 3, 9.5 Hz, HC-1), 3.70-3.65 (1H, m, HC-1'''), 3.33-3.24 (2H, m, HC-4'', HC-5'), 3.14 
(1H, ddd, J = 4.5, 7, 9.5 Hz, HC-3'), 3.10-3.05 (2H, m, H2C-6'), 2.94 (1H, dd, J = 4.5, 
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13.5 Hz, HC-2'), 2.92-2.79 (2H, m, HC-2'', HC-6''), 2.74 (1H, dd, J = 7, 13.5 Hz, HC-2'), 
2.63 (1H, dd, J = 11.5, 13.5 Hz, HC-2'' or HC-6''), 2.55-2.39 (3H, m, HC-3'', HC-5'', HC-
2'' or HC-6''), 2.24 (1H, d, J = 3 Hz, HO), 2.20 (3H, s, H3CC-4), 2.11 (1H, dd, J = 6, 8 
Hz, HC-5), 1.98-1.89 (1H, m, HC-6), 1.71-1.59 (2H, m, HC-2''', HC-6), 1.39 (1H, ddq, J 
= 10.5, 14, 7 Hz, HC-2'''), 1.10 (3H, t, J = 7 Hz, H3C-7), 0.97 (3H, t, J = 7 Hz, H3C-1'''), 
0.92 (3H, s). 
13
C NMR (125 MHz, CDCl3) δ 211.6 (s, C-4'), 138.9 (s, Ph), 138.2 (s, Ph), 138.0 (s, Ph), 
128.65 (d ×2, Ph), 128.64 (d ×2, Ph), 128.53 (d ×2, Ph), 128.2 (d ×2, Ph), 128.13 (d ×2, 
Ph), 128.03 (d, Ph), 127.96 (d ×2, Ph), 127.9 (d, Ph), 127.8 (d, Ph), 103.6 (s, C-4), 88.9 
(d, C-3), 81.4 (d, C-1), 80.1 (d, C-1'''), 77.8 (d, C-4''), 76.2 (d, C-1''), 73.6 (t, CH2Ph), 
71.6 (t, CH2Ph), 70.3 (s, C-2), 69.7 (t, CH2Ph), 68.0 (d, C-5), 55.5 (d, C-3'), 54.3 (d, C-
5'), 48.5 (d, C-3'' or C-5''), 47.4 (d, C-3'' or C-5''), 35.5 (t, C-6'), 33.4 (t, C-2'), 29.7 (t, C-
2'' or C-6''), 27.8 (t, C-2'' or C-6''), 24.7 (t, C-6), 22.7 (t, C-2'''), 19.6 (q, CH3C-4), 15.7 (q, 
C-7), 13.7 (q, CH3C-2), 11.6 (q, C-3''). 
LRMS (ESI), m/z (relative intensity): 891 ([M+23]+, 3), 613 (3), 465 (1), 383 (2), 311 
(100), 215 (3), 127 (6). 
HRMS (ESI), m/z calcd for C47H56FeO8S2+Na: 891.2658; found: 891.2675. 
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Tricarbonyl[(4,5,6,7-η)-(2R,3S,4E,6E)-rel-2-((1S,3S,4S,5R,6R,7S,8R)-3-ethyl-7-
hydroxy-4,6,8-trimethyl-2,9-dioxabicyclo[3.3.1]nonan-1-yl)-4,6-dimethylhepta-4,6-
dien-3-ol)]iron (145).  
 
145 
A suspension of Raney nickel (W2), previously deactivated by refluxing in 
acetone for 15 min; 7 mL settled volume) in EtOH (8 mL) was added to 143 (50 mg, 0.06 
mmol) and the mixture was heated under reflux with vigorous stirring. After 2 h (reaction 
was complete by TLC analysis), the mixture was decanted and the solid was suspended in 
EtOH (8 mL) and heated under reflux with vigorous stirring for several min. This 
washing procedure was repeated using acetone and methanol. The combined organic 
layers were filtered through Celite®, concentrated, and fractionated by FCC (10% acetone 
in pentane) to give the titled compound (12 mg, 40%) as a pale yellow oil. 
IR (DRIFT) νmax: 3477, 2033, 1967, 1950, 1634 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.05 (1H, s, HC-5), 4.19 (1H, s, HOC-3), 3.90 (1H, dd, J 
= 5, 10 Hz, HC-7'), 3.57 (1H, br s, HC-5'), 3.49 (1H, ddd, J = 3.5, 6, 9.5 Hz, HC-3'), 3.46 
(1H, br d, J = 8.5 Hz, HC-3), 2.17 (3H, s, H3CC-6), 2.16-2.12 (2H, m, HC-2, HC-7), 
1.96-1.80 (3H, m, HC-6', HC-8', HC-8), 1.72-1.63 (3H, m, HC-1'', HC-4', HC-8), 1.49-
1.41 (1H, m, HC-1''), 1.12 (3H, s, H3CC-6), 1.08 (3H, t, J = 7.5 Hz, H3C-9), 1.07 (3H, d, 
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J = 7 Hz, H3CC-6 or H3CC-8'), 1.04 (3H, d, J = 6.5 Hz), 0.93 (3H, t, J = 7.5 Hz, H3C-2''), 
0.91 (6H, br d, J = 7 Hz, H3CC-4', H3C-8). 
13
C NMR (125 MHz, C6D6) δ 105.0, 103.1, 90.6, 82.7, 81.3, 75.1, 73.2, 69.2, 66.4, 44.7, 
39.9, 38.5, 38.3, 26.7, 25.2, 19.4, 18.9, 16.1, 14.9, 12.8, 11.9, 11.5, 9.5. 
HRMS m/z calcd for C26H40O7Fe+Na: 543.2015; found: 543.2002 (ESI). 
(1S,3S,4S,5R,6R,7S,8R)-1,3-Diethyl-4,6,8-trimethyl-2,9-dioxabicyclo[3.3.1]nonan-7-
ol (151a).  
 
151a 
A suspension of Raney nickel (W2; 20 mL settled volume) in THF (60 mL) was 
added to 121 (200 mg, 0.548 mmol) and the mixture was heated under reflux with 
vigorous stirring. After 15 min, the mixture was decanted and the solid was suspended in 
THF (60 mL) and heated under reflux with rapid stirring for several min. This washing 
procedure was repeated once by EtOH, MeOH, and ethyl acetate. The combined organic 
layers were filter through Celite® and concentrated. The residue was dissolved in a 5:1 
mixture (v/v) of THF and H2O respectively (9 mL) and aq HCl (10 M; 1 mL). After 2 h, 
the reaction mixture was cooled to 0 °C and neutralized with saturated aq NaHCO3. The 
mixture was extracted with CH2Cl2 and the combined organic layers were dried over 
Na2SO4, concentrated, and fractionated by FCC (50% ethyl acetate in hexane) to give the 
titled compound (110 mg, 83%). 
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IR (DRIFT) νmax: 3396 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 3.95 (1H, ddd, J = 5, 5, 10 Hz, HC-7), 3.49 (1H, dd, J = 
3.5,1.5 Hz, HC-5), 3.34 (1H, ddd, J = 2.5, 8, 10.5 Hz, HC-3 ), 1.85 (1H, ddq, J = 1.5, 7, 7 
Hz, HC-6), 1.72-1.49 (5H, m, H2C-1, HCC-3,HC-4, HC-8), 1.38 (1H, br s, HO), 1.33 
(1H, ddq, J = 8, 14, 7.5 Hz, HCC-3), 1.07 (3H, d, J = 7 Hz, H3CC-6), 1.00 (3H, d, J = 6.5 
Hz, H3CC-8), 0.93 (3H, t, J = 7.5 Hz, H3CCC-3), 0.91 (3H, d, J = 7 Hz, H3CC-4), 0.91 
(3H, t, J = 7.5 Hz, H3CCC-1). 
13C NMR (125 MHz, CDCl3) δ 101.8 (s, C-1), 81.5 (d, C-5), 73.6 (d, C-3), 70.2 (d, C-7), 
39.64 (d, C-4 or C-6), 39.60 (d, C-4 or C-6), 39.2 (d, C-8), 30.5 (t, CH2C-1), 25.6 (t, 
CH2C-3), 18.4 (q, CH3C-4), 12.0 (q, CH3C-6), 11.1 (q, CH3C-8), 9.6 (q, CH3CC-3), 7.5 
(q, CH3CC-1). 
LRMS (EI), m/z (relative intensity): 242 ([M]+, 1), 126 (12), 115 (46), 110 (100), 95 
(29), 69 (36), 57 (83). 
HRMS (EI), m/z calcd for C14H26O3: 243.1882; found: 242.1886. 
 (1S,3S,4S,5S,6S,8R)-1,3-Diethyl-4,6,8-trimethyl-2,9-dioxabicyclo[3.3.1]nonan-7-one 
(152).  
 
152 
 114
IBX (25 mg, 0.09 mmol) was added to a stirred solution of 151a (20 mg, 0.08 
mmol) in DMSO (0.8 mL) and THF (0.4 mL) at ambient temperature. After 2 h (reaction 
was complete by TLC analysis), the mixture was diluted with ethyl acetate and washed 
with saturated aq NaHCO3, dried over Na2SO4, concentrated, and fractionated by PTLC 
(10% ethyl acetate in hexane) to give the titled compound (15 mg, 76%). 
IR (DRIFT) νmax: 2966, 2933, 2878, 1719, 1457, 1206 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 3.64 (1H, br d, J = 3 Hz, HC-5), 3.30 (1H, ddd, J = 2, 8.5, 
9.5 Hz, HC-3), 2.77 (1H, q, J = 6.5 Hz, HC-8), 2.37 (1H, q, J = 7 Hz, HC-6), 1.80 (1H, 
dq, J = 14, 7.5 Hz, HCC-1), 1.62 (1H, dq, J = 14, 7.5 Hz, HCC-1), 1.57 (1H, ddq, J = 
2.5,14, 7.5 Hz, HCC-3), 1.42 (1H, ddq, J = 3, 9.5, 7 Hz, HC-4), 1.30 (3H, d, J = 7 Hz, 
H3CC-6), 1.28-1.19 (1H, m, J = 8.5, 14, 7 Hz, HCC-3), 1.03 (3H, d, J = 7 Hz, H3CC-8), 
0.99 (3H, t, J = 7.5 Hz, H3CCC-1), 0.91 (3H, d, J = 7 Hz, H3CC-4), 0.86 (3H, t, J = 7.5 
Hz, H3CCC-3). 
13C NMR (125 MHz, CDCl3) δ 211.9 (s, C-7), 104.6 (s, C-1), 82.2 (d, C-5), 73.5 (d, C-
3), 51.3 (d, C-6), 48.3 (d, C-8), 41.5 (d, C-4), 30.1 (t, CH2C-1), 25.6 (t, CH2C-3), 17.9 (q, 
CH3C-6), 17.6 (q, CH3C-4), 9.7 (q, CH3CC-3), 8.0 (q, CH3C-8 or CH3CC-1), 7.9 (q, 
CH3C-8 or CH3CC-1). 
LRMS (EI), m/z (relative intensity): 240 ([M]+, 29), 153 (6), 149 (12), 137 (12), 113 
(53), 110 (26), 95 (26), 69 (41), 57 (100), 55 (16). 
HRMS (EI), m/z calcd for C14H24O3: 240.1725; found: 240.1727. 
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(1S,3S,4S,5R,6R,7R,8R)-1,3-Diethyl-4,6,8-trimethyl-2,9-dioxabicyclo[3.3.1]nonan-7-
ol (151b).  
 
151b 
NaBH4 (10 mg, 0.26 mmol) was added to a solution of 152 (15 mg, 0.06 mmol) in 
methanol (2 mL) at ambient temperature. After 45 minutes (reaction was complete by 
TLC analysis), the mixture was diluted with CH2Cl2 (10 mL), washed with water, dried 
over Na2SO4, and concentrated to give the titled compound (12 mg, 79%). 
IR (DRIFT) νmax: 3520 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 4.14 (1H, br s, HO), 3.51 (1H, br s, HC-7), 3.46 (1H, br s, 
HC-5), 3.40 (1H, br dd, J = 9,10 Hz, HC-3), 2.15 (1H, ddq, J = 2, 10, 7 Hz, HC-4), 2.02 
(1H, br q, J = 7 Hz, HC-6), 1.97 (1H, dq, J = 3.5, 7 Hz, HC-8), 1.73-1.54 (3H, m, H2CC-
1' HCC-3), 1.31 (1H, ddq, J = 9, 14, 7.5 Hz, HCC-3), 1.08 (3H, d, J = 7 Hz, H3CC-6), 
1.07 (3H, d, J = 7 Hz, H3CC-8), 0.95 (3H, t, J = 7.5 Hz, H3CCC-3), 0.93 (3H, d, J = 7 Hz, 
H3CC-4), 0.92 (3H, t, J = 7.5 Hz, H3CCC-1). 
13C NMR (125 MHz, CDCl3) δ 103.1 (s, C-1), 80.6 (d, C-5), 76.2 (d, C-7), 75.1 (d, C-3), 
41.1 (d, C-6), 40.7 (d, C-4), 33.9 (d, C-8), 29.4 (t, CH2C-1), 26.4 (t, CH2C-3), 18.9 (q, 
CH3C-4 or CH3C-6), 18.7 (q, CH3C-4 or CH3C-6), 12.4 (q, CH3C-8), 10.2 (q, CH3CC-3), 
7.6 (q, CH3CC-1). 
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LRMS (CI, NH3), m/z (relative intensity): 243 ([M+1]+, 100), 225 (11), 110 (29), 64 
(100), 95 (32), 69 (50), 57 (100), 55 (18). 
HRMS (CI, NH3), m/z calcd for C14H26O3+H: 243.1983; found: 243.1960. 
(4R,5R,6S)-6-(2-Ethyl-1,3-dioxolan-2-yl)-4-methyl-5-((triethylsilyl)oxy)heptan-3-one 
(164). 
 
(-)-164 
A suspension of Raney nickel (W2; 70 mL settled volume) in EtOH (150 mL) 
was added to (+)-O-TES-9a (4.90 g, 11.7 mmol) and the mixture was heated under reflux 
with vigorous stirring. After 2 h (reaction was complete by TLC analysis), the mixture 
was decanted and the solid was suspended in EtOH (200 mL) and heated under reflux 
with vigorous stirring for several min. This washing procedure was repeated twice with 
acetone, and twice with methanol. The combined organic layers were filtered through 
Celite®, concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to give the 
titled compound (3.28 g, 78%): [α]D -60 (c 1.0, CHCl3). 
IR (DRIFT) νmax: 1710 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 4.15 (1H, br dd, J = 3, 4 Hz, HC-5), 3.95-3.87 (4H, m, 
H2C-4', H2C-5'), 2.75 (1H, dq, J = 4, 6.5 Hz, HC-4), 2.64 (1H, dq, J = 18, 7 Hz, HC-2), 
2.41 (1H, dq, J = 18, 7 Hz, HC-2), 1.85 (1H, dq, J = 3, 7 Hz, HC-6), 1.68 (1H, dq, J = 
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14.5, 7.5 Hz, HC-1''), 1.59 (1H, dq, J = 14.5, 7.5 Hz, HC-1''), 1.03 (3H, d, J = 6.5 Hz, 
H3CC-4), 1.02 (3H, t, J = 7.5 Hz, H3C-1), 0.96 (9H, t, J = 8 Hz, H3CCCSi ×3), 0.84 (3H, 
t, J = 7 Hz, H3C-2''), 0.83 (3H, d, J = 7 Hz, H3CC-6), 0.62 (6H, ap q, J = 8 Hz, H2CSi 
×3). 
13
C NMR (125 MHz, CDCl3) δ 214.1 (s, C-3), 113.8 (s, C-2'), 72.9 (d, C-5), 65.2 (t, C-
4'), 65.1 (t, C-5'), 52.7 (d, C-4), 41.9 (d, C-6), 36.4 (t, C-2), 26.9 (t, C-1''), 12.5 (q, CH3C-
4), 10.6 (q, CH3C-6), 7.8 (q, C-2''), 7.4 (q, C-1), 7.3 (q ×3, CH3CSi), 5.6 (t ×3, CH2Si). 
LRMS (CI, NH3), m/z (relative intensity): 359 ([M+1]+, 0.5), 329 (2), 273 (2), 227 (8), 
101 (100), 57 (2). 
HRMS m/z calcd for C19H38O4Si+H: 359.2618; found: 359.2611 (CI, NH3). 
(2S,3R,4R,6S,7R)-2-(2-Ethyl-1,3-dioxolan-2-yl)-7-hydroxy-4,6-dimethyl-3-
(triethylsilyloxy)nonan-5-one (165).  
 
(+)-165 
A solution of (-)-164 (3.61 g, 10.1 mmol) in Et2O (15 mL) was added dropwise 
via syringe to a stirred solution of Et3N (3.1 mL, 2.2 g, 22 mmol) and 9-BBN-OTf (0.5 M 
in hexane; 40 mL, 20 mmol) in Et2O (220 mL) at -78 °C under argon. After 2 h, a 
solution of propanal (3.6 mL, 2.9 g, 50 mmol) in Et2O (30 mL) was slowly added via 
syringe. After 4 h, the reaction was quenched by sequential addition of MeOH (90 mL), 
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phosphate buffer (pH 7; 300 mL), and 30% aqueous H2O2 (90 mL). The reaction vessel 
was transferred to an ice bath and after vigorous stirring for 20 min, the mixture was 
extracted with CH2Cl2. The combined organic layers were dried over Na2SO4, 
concentrated to give the crude product whose 1H NMR spectrum indicated the presence 
of 2.4:1 mixture of a single adduct (>20:1 dr) and (-)-164, respectively. Fractionation of 
the crude by FCC (20% ethyl acetate in hexane) gave recovered (-)-164 (0.80 g, 22%) 
and the titled compound (2.6 g, 62%): [α]D +92 (c 1.7, CHCl3). 
IR (DRIFT) νmax 3510, 1696, 2878 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 4.09 (1H, dd, J = 3, 4.5 Hz, HC-3), 3.94-3.85 (5H, m, 
H2C-4', H2C-5', HC-7), 3.29 (1H, br d, J = 1.5 Hz, HOC-3), 2.99 (1H, dq, J = 4.5, 7 Hz, 
HC-4), 2.82 (1H, dq, J = 2, 7.5 Hz, HC-6), 1.91 (1H, dq, J = 3, 7 Hz, HC-2), 1.66 (1H, 
dq, J = 14.5, 7.5 Hz, HC-1''), 1.61-1.51 (2H, m, HC-1'', HC-8), 1.10 (3H, d, J = 7.5 Hz, 
H3CC-6), 1.01 (3H, d, J = 7 Hz, H3CC-4), 0.96 (9H, t, J = 8 Hz, H3CCSi ×3), 0.93 (3H, 
d, J = 7.5 Hz, H3C-9), 0.84 (3H, t, J = 7.5 Hz, H3C-2''), 0.82 (3H, d, J = 7 Hz, H3C-1), 
0.62 (6H, ap q, J = 8 Hz, H2CSi ×3). 
13C NMR (125 MHz, CDCl3) δ 220.3 (s, C-5), 113.7 (s, C-2'), 73.0 (d, C-3), 72.2 (d, C-
7), 65.1 (t, C-4'), 65.0 (t, C5'), 51.3 (d, C-4), 49.3 (d, C-6), 41.2 (d, C-2), 26.9 (t, C-1''), 
26.7 (t, C-8), 13.0 (q, CH3C-4), 10.6 (q, C-1 or C-9), 10.5 (q, C-1 or C-9), 9.3 (q, CH3C-
6), 7.5 (q, C-2''), 7.2 (q ×3, CH3CSi), 5.5 (t ×3, CH2Si). 
LRMS (CI, NH3), m/z (relative intensity): 417 ([M+1]+, 6), 387 (20), 355 (30), 329 (30), 
297 (23), 229 (13), 199 (10), 165 (6), 101 (100). 
HRMS (CI, NH3), m/z calcd for C22H44O5Si+H: 417.3036; found: 417.3040. 
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(4R,5S,6R)-4-Ethyl-6-[(2R,3R,4S)-4-(2-ethyl-1,3-dioxolan-2-yl)-3-
(trimethylsilyl)oxypentan-2-yl]-2,2,5-trimethyl-1,3-dioxane (167). 
 
167 
A solution of (+)-165 (20 mg, 0.048 mmol) in THF (2 ml) was added dropwise 
via syringe to a stirred suspension of LiAlH4 (3.5 mg, 0.09 mmol) in THF (3 mL) at 0 °C. 
After 15 min, H2O (0.3 mL), and 15% aq NaOH (0.3 mL) were sequentially added to the 
reaction mixture at 0 °C [Caution: H2 evolution]. After 5 min, the reaction mixture was 
diluted with CH2Cl2, washed with water, dried over Na2SO4, and concentrated to give the 
crude product (12 mg). The crude mixture was taken up in CH2Cl2 (1 mL) and 2,2-
dimethoxypropane (0.5 mL) and p-TsOH·H2O (2 mg, 0.01 mmol) were sequentially 
added to the stirred solution. After 5 min, the mixture was diluted with CH2Cl2 and 
washed with saturated aq NaHCO3, dried over Na2SO4, concentrated, and fractionated by 
PTLC (15% ethylacetate in hexane) to give the titled compound (10 mg, 43%). 
1
H NMR (500 MHz, CDCl3) δ 3.95-3.88 (5H, m, HC-3'', H2C-4''', H2C-5'''), 3.73 (1H, 
ddd, J = 2, 7, 7 Hz, HC-4), 3.64 (1H, dd, J = 2. 9.5 Hz, HC-6), 1.97 (1H, dq, J = 4.5, 7 
Hz, HC-4''), 1.70 (1H, ddq, J = 1.5, 9.5, 6.5 Hz, HC-2''), 1.67-1.52 (4H, m, HC-1', H2C-
1'''', HC-5), 1.47-1.39 (1H, m, HC-1'), 0.98 (9H, t, J = 8 Hz, H3CCSi ×3), 0.93 (3H, d, J = 
7 Hz, H3C-5''), 0.90 (3H, d, J = 6.5 Hz, H3C-1''), 0.89 (3H, t, J = 7 Hz, H3C-2'), 0.87 (3H, 
d, J = 6.5 Hz, H3CC-5), 0.85 (3H, t, J = 7.5 Hz, H3C-1''''), 0.67-0.54 (6H, m, H2CSi ×3). 
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13
C NMR (125 MHz, CDCl3) δ 114.3 (s), 99.1 (s), 75.3 (d), 75.2 (d), 69.3 (d), 65.0 (t), 
64.8 (t), 43.1 (d), 42.6 (d), 32.1 (d), 30.3 (q, CH3C-2), 26.6 (t), 25.7 (t), 20.0 (q, CH3C-2), 
12.3 (q), 9.8 (q), 9.3 (q), 7.7 (q), 7.4 (q), 6.0 (t ×3), 4.7 (q ×3). 
LRMS (CI, NH3), m/z (relative intensity): 459 ([M+1]+, 3), 401 (8), 327 (22), 215 (9), 
157 (22), 132 (10), 101 (100). 
HRMS (CI, NH3), m/z calcd for C25H50O5Si+H: 459.3506; found: 459.3495. 
4R,5S,6R)-4-[(S)-1-(2-Ethyl-1,3-dioxolan-2-yl)ethyl]-6-[(2S,3R)-3-
(trimethylsilyl)oxypentan-2-yl]-2,2,5-trimethyl-1,3-dioxane (169). 
 
169 
A solution of (+)-165 (20 mg, 0.048 mmol) in THF (2 ml) was added dropwise 
via syringe to a stirred suspension of LiAlH4 (3.5 mg, 0.09 mmol) in THF (3 mL) at 0 °C. 
After 15 min, H2O (0.3 mL), and 15% aq NaOH (0.3 mL) were sequentially added to the 
reaction mixture at 0 °C [Caution: H2 evolution]. After 5 min, the reaction mixture was 
diluted with CH2Cl2, washed with water, dried over Na2SO4, and concentrated to give the 
crude product (12 mg). TBAF (20 mg, 0.08 mmol) was added to a stirred solution of the 
above crude product in THF (2 mL) at ambient temperature. After 2 h, the reaction 
mixture diluted with CH2Cl2, washed with saturated aq NH4Cl, dried over Na2SO4, 
concentrated, and fractionated by PTLC (20% ether in dichloromethane) to give a crude 
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triol (7.2 mg). TESOTf (6.0 µL, 7.0 mg 0.03 mmol) and 2,6 lutidine (6 µl, 5.5 mg, 0.05 
mmol) were added sequentially to a solution of the crude triol (7.2 mg, 0.02 mmol) in 
CH2Cl2 (1 mL) at 0 °C under argon. After 1 h, the reaction mixture was diluted with 
CH2Cl2, washed with saturated aq NaHCO3, dried over Na2SO4, concentrated, and 
fractionated by PTLC (20% ethyl acetate in hexane) to give the mono-silyl protected diol 
(8 mg, 40% from (+)-165). 2,2-dimethoxypropane (0.5 mL) and p-TsOH·H2O (2 mg, 
0.01 mmol) were sequentially added to a solution of the above mono-silyl protected diol 
(8.0 mg, 0.02 mmol) in CH2Cl2 (1 mL). After 5 min, the reaction mixture was diluted 
with CH2Cl2, and washed with saturated aq NaHCO3, dried over Na2SO4, concentrated, 
and fractionated by PTLC (15% ethyl acetate in hexane) to give the titled compound (8 
mg, 91%; 36% from (+)-165). 
1
H NMR (500 MHz, CDCl3) δ 3.94-3.88 (4H, m, H2C-4''', HC-5'''), 3.82 (1H, dd, J = 2, 
6.5 Hz, HC-4), 3.71 (1H, dd, J = 1.5, 9.5 Hz, HC-6), 3.64 (1H, br ddd, J = 1.5, 7, 7.5 Hz, 
HC-3''), 1.87 (1H, dq, J = 6.5, 7 Hz, HC-1'), 1.79 (1H, ddq, J = 1.5, 2, 6.5 Hz, HC-5), 
1.74 (1H, dq, J = 14, 7.5 Hz, HC-1''''), 1.64 (1H, ddq, J = 1.5, 9.5, 6.5 Hz, HC-2''), 1.57 
(1H, dq, J = 14, 7.5 Hz, HC-1''''), 1.56-1.46 (2H, m, H2C-4''), 1.37 (6H, s, H3CC-2 ×2), 
0.98 (3H, d, J = 7 Hz, H3C-2'), 0.96 (9H, t, J = 8 Hz, H3CCSi ×3), 0.87 (3H, d, J = 6.5 
Hz, H3C-1''), 0.86 (3H, d, J = 6.5 Hz, H3CC-5), 0.86 (3H, t, J = 7.5 Hz, H3C-2''''), 0.81 
(3H, t, J = 7.5 Hz, H3C-5''), 0.64-0.52 (6H, m, H2CSi ×3). 
13C NMR (125 MHz, CDCl3) δ 113.6 (s), 99.0 (s), 75.9 (d), 73.8 (d), 72.4 (d), 65.5 (t), 
65.1 (t), 42.3 (d), 36.9 (d), 34.1 (d), 30.3 (q, CH3C-2), 28.3 (t), 25.7 (t), 19.7 (q, CH3C-2), 
12.3 (q), 10.4 (q), 8.6 (q), 7.3 (q), 6.8 (q), 6.3 (q ×3), 5.8 (t ×3). 
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 (4R,5R,6R)-4-[(2R,3R,4S)-4-(2-Ethyl-1,3-dioxolan-2-yl)-3-(triethylsilyloxy)pentan-2-
yl]-2,2,5-trimethyl-6-[(2E,4E)-4-methylhepta-2,4-dien-2-yl]-1,3-dioxane (172).  
 
172 
(c-Hex)2BCl (1 M in hexane; 280 µL, 0.280 mmol) and Et3N (0.040 mL, 29 mg, 
0.29 mmol) were sequentially added via syringe in to a solution of (-)-164 (50 mg, 0.14 
mmol) in Et2O (1.4 mL) at 0 °C under argon. After 1 h, the mixture was cooled to –78 °C 
and after 10 min, the dienealdehyde 73 (38 mg, 0.27 mmol) was added dropwise via 
syringe. After 4 h, the reaction was quenched by sequential addition of MeOH (1 mL), 
phosphate buffer (pH 7; 2 mL), and 30% aqueous H2O2 (0.6 mL). The reaction vessel 
was transferred to an ice bath and after vigorously stirring for 15 min, the mixture was 
extracted with CH2Cl2. The combined organic layers were dried over Na2SO4, 
concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to give an aldol 
adduct (30 mg, 42%; dr >10). DIBAL-H (1 M in toluene; 30 µL, 0.030 mmol) was added 
to a solution of the above aldol adduct (10 mg, 0.02 mmol) in THF (1 mL) at –78 °C. The 
mixture was allowed to warm to 0 °C and after 5 min, was diluted with ethyl acetate, 
washed sequentially with water and brine, dried over Na2SO4, concentrated, and 
fractionated by PTLC (10% ethyl acetate in hexane) to give the desired 1,3-syn diol (5.7 
mg, 57%). 2,2-Dimethoxypropane (0.5 mL) and p-TsOH·H2O (1.2 mg, 6.9 µmol) were 
added to a solution of the above diol (5.7 mg, 0.011 mmol) in CH2Cl2 (1 mL). After 5 
minutes, the reaction mixture was diluted with CH2Cl2, washed with saturated aq 
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NaHCO3, dried over Na2SO4, concentrated, and fractionated by PTLC (10% ethyl acetate 
in hexane) to give the titled compound (5.2 mg, 85%). 
1
H NMR (500 MHz, CDCl3) δ 5.85 (1H, s, HC-3''), 5.35 (1H, dd, J = 3, 4 Hz, HC-5''), 
4.20 (1H, dd, J = 4, 3 Hz, HC-3'), 3.94-3.88 (4H, m, H2C-4'', H2C-5'''), 3.76 (1H, d, J = 
10 Hz, HC-6), 3.43 (1H, dd, J = 10.5, 3 Hz, HC-4), 2.11-2.05 (2H, m, H2C-6''), 1.89-1.81 
(3H, m, HC-2', HC-4', HC-5), 1.79 (3H, s, H3C-1''), 1.73 (3H, s, H3CC-4''), 1.68 (2H, q, J 
= 7 Hz, H2C-1''''), 1.44 (3H, s, H3CC-2), 1.39 (3H, s, H3CC-2), 0.98 (3H, t, J = 7.5 Hz, 
H3C-7''), 0.96 (9H, t, J = 8 Hz, H3CCSi ×3), 0.95 (3H, d, J = 7 Hz, H3C-5' ), 0.92 (3H, d, 
J = 7 Hz, H3C-1'), 0.86 (3H, t, J = 7.5 Hz, H3C-2''''), 0.71 (3H, d, J = 7 Hz, H3CC-5), 0.67 
(6H, ap q, J = 8 Hz, H2CSi ×3). 
13C NMR (125 MHz, CDCl3) δ 133.9 (d, HC-3''), 133.0 (d, HC-5''), 132.9 (s, C-2'' or C-
4''), 131.7 (s, C-2'' or C-4''), 114.3 (s, C-2'''), 98.1 (s, C-2), 83.3 (d, C-6), 77.9 (d, C-4), 
69.9 (d, C-3'), 65.2 (t, C-4'''), 65.0 (t, C-4'''), 45.3 (d, C-4'), 43.0 (d, C-2'), 32.9 (d, C-5), 
30.4 (q, H3CC-2), 27.2 (t, H2C-1''''), 21.6 (t, H2C-6''), 20.0 (q, H3CC-2), 16.9 (q, CH3C-
4''), 14.3 (q, C-7''), 13.9 (q, C-1'), 13.4 (q, CH3C-5), 13.1 (q, C-1''), 10.4 (q, C-5'), 7.6 (q, 
C-2''''), 7.4 (t 3, CH2Si ×3), 5.7 (q ×3, CH3CSi ×3). 
LRMS (ESI), m/z (relative intensity): 561 ([M+23]+, 35), 501 (20), 427 (100), 351 (12). 
HRMS (ESI), m/z calcd for C31H58O5Si+Na: 561.3945; found: 561.3965. 
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(4R,5R,6R)-4-[(2R,3R,4S)-4-(2-Ethyl-1,3-dioxolan-2-yl)-3-(hydroxyoxy)pentan-2-yl]-
2,2,5-trimethyl-6-[(2E,4E)-4-methylhepta-2,4-dien-2-yl]-1,3-dioxane (173). 
 
173 
TBAF (60 mg, 0.23 mmol) was added to a stirred solution of 172 (9.7 mg, 0.18 
mmol) in THF (2 mL) at ambient temperature. After 2 days (reaction was complete by 
TLC analysis), the mixture was diluted with CH2Cl2, washed with saturated aq NH4Cl, 
dried over Na2SO4, concentrated, and fractionated by PTLC (10% ethyl acetate in 
hexane) to give the titled compound (7.2 mg, 94%). 
1
H NMR (500 MHz, C6D6) δ 5.93 (1H, s, HC-3''), 5.39 (1H, br dd, J = 7, 7 Hz, HC-5''), 
4.42 (1H, dd, J = 1.5, 6 Hz, HC-3'), 3.82 (1H, d, J = 10 Hz, HC-6), 3.61 (1H, s, HO), 
3.55-3.49 (5H, m, H2C-4''', H2C-5''', HC-4 [NOE on irradiation of H3C-1']), 2.30 (1H, 
ddq, J = 1.5, 2, 7 Hz, HC-2' [NOE on irradiation of H3CC-5]), 2.15 (1H, ddq, J = 10,10, 
6.5 Hz, HC-5), 2.11 (1H, dq, J = 6, 7 Hz, HC-4'), 2.01-1.95 (2H, m, H2C-6''), 1.92 (1H, 
dq, J = 14, 7.5 Hz, HC-1''''), 1.90 (3H, s, H3C-1''), 1.81 (1H, dq, J = 14, 7.5 Hz, HC-1''''), 
1.65 (3H, s, H3CC-4''), 1.48 (3H, d, J = 7 Hz, H3C-5'), 1.38 (3H, s, H3CC-2), 1.31 (3H, d, 
J = 7 Hz, H3C-1'), 1.26 (3H, s, H3C-2), 0.98 (3H, t, J = 7.5 Hz, H3C-2''''), 0.90 (3H, t, J = 
7.5 Hz, H3C-7''), 0.78 (3H, d, J = 6.5 Hz, H3CC-5 [NOE on irradiation of HC-2']). 
13C NMR (125 MHz, C6D6) δ 134.2 (d, C-3'), 134.0 (s, C-2' or C-4'), 133.3 (d, C-5'), 
132.3 (s, C-2' or C-4'), 114.8 (s, C-2'''), 99.2 (s, C-2), 83.8 (d, C-6), 82.1 (d, C-4), 70.1 (d, 
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C-3'), 65.8 (t, C-4'''), 65.5 (t, C-5'''), 44.3 (d, C-4'), 38.3 (d, C-2'), 34.0 (d, C-5), 30.9 (q, 
CH3C-2), 27.0 (t, C-1''''), 22.3 (t, C-6''), 19.8 (q, CH3C-2), 17.4 (q, CH3C-4''), 14.9 (q, C-
7''), 13.7 (q, C-1''), 13.2 (q, C-1'), 12.9 (q, CH3C-5), 12.7 (q, C-5'), 7.9 (q, C-2''''). 
LRMS (ESI), m/z (relative intensity): 447 ([M+23]+, 100), 367 (1), 269 (1), 228 (2), 186 
(10), 112 (11), 101 (31). 
HRMS (ESI), m/z calcd for C25H44O5+Na: 447.3080 ; found: 447.3091. 
(2S,3R,4R,6S,7R)-2-(2-Ethyl-1,3-dioxolan-2-yl)-4,6-dimethyl-3,7-
bis[(triethylsilyl)oxy]nonan-5-one (175). 
 
175 
TES-Cl (1.40 mL, 1.27 g, 8.43 mmol) and imidazole (0.62 g, 9.0 mmol) were 
added sequentially to a stirred solution of (+)-165 (2.50 g, 6.45 mmol) in DMF (20 mL) 
at ambient temperature under argon. After 18 h, the mixture was diluted by ethyl acetate, 
washed with 1 M aq HCl, dried over Na2SO4, concentrated, and fractionated by FCC 
(10% ethyl acetate in hexane) to give the titled compound (2.84 g, 83%): [α]D +16 (c 0.5, 
CHCl3). 
IR (DRIFT) νmax: 1704 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 4.26 (1H, dd, J = 4.5, 4.5 Hz, HC-3), 3.95-3.86 (4H, m, 
H2C-4', H2C-5'), 3.82 (1H, ddd, J = 5, 5.5, 6 Hz, HC-7), 2.95 (1H, dq, J = 4.5, 7 Hz, HC-
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4), 2.85 (1H, dq, J = 6, 7 Hz, HC-6), 1.83 (1H, dq, J = 4.5, 7 Hz, HC-2), 1.69 (1H, dq, J = 
14.5, 7.5 Hz, HC-1''), 1.58 (1H, dq, J = 14.5, 7.5 Hz, HC-1''), 1.49 (1H, ddq, J = 4.5, 
14.5, 7.5 Hz, HC-8), 1.32 (1H, ddq, J = 4.5, 14.5, 7.5 Hz, HC-8), 1.12 (3H, d, J = 7 Hz, 
H3CC-4), 1.07 (3H, d, J = 7 Hz, H3CC-6), 0.96 (9H, t, J = 8 Hz, H3CCSi ×3), 0.95 (9H, t, 
J = 8 Hz, H3CCSi ×3), 0.90 (3H, d, J = 7 Hz, H3C-1), 0.88 (3H, t, J = 7.5 Hz, H3C-9), 
0.84 (3H, t, J = 7.5 Hz, H3C-2''), 0.65-0.59 (12H, m, H2CSi ×6). 
13
C NMR (125 MHz, CDCl3) δ 216.0 (s, C-5), 113.8 (s, C-2'), 74.8 (d, C-7), 71.1 (d, C-
3), 65.2 (t ×2, C-4', C-5'), 52.4 (d, C-4), 49.7 (d, C-6), 43.1 (d, C-2), 28.0 (t, C-8), 27.2 (t, 
C-1''), 13.5 (q, CH3C-6), 12.4 (q, CH3C-4), 11.2 (q, C-1), 9.7 (q, C-9), 7.5 (q, C-2''), 7.4 
(q ×3, CH3CSi), 7.2 (q ×3, CH3CSi), 5.6 (t ×3, CH2Si), 5.4 (t ×3, CH2Si). 
LRMS (CI, NH3), m/z (relative intensity): 531 ([M+1]+, 0.4), 501 (1), 399 (12), 337 (7), 
273 (5), 173 (32), 132 (31), 101 (100). 
HRMS (CI, NH3), m/z calcd for C28H58O5Si2+H: 531.3901; found: 531.3897. 
(2S,3R,4S,5S,6R,7R)-2-(2-Ethyl-1,3-dioxolan-2-yl)-4,6-dimethyl-3,7-
bis((triethylsilyl)oxy)nonan-5-ol (176). 
 
176 
LiHBEt3 (1 M in THF; 1.5 mL, 1.5 mmol) was added dropwise via syringe to a 
pre-cooled, stirred solution of 175 (270 mg, 0.51 mmol) in THF (24 mL) at 0 °C under 
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argon. The reaction mixture was removed from the ice bath and allowed to slowly warm 
to ambient temperature. After 18 h, the reaction mixture was cooled to 0 °C and 
quenched by sequential addition of MeOH (4 mL), phosphate buffer (pH 7; 5 mL), and 
30% aqueous H2O2 (3 mL) with vigorous stirring. After 20 min, the mixture was diluted 
with water and extracted with CH2Cl2. The combined organic layers were washed with 
H2O, dried over Na2SO4, and concentrated to give crude product whose 1H NMR 
spectrum indicated the presence of a 7:1 mixture of diastereomers (283 mg). Fractionated 
crude by FCC (10% ethyl acetate in hexane) gave the titled compound (219 mg, 81%): 
[α]D –11 (c 1.1, CHCl3). 
IR (DRIFT) νmax: 3512 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 4.30 (1H, dd, J = 1, 6.5 Hz, HC-3), 4.04 (1H, ddd, J = 1.5, 
5.5, 9.5 Hz, HC-7), 3.95-3.86 (4H, m, H2C-4', H2C-5'), 3.48 (1H, ap d, J = 8.5 Hz, HO), 
3.29 (1H, ddd, J = 3.5, 8.5, 9.5 Hz, HC-5), 1.93 (1H, dq, J = 6.5, 7 Hz, HC-2), 1.88 (1H, 
ddq, J = 1, 9.5, 7 Hz, HC-4), 1.79-1.67 (2H, m, HC-1'', HC-6), 1.66-1.54 (3H, m, HC-1'', 
H2C-8), 1.04 (3H, d, J = 7 Hz, H3CC-6), 0.98 (3H, d, J = 7 Hz, H3C-1), 0.96 (9H, t, J = 8 
Hz, H3CCSi ×3), 0.95 (9H, t, J = 8 Hz, H3CCSi ×3), 0.84 (3H, t, J = 7.5 Hz, H3C-2''), 
0.81 (3H, t, J = 7.5 Hz, H3C-9), 0.71 (3H, d, J = 7 Hz, H3CC-4), 0.65 (6H, ap q, J = 8 Hz, 
H2CSi ×3), 0.62 (6H, ap q, J = 8 Hz, H2CSi ×3). 
13C NMR (125 MHz, CDCl3) δ 114.2 (s, C-2'), 77.5 (s, C-5), 75.1 (d, C-7), 71.5 (d, C-3), 
65.3 (t, C-4'), 65.1 (t, C-5'), 43.8 (d, C-4), 43.5 (d, C-2), 34.2 (d, C-6), 28.0 (t, C-8), 27.1 
(t, C-1''), 13.1 (q, C-1), 11.1 (q, CH3C-6), 10.2 (q, C-9), 9.9 (q, CH3C-4), 7.6 (q, C-2''), 
7.4 (q ×3, CH3CSi), 7.1 (q ×3, CH3CSI), 5.8 (t ×3, CH2Si), 5.7 (t ×3, CH2Si). 
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LRMS (CI, NH3), m/z (relative intensity): 533 ([M+1]+, 1), 401 (6), 373 (7), 339 (39), 
201 (11), 173 (12), 132 (31), 132 (11), 101 (100). 
HRMS (CI, NH3), m/z calcd for C28H60O5Si2+H: 533.4058 ; found: 533.4032. 
(2S,3R)-2-[(4S,5S,6R)-6-((S)-1-(2-Ethyl-1,3-dioxolan-2-yl)ethyl]-2,2,5-trimethyl-1,3-
dioxan-4-yl)pentan-3-ol (177) and (2S,3R,4R)-2-(2-Ethyl-1,3-dioxolan-2-yl)-4-
[(4R,5S,6R)-6-ethyl-2,2,5-trimethyl-1,3-dioxan-4-yl]pentan-3-ol (178). 
 
177 178 
p-TsOH·H2O (2.5 mg, 0.01 mmol) was added to a stirred solution of 182 (10 mg, 
0.033 mmol) in CH2Cl2 (1 mL) and 2,2-dimethoxypropane (0.5 mL). After 5 min, the 
mixture was diluted with CH2Cl2, washed with saturated aq NaHCO3, dried over Na2SO4, 
concentrated, and fractionated by PTLC (20% ethyl acetate in hexane) to give an 
inseparable 7:3 mixture of 177 and 178, respectively (8 mg, 70%). 
1
H NMR (500 MHz, C6D6) δ (* major isomer) 4.31 (0.7H, ddd, J = 1, 3.5, 5 Hz, *HC-3), 
4.08 (0.3H, dd, J = 4.5, 7.5 Hz, HC-6'), 4.05-4.01 (0.3H, m, HC-3), 3.73 (0.7H, ddd, J = 
4.5, 4.5, 9 Hz, *HC-6'' [3JHC-5'' = 4.5 Hz]), 3.48 (4H, br s, *H2C-C-4', H2C-4''', *H2C-5', 
H2C-5'''), 3.36 (1H, ap dd, J = 4, 8 Hz, *HC-4'', HC-4'), 3.24 (0.7H, d, J = 1 Hz, *HOC-
3), 3.11 (0.3H, d, J = 2 Hz, HOC-3), 2.17 (0.7H, dq, J = 5, 7 Hz, *HC-2), 2.14-2.04 
(1.3H, m, *HC-4, HC-1'', HC-5'), 1.91 (0.7H, ddq, J = 4.5, 8, 7 Hz, *HC-5'' [3JHC-6'' = 4.5 
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Hz, 3JHC-4'' = 8 Hz]), 1.85 (0.7H, dq, J = 14, 7.5 Hz, *HC-1'''), 1.81-1.60 (2H, m, *HC-1''', 
H2C-1'''', HC-4), 1.56 (0.3H, ddq, J = 2,5, 4, 7 Hz, HC-2), 1.44 (0.7H, ddq, J = 9, 13.5, 
7.5 Hz, *HC-1''''), 1.39 (2.1H, d, J = 7 Hz, *H3C-1), 1.37-1.30 (0.3H, m, HC-4), 1.29 
(2.1H, s, *H3C-2''), 1.27 (2.1H, d, J = 7 Hz, *H3C-5), 1.26 (0.9H, s, H3C-2'), 1.23 (2.1H, 
s, *H3C-2''), 1.23 (0.9H, d, J = 7 Hz, H3C-2''), 1.22 (0.9H, s, H3C-2'), 1.15 (0.7H, ddq, J = 
4.5, 13.5, 7.5 Hz, *HC-1''''), 1.06 (0.9H, t, J = 7 Hz, H3C-5), 1.06 (0.9H, d, J = 7 Hz, HC-
2), 0.98 (2.1H, t, J = 7.5 Hz, *H3C-2'''), 0.97 (0.9H, d, J = 7 Hz, H3CC-5'), 0.93 (0.9H, t, 
J = 7.5 Hz, H3C-2''''), 0.88 (2.1H, t, J = 7.5 Hz, *H3C-2''''), 0.81 (2.1H, d, J = 7 Hz, 
*H3CC-5'').  
13C NMR (125 MHz, CDCl3) δ (* major isomer) 114.4* (s), 113.8 (s), 101.2 (s), 100.9* 
(s), 81.0 (d), 80.2* (d), 73.7 (d), 71.5* (d), 70.8* (d), 69.3 (d), 65.3 (t), 65.23* (t), 65.21* 
(t), 65.0 (t), 42.4* (d), 40.0* (d), 39.8 (d), 39.2 (d), 39.0 (d), 37.0* (d), 27.4 (t), 26.78* 
(t), 26.73 (t), 25.4* (q, CH3C-2''), 25.3 (q, CH3C-2'), 23.8* (t ), 23.7* (q, CH3C-2''), 23.6 
(q, CH3C-2'), 13.6 (q), 12.4 (q), 12.34* (q), 12.29* (q), 12.0 (q), 11.2 (q), 10.8* (q ×2), 
7.6* (q), 7.4 (q). 
HRMS (ESI), m/z calcd for C19H36O5+Na: 367.2454; found: 367.2443. 
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2-[(2S,3R,4S,5S,6S,7R)-3-Allyloxy-4,6-dimethyl-5,7-bis[(triethylsilyl)oxy]nonan-2-
yl]-2-ethyl-1,3-dioxolane (180).  
 
180 
KHMDS (0.5 M in toluene; 1.3 mL, 0.65 mmol) was added dropwise via syringe 
to a stirred solution of 176 (170 mg, 0.32 mmol) in THF (10 mL) at −78 °C under argon. 
After 5 min, allyl bromide (140 µL, 193 mg, 1.59 mmol) was added. The reaction was 
allowed to warm to ambient temperature and after 18 h, was quenched by addition of 
MeOH (2 mL). The mixture was diluted with CH2Cl2, washed with saturated aq NH4Cl, 
dried over Na2SO4, concentrated, and fractionated by FCC (10% ethyl acetate in hexane) 
to give the titled compound (168 mg, 92%): [α]D –21 (c 1.1, CHCl3). 
IR (DRIFT) νmax: 3080, 1642 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.93-5.85 (1H, ap ddt, J = 10.5, 17, 5 Hz, HC=), 5.23 
(1H, ap dddd, J = 1.5, 1.5, 2, 17 Hz, HC=), 5.06 (1H, dddd, J = 1.5, 1.5, 2, 10.5 Hz, 
HC=), 4.09 (1H, dddd, J = 1.5, 1.5, 5, 13 Hz, H2CO), 3.98 (1H, dddd, J = 1.5, 1.5, 5, 13 
Hz, H2CO), 3.95-3.88 (4H, m, H2C-4, H2C-5), 3.81-3.77 (2H, m, HC-3', HC-7'), 3.66 
(1H, dd, J = 4, 6 Hz, HC-5'), 1.87-1.78 (2H, m, HC-2', HC-4'), 1.75-1.67 (3H, m, H2C-1'', 
HC-6'), 1.62-1.49 (2H, m, H2C-8'), 1.00 (3H, d, J = 7 Hz, H3C-1'), 0.965 (9H, t, J = 8 Hz, 
H3CCSi ×3), 0.96 (3H, d, J = 7 Hz, H3CC'4'), 0.955 (9H, t, J = 8 Hz, H3CCSi ×3), 0.87 
 131
(3H, d, J = 7 Hz, H3CC-6'), 0.86 (3H, t, J = 7.5 Hz, H3C-2''), 0.85 (3H, t, J = 7.5 Hz, 
H3C-9'), 0.69-0.55 (6H, m, H2CSi ×6). 
13
C NMR (125 MHz, CDCl3) δ 136.0 (d, CH=), 115.2 (s, C-9), 114.1 (t, CH2=), 77.6 (d, 
C-3'??), 76.2 (d, C-5), 74.7 (d, C-7), 72.5 (t, CH2OAll), 65.7 (t, C-4), 65.0 (t, C-5), 44.6 
(d, C-2'), 43.5 (d, C-4'), 42.4 (d, C-6'), 28.3 (t, C-8'), 27.2 (t, C-1''), 12.8 (q, CH3C-4'), 
10.5 (q, CH3C-6'), 10.1 (q, CH3C-1'), 9.7 (q, C-9'), 7.45 (q, C-2''), 7.36 (q ×3, CH3CSi), 
7.33 (q ×3, CH3CSi), 6.0 (t ×3, CH2Si), 5.8 (t ×3, CH2Si). 
LRMS (CI, NH3), m/z (relative intensity): 573 ([M+1]+, 7), 311 (11), 247 (21), 173 (22), 
132 (35), 101 (100). 
HRMS (CI, NH3), m/z calcd for C31H64O5Si2+H: 573.4371; found: 573.4373. 
 (2S,3R,4S,5S,6S,7R)-2-(2-Ethyl-1,3-dioxolan-2-yl)-4,6-dimethylnonane-3,5,7-triol 
(182). 
 
182 
TBAF (110 mg, 0.42 mmol) was added to a stirred solution of 176 (200 mg, 0.40 
mmol) in THF (5 mL) at ambient temperature. After 2 h, the mixture was diluted with 
CH2Cl2, washed with saturated aq NH4Cl, dried over Na2SO4, concentrated, and 
fractionated by FCC (40% ether in CH2Cl2) to give the titled compound (88 mg, 77%): 
[α]D –13 (c 0.1, CHCl3). 
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IR (DRIFT) νmax: 3431 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 4.48 (1H, br s, HOC-5), 4.23 (1H, br s, HC-3), 4.01-3.94 
(4H, m, H2C-4', H2C-5'), 3.83 (1H, br dd, J = 5.5, 7 Hz, HC-7), 3.68 (1H, br dd, J = 7, 8 
Hz, HC-5), 3.48 (1H, br s, HOC-7), 2.98 (1H, br s, HOC-3), 2.06 (1H, ddq, J = 3.5, 7, 7 
Hz, HC-4), 2.02 (1H, dq, J = 1.5, 7 Hz, HC-2), 1.82 (1H, ddq, J = 1.5, 6, 7 Hz, HC-6), 
1.73-1.60 (2H, m, H2C-1''), 1.56 (1H, ddq, J = 7, 13,5, 7.5 Hz, HC-8), 1.42 (1H, ddq, J = 
5.5, 13.5, 7.5 Hz, HC-8), 1.08 (3H, d, J = 7 Hz, H3C-1), 0.97 (3H, d, J = 7 Hz, H3CC-6), 
0.96 (3H, t, J = 7.5 Hz, H3C-9), 0.93 (3H, d, J = 7 Hz, H3CC-4), 0.89 (3H, t, J = 7.5 Hz, 
H3C-2''). 
13C NMR (125 MHz, CDCl3) δ 115.1 (s, C-2'), 80.6 (d, C-5), 74.2 (d, C-7), 72.1 (d, C-3), 
65.4 (t, C-4'), 65.1 (t, C-5'), 40.0 (d, C-2), 39.6 (d, C-4), 38.3 (d, C-6), 27.1 (t, C-1'' or C-
8), 27.0 (t, C-1'' or C-8), 13.2 (q, CH3C-4), 11.8 (q, CH3C-6), 11.0 (q, C-9), 10.1 (q, C-1), 
8.1 (q, C-2''). 
LRMS (CI, NH3), m/z (relative intensity): 305 ([M+1]+, 6), 243 (38), 225 (44), 101 
(100). 
HRMS (CI, NH3), m/z calcd for C16H32O5+H: 305.2328; found: 533.2325. 
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2-[(2S,3R,4S,5S,6S,7R)-3,5,7-Tris(allyloxy)-4,6-dimethylnonan-2-yl]-2-ethyl-1,3-
dioxolane (187). 
 
187 
A solution of 182 (93 mg, 3.06 mmol) in THF (20 mL) was added dropwise via 
syringe to a stirred suspension of KH (oil free; 0.52 g, 13 mmol) and DMPU (1.6 mL, 1.7 
g, 13 mmol) in THF (100 mL) at 0 °C. After 10 min, allyl bromide (1.7 mL, 2.4 g, 19 
mmol) was added dropwise via syringe. The reaction mixture was allowed to warm to 
ambient temperature and after18 h, was cooled down to 0 °C and quenched by slow 
addition of MeOH (6 mL) (Caution: H2 evolution). The mixture was diluted with CH2Cl2, 
washed sequentially with saturated aq NH4Cl and brine, dried over Na2SO4, and 
fractionated by FCC (10% ethyl acetate in hexane) to give the titled compound (1.18 g, 
91%): [α]D –25 (c 1.0, CHCl3). 
IR (DRIFT) νmax: 3088, 1646 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.95-5.86 (3H, m, HC= ×3), 5.25 (3H, br d, J = 17 Hz, 
HC= ×3), 5.11-5.06 (3H, m, HC= ×3), 4.09-4.01 (5H, m, H2CO-allyl ×2.5), 3.96-3.88 
(5H, m, H2C-4, H2C-5, H2CO-allyl ×0.5), 3.76 (1H, dd, J = 3, 4.5 Hz, HC-3'), 3.50 (1H, 
ddd, J = 3, 6, 7 Hz, HC-7'), 3.21 (1H, dd, J = 5, 7 Hz, HC-5'), 1.91 (1H, ddq, J = 4.5, 5, 7 
Hz, HC-4'), 1.87 (1H, dq, J = 3, 7 Hz, HC-2'), 1.81 (1H, ddq, J = 3, 7, 7 Hz, HC-6'), 1.76, 
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1.63 (3H, m, H2C-1'', HC-8'), 1.46 (1H, ddq, J = 7, 14, 7.5 Hz, HC-8'), 1.01 (3, d, J = 7 
Hz, H3C-1'), 0.99 (3, d, J = 7 Hz, H3CC-4'), 0.94 (3, d, J = 7 Hz, H3CC-6'), 0.89 (3, t, J = 
7.5 Hz, H3C-9'), 0.86 (3, t, J = 7.5 Hz, H3C-2''). 
13
C NMR (125 MHz, CDCl3) δ 136.1 (d, CH=), 136.0 (d, CH=), 135.9 (d, CH=), 115.9 
(t, CH2=), 115.5 (t, CH2=), 115.3 (t, CH2=), 114.2 (s, C-2), 84.2 (d, C-5'), 80.5 (d, C-7'), 
77.3 (d, C-3'), 72.8 (t, CH2O), 72.4 (t, CH2O), 71.0 (t, CH2O), 65.6 (t, C-4), 65.1 (t, C-5), 
44.6 (d, C-2'), 41.8 (d, C-4'), 38.6 (d, C-6'), 27.2 (t, C-1''), 25.0 (t, C-8'), 12.8 (q, CH3C-
4'), 11.3 (q, CH3C-6'), 10.4 (q, C-9'), 10.1 (q, C-1'), 7.5 (q, C-2''). 
LRMS (CI, NH3), m/z (relative intensity): 425 ([M+1]+, 5), 367 (4), 237 (26), 141 (3), 
101 (100), 99 (12), 57 (4). 
HRMS (CI, NH3), m/z calcd for C25H44O5+H: 425.3267; found: 425.3259. 
(4S,5R,6S,7S,8S,9R)-5,7,9-Tris(allyloxy)-4,6,8-trimethylundecan-3-one (188). 
 
188 
FeCl3·6H2O (150 mg, 0.55 mmol) was added to a stirred solution of 187 (603 mg, 
1.42 mmol) in THF (8.5 mL) and CH2Cl2 (8.5 mL). After 19 h, the reaction mixture was 
diluted with CH2Cl2, washed sequentially with H2O and brine, dried over Na2SO4, and 
concentrated to give the titled compound (538 mg, quantitative) that was homogeneous 
by TLC and 1H NMR: [α]D –4 (c 2.2, CHCl3). 
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IR (DRIFT) νmax: 3087, 1711, 1646 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.93-5.83 (3H, m, HC= ×3), 5.26-5.21 (3H, m, HC= ×3), 
5.10-5.07 (3H, m, HC= ×3 ), 4.12-3.96 (5H, m, H2CO ×2.5), 3.86 (1H, dddd, J = 1.5, 1.5, 
5, 12.5 Hz, H2CO ×0.5), 3.76 (1H, dd, J = 3, 6.5 Hz, HC-5), 3.50 (1H, ddd, J = 3, 5.5, 8 
Hz, HC-9), 3.16 (1H, dd, J = 4, 7.5 Hz, HC-7), 2.84 (1H, dq, J = 7, 7 Hz, HC-4), 2.53 
(1H, dq, J = 18, 7.5 Hz, HC-2), 2.46 (!H, dq, J = 18, 7.5 Hz, HC-2), 1.76 (1H, ddq, J = 3, 
7, 7 Hz, HC-8), 1.73-1.63 (2H, m, HC-6, HC-10), 1.44 (1H, ddq, J = 8, 14, 7.5 Hz, HC-
10), 1.13 (3H, d, J = 7 Hz, H3CC-4), 1.02 (3H, t, J = 7 Hz, H3C-1), 1.00 (3H, d, J = 7 Hz, 
H3CC-6), 0.87 (3H, t, J = 7.5 Hz, H3C-11), 0.86 (3H, d, J = 7 Hz, H3CC-8). 
13C NMR (125 MHz, CDCl3) δ 214.3 (s, C-3), 136.0 (d, CH=), 135.8 (d, CH=), 135.5 (d, 
CH=), 116.1 (t, CH2=), 115.7 (t, CH2=), 115.5 (t, CH2=), 85.0 (d, C-7), 80.3 (d, C-9), 
80.0 (d, C-5), 73.3 (t, CH2O), 72.8 (t, CH2O), 70.8 (t, CH2O), 50.2 (d, C-4), 38.9 (d, C-6 
or C-8), 38.8 (d, C-6 or C-8), 35.8 (t, C-2), 24.7 (t, C-10), 13.6 (q, CH3C-6), 13.1 (q, 
CH3C-4), 11.0 (q, CH3C-8), 10.5 (q, C-11 ), 7.9 (q, C-1). 
LRMS (CI, NH3), m/z (relative intensity): 381 ([M+1]+, 100), 323 (39), 265 (33), 237 
(34), 195 (47), 155 (17), 101 (18), 99 (32), 57 (10). 
HRMS (CI, NH3), m/z calcd for C23H40O4+H: 381.3005; found: 381.2997. 
 136
(2R,3S,5S,6S)-2-Ethyl-2-methoxy-3,5-dimethyl-6-((R)-3-oxopentan-2-yl)dihydro-2H-
pyran-4(3H)-one (189).  
O
H OMe
O
O
2
35
6
1'
2'
2"
4"
 
189 
 
A solution of 188 (10 mg, 0.026 mmol) in methanol (1.3 mL) was added via 
syringe to a dry Schlenk flask containing a magnetic stir bar and Ru(IV) catalyst 190 (0.3 
mg, 0.6 µmol) under argon. Stirring was initiated and after 10 min, the mixture was 
diluted with ethyl acetate and washed with distilled water (×3). The organic layer was 
dried over Na2SO4, concentrated to give the crude product (8 mg) whose 1H NMR 
spectrum indicated a single compound without an allyl group. IBX (15 mg, 0.05 mmol) 
was added to the solution of the above crude in DMSO (1 mL). After 2 h, the mixture 
was diluted with ethyl acetate, and washed sequentially with NaHCO3 and brine, dried 
over Na2SO4, concentrated, and fractionated by PTLC (15% ethyl acetate in hexane) to 
give the titled compound (5.1 mg, 72 %): [α]D –118 (c 0.1, CHCl3). 
IR (neat) νmax: 1722, 1703 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 3.55 (1H, dd, J = 3, 10.5 Hz, HC-6), 3.15 (3H, s, H3CO), 
2.77 (1H, dq, J = 3, 7 Hz, HC-1''), 2.66 (1H, dq, J = 18.5, 7 Hz, HC-4''), 2.63 (1H, dq, J = 
1, 6.5 Hz, HC-3), 2.55 (1H, dq, J = 18.5, 7 Hz, HC-4''), 2.45 (1H, ddq, J = 1,10.5, 6.5 Hz, 
HC-5), 1.95 (1H, dq, J = 13.5, 7.5 Hz, HC-1'), 1.56 (1H, dq, J = 13.5, 7.5 Hz, HC-1'), 
 137
1.34 (3H, d, J = 7 Hz, H3C-1''), 1.05 (3H, t, J = 7 Hz, H3C-5''), 1.03 (3H, d, J = 6.5 Hz, 
H3CC-5), 0.99 (3H, d, J = 6.5 Hz, H3CC-3), 0.98 (3H, t, J = 7.5 Hz, H3C-2'). 
13
C NMR (125 MHz, CDCl3) δ 213.3 (s, C-4 or C-3''), 208.8 (s, C-4 or C-3''), 106.2 (s, 
C-2), 78.5 (d, C-6), 49.4 (d, C-3), 49.0 (d, C-2''), 47.8 (q, CH3O), 47.2 (d, C-5), 35.0 (t, 
C-4''), 26.4 (t, C-1'), 14.4 (q, C-1''), 9.9 (q, C-5''), 8.9 (q, CH3C-3 or CH3C-5), 8.4 (q, 
CH3C-3 or CH3C-5), 7.7 (q, C-2'). 
LRMS (EI), m/z (relative intensity): 270 ([M]+, 1), 185 (13), 182 (20), 153 (53), 126 
(42), 108 (15), 100 (100), 69 (25), 57 (75). 
HRMS (EI), m/z calcd for C15H26O4: 270.1831; found: 270.1839. 
(3R,4S,5S,6S,7R,8S,10R,11S,12E,14E)-3,5,7-Tris(allyloxy)-11-hydroxy-
4,6,8,10,12,14-hexamethylheptadeca-12,14-dien-9-one (192).  
 
192 
(c-Hex)2BCl (1 M in hexane, 1.6 mL, 1.6 mmol), and Et3N (0.24 mL, 0.17 g, 1.7 
mmol) were added sequentially via syringe to a stirred solution of 188 (200 mg, 0.53 
mmol) in Et2O (9 mL) at 0 °C under argon. After 1 h, the reaction mixture was cooled to 
−78 °C and a solution of the aldehyde 73 (145 mg, 1.05 mmol) in Et2O (1 mL) was added 
dropwise via syringe. After 18 h, the reaction was quenched by sequential addition of 
MeOH (5 mL), phosphate buffer (pH 7; 10 mL), and 30% aqueous H2O2 (5 mL) with 
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vigorous stirring. The reaction vessel was transferred to an ice bath and after 15 min, was 
extracted with CH2Cl2. The combined organic layers were dried over Na2SO4, 
concentrated, and fractionated by FCC (10% ethyl acetate in hexane) to give the titled 
compound: (220 mg, 80%) [α]D +14 (c 0.8, CHCl3). 
IR (DRIFT) νmax: 3444, 3087, 1707, 1646 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.94-5.86 (3H, m, HC= ×3), 5.84 (1H, br s, HC-13), 5.32 
(1H, dd, J = 7, 7 Hz, HC-15), 5.28-5.22 (3H, m, HC= ×3), 5.10-5.07 (3H, m, HC= ×3), 
4.13-3.99 (6H, m, H2CO ×2.5, HC-11), 3.91-3.85 (2H, m, H2CO ×0.5, HC-7), 3.53 (1H, 
ddd, J = 2.5, 5.5, 8 Hz, HC-3), 3.19 (1H, dd, J = 4, 7.5 Hz, HC-5), 3.04 (1H, dq, J = 7, 7 
Hz, HC-8), 2.92 (1H, dq, J = 9, 7 Hz, HC-10), 2.14 (1H, d, J = 3.5 Hz, HO), 2.09 (2H, ap 
qn, J = 7.5 Hz, H2C-16), 1.88-1.79 (2H, m, HC-4, HC-6), 1.75 (3H, br s, H3CC-12), 1.72 
(3H, br s, H3CC-14), 1.72-1.64 (1H, m, HC-2), 1.46 (1H, ddq, J = 8, 14, 7.5 Hz, HC-2), 
1.18 (3H, d, J = 7 Hz, H3CC-8), 1.06 (3H, d, J = 7 Hz, H3CC-6), 0.99 (3H, t, J = 7.5 Hz, 
H3C-17), 0.93 (3H, d, J = 7 Hz, H3CC-10), 0.89 (3H, d, J = 7 Hz, H3CC-4), 0.89 (3H, t, J 
= 7.5 Hz, H3C-1). 
13C NMR (125 MHz, CDCl3) δ 217.8 (s, C-9), 136.1 (d, CH=), 135.9 (d, CH=), 135.7 (d, 
CH=), 133.8 (s, C-12 or C-14), 133.2 (d ×2, C-13, C-15), 131.5 (s, C-12 or C-14), 116.0 
(t, CH2=), 115.8 (t, CH2=), 115.5 (t, CH2=), 85.1 (d, C-5), 81.2 (d, C-11), 80.4 (d, C-3), 
79.2 (d, C-7), 73.4 (t, CH2O), 73.0 (t, CH2O), 70.8 (t, CH2O), 50.8 (d, C-8), 49.0 (d, C-
10), 39.4 (d, C-6), 38.9 (d, C-4), 24.7 (t, C-2), 21.6 (t, C-16), 16.9 (q, CH3C-14), 14.8 (q, 
CH3C-10), 14.3 (q, C-17), 13.8 (q, CH3C-6), 12.8 (q, CH3C-8), 12.6 (q, CH3C-12), 11.0 
(q, CH3C-4), 10.5 (q, C-1). 
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LRMS (CI, NH3), m/z (relative intensity): 536 ([M+18]+, 1), 519 ([M+1]+, 3), 501 (12), 
381 (100), 351 (16), 323 (25), 265 (43), 237 (56), 195 (15), 109 (82). 
HRMS (CI, NH3), m/z calcd for C32H54O5+NH4: 536.4315; found: 536.4335. 
 (3R,4S,5S,6S,7R,8S,10R,11S,12E,14E)-3,5,7-Tris(allyloxy)-4,6,8,10,12,14-
hexamethyl-11-(triethylsilyloxy)heptadeca-12,14-dien-9-one (193a).  
 
193a 
TESOTf (26 µl, 30 mg, 0.11 mmol) and 2,6-lutidine (22 µl, 20 mg, 0.19 mmol) 
were added sequentially to a stirred solution of 192 (50 mg, 0.096 mmol) in CH2Cl2 (1 
mL). After 1 h, the mixture was diluted with CH2Cl2, washed with saturated aq NaHCO3, 
dried over Na2SO4, concentrated, and fractionated by FCC (10% ethyl acetate in hexane) 
to give the titled compound (53 mg, 87%). 
IR (DRIFT) νmax: 3080, 1709, 1647 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.95-5.83 (3H, m, HC= ×3), 5.77 (1H, br s, HC-13), 5.29-
5.21 (4H, m, HC= ×3, HC-15), 5.10-5.06 (3H, m, HC= ×3), 4.15 (1H, d, J = 9.5 Hz, HC-
11), 4.08-4.01 (5H, m, H2CO ×2, HC-7), 3.97 (1H, dddd, J = 1.5, 1.5, 5.5, 12.5 Hz, H2CO 
×0.5), 3.89 (1H, dddd, J = 1.5, 1.5, 5.5, 12.5 Hz, H2CO ×0.5), 3.50 (1H, ddd, J = 3, 5.5, 
7.5 Hz, HC-3), 3.2 (1H, dd, J = 5, 7 Hz, HC-5), 3.03 (1H, dq, J = 7, 9.5 Hz, HC-10), 2.73 
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(1H, dq, J = 5, 7 Hz, HC-8), 2.09 (2H, ap dq, J = 7, 7.5 Hz, H2C-16), 1.89-1.80 (2H, m, 
HC-4, HC-6), 1.71 (3H, s, H3CC-14), 1.70 (3H, d, J = 1 Hz, H3CC-12), 1.70-1.62 (1H, m, 
HC-2), 1.46 (1H, ddq, J = 7, 14, 7.5 Hz, HC-2), 1.26 (3H, d, J = 7 Hz, H3CC-8), 1.03 
(3H, d, J = 7 Hz, H3CC-4), 0.99 (3H, t, J = 7.5 Hz, H3C-17), 0.95 (3H, d, J = 7 Hz, 
H3CC-4), 0.88 (9H, t, J = 8 Hz, H3CCSi ×3), 0.88 (3H, t, J = 7.5 Hz, H3CC-1), 0.81 (3H, 
d, J = 7 Hz, H3CC-10), 0.51 (6H, ap q, J = 8 Hz, H2CSi ×3). 
13
C NMR (125 MHz, CDCl3) δ 216.3 (s, C-9), 136.1 (d, CH=), 135.9 (d, CH=), 135.7 (d, 
CH=), 134.6 (s, C-12 or C-14), 132.9 (d, C-13), 132.6 (d, C-15), 131.5 (s, C-12 or C-14), 
115.7 (t ×2, CH2=), 115.5 (t, CH2=), 84.6 (d, C-5), 82.5 (d, C-11), 80.4 (d, C-3), 78.3 (d, 
C-7), 73.1 (t, CH2O), 73.0 (t, CH2O), 70.9 (t, CH2O), 52.0 (d, C-8), 47.4 (d, C-10), 40.1 
(d, C-6), 38.8 (d, C-4), 24.9 (t, C-2), 21.6 (t, C-16), 16.8 (q, CH3C-14), 15.1 (q, CH3C-
10), 14.3 (q, C-17), 13.4 (q, CH3C-6), 12.4 (q, CH3C-12), 11.8 (q, CH3C-8), 11.4 (q, 
CH3C-4), 10.4 (q, CH3C-1), 7.1 (q ×3, CH3CSi), 5.0 (t ×3, CH2Si). 
HRMS (ESI), m/z calcd for C38H68O5Si+Na: 655.4728; found: 655.4740. 
(3R,4S,5S,6S,7R,8S,10R,11S,12E,14E)-3,5,7-Tris(allyloxy)-4,6,8,10,12,14-
hexamethyl-9-oxoheptadeca-12,14-dien-11-yl Acetate (193b).  
 
193b 
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Ac2O (100 µL, 108 mg, 1.05 mmol), iPr2EtN (0.27 mL, 0.20 g, 1.6 mmol), and 
DMAP (10 mg, 0.08 mmol) were added sequentially to a stirred solution of 192 (136 mg, 
0.262 mmol) in CH2Cl2 (8 mL). After 18 h, the mixture was diluted with CH2Cl2, washed 
with saturated aq NaHCO3, dried over Na2SO4, concentrated, and fractionated by PTLC 
(10% ethyl acetate in hexane) to give the titled compound (146 mg, quantitative): [α]D +4 
(c 1.3, CHCl3). 
IR (DRIFT) νmax: 3086, 1745, 1711 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.99 (1H, br s, HC-5), 5.94-5.84 (3H, m, HC= ×3), 5.33 
(1H, br dd, J = 7, 7 Hz, HC-3), 5.28-5.21 (4H, m, HC= ×3, HC-11), 5.11-5.08 (3H, m, 
HC= ×3), 4.14-3.96 (5H, m, H2CO ×2.5), 3.87 (1H, dddd, J = 1.5, 1.5, 5, 12.5 Hz, H2CO 
×0.5), 3.84 (1H, dd, J = 3.5, 6 Hz, HC-7), 3.53 (1H, ddd, J = 3, 5.5, 8 Hz, HC-3), 3.19 
(1H, dd, J = 4, 8 Hz, HC-5), 3.10 (1H, dq, J = 10.5, 7 Hz, HC-10), 2.97 (1H, dq, J = 6, 7 
Hz, HC-8), 2.11-2.03 (2H, m, H2C-16), 1.91 (3H, s, H3CCO), 1.84 (1H, ddq, J = 3, 8, 7 
Hz, HC-4), 1.71 (1H, ddq, J = 3.5, 4, 7 Hz, HC-6), 1.74-1.64 (1H, m, HC-2), 1.72 (6H, s, 
H3CC-12, H3CC-14), 1.46 (1H, ddq, J = 8, 14, 7.5 Hz, HC-2), 1.19 (3H, d, J = 7 Hz, 
H3CC-8), 1.07 (3H, d, J = 7 Hz, H3CC-6), 0.97 (3H, t, J = 7.5 Hz, H3C-17), 0.96 (3H, d, J 
= 7 Hz, H3CC-10), 0.88 (3H, t, J = 7.5 Hz, H3C-1), 0.87 (3H, d, J = 7 Hz, H3CC-4). 
13C NMR (125 MHz, CDCl3) δ 214.3 (s, C-9), 169.5 (s, O=CO), 136.0 (d, CH=), 135.8 
(d, CH=), 135.7 (d, C-13), 135.5 (d, CH=), 133.8 (d, C-3), 131.4 (s, C-12 or C-14), 129.6 
(s, C-12 or C-14), 116.0 (t, CH2=), 115.7 (t, CH2=), 115.6 (t, CH2=), 85.0 (d, C-5), 82.0 
(d, C-11), 80.4 (d, C-3), 79.0 (d, C-7), 73.4 (t, CH2O), 72.9 (t, CH2O), 70.7 (t, CH2O), 
50.3 (d, C-8), 46.8 (d, C-10), 39.5 (d, C-6), 38.8 (d, C-4), 24.5 (t, C-2), 21.6 (t, C-16), 
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21.4 (q, CH3CO), 16.8 (q, CH3C-14), 14.7 (q, CH3C-10), 14.2 (q, C-17), 13.9 (q, CH3C-
6), 13.3 (q, CH3C-12), 12.6 (q, CH3C-8), 10.9 (q, CH3C-4), 10.5 (q, C-1). 
LRMS (CI, NH3), m/z (relative intensity): 578 ([M+18]+, 17), 561 ([M+1]+, 3), 535 (18), 
501 (27), 443 (22), 351 (55), 295 (15), 237 (100), 99 (58). 
HRMS (CI, NH3), m/z calcd for C34H56O6+NH4: 578.4415; found: 578.4408. 
(2R,3S,4E,6E)-2-((1R,3R,4S,5R,6R)-3-Ethyl-4,6,8-trimethyl-2,9-
dioxabicyclo[3.3.1]non-7-en-1-yl)-4,6-dimethylnona-4,6-dien-3-ol (194a).  
 
194a 
A solution of 193a (11 mg, 0.017 mmol, 0.02M) in methanol (8 mL) was added 
via syringe to a dry Schlenk flask containing Ru(IV) catalyst 190 (0.4 mg, 0.8 µmol) 
under argon. The reaction mixture was kept at 30 °C. After 20 min, the reaction mixture 
was diluted with ethyl acetate, washed sequentially with distilled water and brine, dried 
over Na2SO4, concentrated, and fractionated by PTLC (40 % ethyl acetate in hexane) to 
give the titled compound (5 mg, 79%). 
IR (DRIFT) νmax: 3479 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.90 (1H, br s, HC-5), 5.76 (1H, br d, J = 5 Hz, HC-7 '), 
5.31 (1H, br t, J = 7 Hz, HC-7), 5.06 (1H, br s, HO), 4.44 (1H, d, J = 9 Hz, HC-3), 3.95 
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(1H, ddd, J = 3, 5.5, 8 Hz, HC-3'), 3.67 (1H, br s, HC-5'), 2.11-2.02 (3H, m, HC-2, H2C-
8), 1.98 (, br dq, J = 5, 7 Hz, HC-6'), 1.77 (3H, s, H3CC-4), 1.72 (3H, s, H3CC-6), 1.61 
(3H, s, H3CC-8'), 1.53 (1H, ddq, J = 8, 13, 7.5 Hz, HC-1''), 1.41-1.31 (2H, m, HC-1'', 
HC-4'), 1.15 (3H, d, J = 7 Hz, H3CC-4'), 1.09 (3H, d, J = 7 Hz, H3CC-6'), 0.98 (3H, t, J = 
7.5 Hz, H3C-9), 0.86 (3H, t, J = 7.5 Hz, H3C-2''), 0.65 (3H, d, J = 7 Hz, H3C-1). 
13
C NMR (125 MHz, CDCl3) δ 135.0 (s, C-4), 132.6 (d, C-5), 132.02 (d, C-7), 131.93 (s, 
C-6), 131.1 (d, C-7'), 129.9 (s, C-8'), 101.3 (s, C-9'), 79.94 (d, C-3 or C-5'), 79.86 (d, C-3 
or C-5'), 72.1 (d, C-3'), 40.5 (d, C-2), 36.6 (d, C-4'), 34.7 (d, C-6'), 25.7 (t, C-1''), 21.6 (t, 
C-8), 20.6 (q, CH3C-6'), 18.2 (q, CH3C-8'), 17.0 (q, CH3C-6), 14.4 (q, C-9), 13.1 (q, 
CH3C-4'), 12.5 (q, CH3C-4), 12.2 (q, C-1), 10.0 (q, C-2''). 
LRMS (EI), m/z (relative intensity): 362 ([M]+, 4), 224 (37), 139 (35), 137 (100), 122 
(10), 109 (24), 69 (14), 57 (16). 
HRMS (EI), m/z calcd for C23H38O3: 362.2821; found: 362.2825. 
 (2R,3S,4E,6E)-2-((1R,3R,4S,5R,6R)-3-Ethyl-4,6,8-trimethyl-2,9-
dioxabicyclo[3.3.1]non-7-en-1-yl)-4,6-dimethylnona-4,6-dien-3-yl Acetate (194b).  
 
194b 
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A solution of 193b (12 mg, 0.021 mmol) in methanol (10 mL) was added via 
syringe to a dry Schlenk flask containing Ru(IV) catalyst 190 (0.3 mg, 0.6 µmol) under 
argon. The reaction mixture was kept at 30 °C. After 20 min, the reaction mixture was 
diluted with ethyl acetate, washed sequentially with distilled water and brine, dried over 
Na2SO4, concentrated, and fractionated by PTLC (40 % ethyl acetate in hexane) to give 
the titled compound (6.2 mg, 72%): [α]D –52 (c 0.1, CHCl3). 
IR (DRIFT) νmax: 1737 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.98 (1H, s, HC-5), 5.74 (1H, d, J = 8.5 Hz, HC-3), 5.72 
(1H, dq, J = 5, 1.5 Hz, HC-7'), 5.33 (1H, br dd, J = 7, 7 Hz, HC-7), 3.78 (1H, ddd, J = 3, 
5.5, 8 Hz, HC-3'), 3.61 (1H, br s, HC-5'), 2.25 (1H, dq, J = 8.5, 7 Hz, HC-2), 2.07 (2H, ap 
dq, J = 7, 7.5 Hz, H2C-8), 1.97 (3H, s, H3CCO), 1.95-1.90 (1H, m, HC-6'), 1.75 (3H, d, J 
= 1 Hz, H3CC-4), 1.72 (3H, br s, H3CC-6), 1.59 (3H, dd, J = 1.5, 1.5 Hz, H3CC-8'), 1.45-
1.36 (1H, ddq, J = 8, 13, 7.5 Hz, HC-1''), 1.30-1.21 (2H, m, HC-1'', HC-4'), 1.08 (3H, d, J 
= 7 Hz, H3CC-4'), 1.05 (3H, d, J = 7 Hz, H3CC-6'), 0.97 (3H, t, J = 7.5 Hz, H3C-9), 0.82 
(3H, t, J = 7.5 Hz, H3C-2''), 0.7 (3H, d, J = 7 Hz, H3C-1). 
13C NMR (125 MHz, CDCl3) δ 169.9 (s, CO), 133.8 (d, C-5), 133.0 (d, C-7), 131.9 (s, C-
4 or C-6), 131.7 (s, C-4 or C-6), 130.9 (d, C-7'), 130.4 (s, C-8'), 99.5 (s, C-9'), 80.0 (d, C-
5'), 79.5 (d, C-3), 71.2 (d, C-3'), 39.5 (d, C-2), 36.7 (d, C-4'), 35.0 (d, C-6'), 25.6 (t, C-1''), 
21.9 (q, CH3CO), 21.6 (t, C-8), 20.6 (q, CH3C-6'), 18.5 (q, CH3C-8'), 16.9 (q, CCH3C-6), 
14.3 (q, C-9), 13.8 (q, CCH3C-4), 13.3 (q, CH3C-4'), 12.1 (q, C-1), 10.1 (q, C-2''). 
LRMS (EI), m/z (relative intensity): 404 ([M]+, 9), 344 (23), 228 (13), 207 (14), 149 
(28), 137 (100), 121 (60), 109 (33), 93 (16), 69 (29). 
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HRMS (EI), m/z calcd for C25H40O4: 404.2927; found: 404.2918. 
 (3R,4S,5S,6S,7R,8S,10R,11S,12E,14E)-3,5,7-Tris(allyloxy)-9-cyano-4,6,8,10,12,14-
hexamethyl-9-((trimethylsilyl)oxy)heptadeca-12,14-dien-11-yl Acetate (196).  
 
196 
The solid complex KCN·18-crown-6 (87 mg, 0.26 mmol) was added to a stirred 
solution of 193b (96 mg, 0.171 mmol) in TMSCN (1 mL) at ambient temperature under 
argon. After 12 h, the solvent was removed under vacuum and the residue was 
fractionated by FCC to give the titled compound as a ca. 1.4:1 mixture of diastereomers 
(95 mg, 84%). 
IR (DRIFT) νmax: 3079, 1743, 1646 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 6.03-5.86 (4H, m, HC= ×3, HC-13), 5.33-5.22 (4H, m, 
HC= 3, HC-15), 5.14-5.06 (4H, m, HC= ×3, HC-11), 4.26-3.85 (6.6H, m, H2C ×3, HC-7 
×0.6), 3.77 (0.4H, br dd, J = 3, 3 Hz, HC-7), 3.46 (0.6H, ddd, J = 4, 5.5, 7 Hz, HC-3), 
3.36 (0.4H, ddd, J = 4, 6, 7 Hz, HC-3), 3.22 (1H, ap t, J = 6 Hz, HC-5), 2.50 (0.6H, dq, J 
= 9.5, 7 Hz, HC-10), 2.43 (0.4H, dq, J = 9.5, 7 Hz, HC-10), 2.12-2.00 (3H, m, HC-8, 
H2C-16), 2.08 (1H, s, H3CCO), 2.02 (2H, s, H3CCO), 1.90-1.75 (2H, m, HC-4, HC-6), 
1.72 (s) and 1.71 (s) (6H, s, H3C-12, H3C-14), 1.71-1.41 (2H, m, H2C-2), 1.19 (1H, d, J = 
7 Hz, H3CC-8), 1.15 (2H, d, J = 7 Hz, H3CC-8), 1.02 (2H, d, J = 7 Hz, H3C-10), 1.01-
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0.86 (9H, m, CH3 ×3), 0.72 (1H, d, H3C-10), 0.31 (5.4H, s, J = 7 Hz, H3CSi ×3), 0.28 
(3.6H, s, H3CSi ×3). 
13
C NMR (125 MHz, CDCl3) δ (* major isomer) 170.5* (s, C=O), 169.6 (s, C=O), 135.9 
(d, CH=), 135.83 (d, CH=), 135.77 (d, CH=), 135.7 (d ×2, CH=), 135.5 (d, CH=), 135.2* 
(d) and 133.8* (d), 135.1 (d) and 133.6 (d), 131.3 (s) and 130.7 (s), 131.2* (s) and 130.6* 
(s), 120.9* (s, CN), 120.8 (s, CN), 116.1 (t ×2, CH2=), 115.9 (t ×2, CH2=), 115.6 (t, 
CH2=), 115.4 (t, CH2=), 84.42* (d, C-5), 84.37 (d, C-5), 80.7 (d, C-3 or C-11), 80.64* (d, 
C-11), 80.56 (d, C-3 or C-11), 80.5* (d, C-3), 77.35* (s, C-9; confirmed by DEPT), 76.2 
(d, C-7), 75.8* (d, C-7), 73.4 (t, CH2O), 73.2* (t, CH2O), 73.1 (t, CH2O), 72.4* (t, 
CH2O), 71.0 (t, CH2O), 70.6* (t, CH2O), 47.3 (d, C-8), 46.4* (d, C-8), 42.6 (d, C-4), 
42.2* (d ×2, C-4, C-10), 40.5 (d, C-10), 38.63 (d, C-6), 38.56* (d, C-6), 25.1 (t, C-2), 
24.7* (t, C-2), 21.7 (q, CH3CO), 21.62* (t ×2, C-16), 21.57* (q, CH3CO), 16.7* (q ×2, 
CH3C-14), 14.2* (q ×2, C-17), 13.6 (q, CH3C-12), 13.4* (q, CH3C-10), 13.3* (q, CH3C-
12), 12.4 (q), 12.0 (q), 11.7* (q), 10.94 (q), 10.89 (q), 10.85 (q), 10.3* (q, C-1), 10.1 (q, 
C-1), 2.1* (q ×6, CH3Si). 
HRMS (ESI), m/z calcd for C38H65NO6Si+Na: 682.4479; found: 682.4486. 
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(3R,4S,5S,6S,7R,8S,10R,11S,12E,14E)-9-Cyano-3,5,7-trihydroxy-4,6,8,10,12,14-
hexamethyl-9-((trimethylsilyl)oxy)heptadeca-12,14-dien-11-yl Acetate (197).  
 
197 
A solution of 196 (81 mg, 0.12 mmol) in MeOH (4 mL) was added via syringe to 
a dry Schlenk flask containing a magnetic stir bar and the Ru(IV) catalyst 190 (1.2 mg, 
1.1µmol) under argon. The reaction mixture was stirred at 30 °C for 20 min, and then 
additional Ru(IV) catalyst 190 (1.2 mg, 1.1 µmol) was added. After 20 min, the mixture 
was diluted with ethyl acetate and washed sequentially with water (×3) and brine, dried 
over Na2SO4, concentrated, and fractionated by FCC (40% ethyl acetate in hexane) to 
give the titled compound as a 1.1:1 mixture of diastereomers (44 mg, 67%). 
IR (DRIFT) νmax: 3439, 1742 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.93 (0.6H, br s, HC-13), 5.90 (0.4H, br s, HC-13), 5.35-
5.31 (1H, m, HC-15), 5.20 (0.4H, d, J = 9 Hz, HC-11), 5.11 (0.6H, d, J = 9 Hz, HC-11), 
4.40 (0.4H, br s, HC-7), 4.33 (0.6H, br s, HC-7), 4.30-4.22 (1H, m, HOC-5), 3.88-3.84 
(1H, m, J = 7 Hz, HC-3), 3.61-3.57 (1H, m, HC-5), 3.20 (0.4H, br s, HOC-3), 3.07 (0.4H, 
br s, HOC-7), 2.99 (1.2H, br s, HOC-3, HOC-7), 2.52 (0.4H, dq, J = 9, 7 Hz, HC-10), 
2.36 (0.6H, dq, J = 9, 7 Hz, HC-10), 2.14-2.01 (3H, m, HC-8, H2C-16), 2.07 (1.8H, s, 
H3CCO), 2.03 (1.2H, s, H3CCO), 1.94-1.76 (2H, m, HC-4, HC-6), 1.73-1.71 (6H, m, 
H3CC-12, H3CC-14), 1.60-1.50 (1H, m, HC-2), 1.49-1.38 (1H, m, HC-2), 1.22 (1.2H, d, J 
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= 7 Hz, H3CC-8), 1.16 (1.8H, d, J = 7 Hz, H3CC-8), 1.08 (1.2H, d, H3CC-8), 1.00-0.92 
(10.8H, m, H3C ×3.6), 0.89 (1.8H, d, J = 7 Hz, H3CC-10), 0.88 (1.2H, d, J = 7 Hz, H3C 
×0.4), 0.31 (9, s, H3C-Si×3), 0.28 (9, s, H3C-Si×3).  
13
C NMR (125 MHz, CDCl3) δ (* major isomer) 170.1* (s, CO), 169.7 (s, CO), 135.45* 
(d, C-13), 135.40 (d, C13), 134.03 (d, C15), 133.95* (d, C-15), 131.19* (s, C-12 or C-
14), 131.18 (s, C-12 or C-14), 130.35 (s, C-12 or C-14), 130.33* (s, C-12 or C-14), 121.1 
(s, CN), 121.0* (s, CN), 80.8* (d, C-11), 80.5 (d, C-11), 80.2 (d, C-5), 79.9* (d, C-5), 
79.6 (s, C-9), 78.9* (s, C-9), 74.5* (d, C-3), 73.8 (d, C-3), 71.2* (d, C-7), 71.0 (d, C-7), 
44.8* (d, C-8), 44.1 (d, C-8), 41.4* (d, C-10), 41.3* (d, C-4), 41.2 (d ×2, C-4, C-10), 
38.0* (d, C-6), 37.4 (d, C-6), 27.3 (t, C-2), 26.9* (t, C-2), 21.62* (t ×2, C-16), 21.61* (q 
×2, CH3CO), 16.76 (q, CH3C-14), 16.73* (q, CH3C-14), 14.2* (q ×3, C-17, CH3C-10), 
13.7* (q, CH3C-12), 13.6 (q, CH3C-12), 13.0* (q, CH3C-10), 12.3 (q), 12.2* (q), 11.7* 
(q), 11.6 (q), 11.2 (q, CH3C-8), 10.9* (q), 10.8 (q), 10.1* (q, CH3C-8), 1.98* (q ×3, 
CH3Si), 1.93 (q ×3, CH3Si). 
LRMS (EI), m/z (relative intensity): 539 ([M]+, 2), 479 (3), 334 (10), 334 (10), 276 (8), 
167 (22), 149 (100), 139 (56), 121 (37), 69 (40). 
HRMS (EI), m/z calcd for C29H53NO6Si: 539.3642; found: 539.3637. 
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(3R,4S,5S,6S,7R,8S,10R,11S,12E,14E)-3,5,7-Trihydroxy-4,6,8,10,12,14-hexamethyl-
9-oxoheptadeca-12,14-dien-11-yl Acetate (198a/b).  
 
198a/b 
Pyridine (48 µL, 47 mg, 0.6 mmol), HF·Py (32 µL), and water (2 µL) were added 
sequentially to a stirred solution of 197 (10.6 mg, 19.6 µmol) in THF (0.6 mL). After 24 
h, the reaction mixture was diluted with ethyl acetate and washed sequentially with 
saturated aq NaHCO3, saturated aq NH4Cl and brine, dried over Na2SO4, and 
concentrated. The resulting crude product was taken up in a 1:1 (v/v) mixture of water 
and MeOH and heated to 60 ºC. After 3 h, the mixture was diluted with CH2Cl2 and 
washed with water. The aqueous phase was extracted with CH2Cl2 and the combined 
organic layers were dried over Na2SO4, concentrated, and fractionated by PTLC to give 
the titled compound as a 3:1 mixture of keto and hemiacetal forms, respectively (6.3 mg, 
73%). 
IR (DRIFT) νmax: 3398, 1743, 1711 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.91 (0.75H, s, HC-13), 5.90 (0.25H, s, HC-13), 5.33 
(0.75H, dd, J = 7, 7 Hz, HC-15), 5.32 (0.25H, dd, J = 7, 7 Hz, HC-15), 5.19 (0.75H, d, J 
= 10.5 Hz, HC-11), 5.18 (0.25H, d, J = 9.5 Hz, HC-11), 4.54 (0.75H, br s, HO), 4.20 
(0.75H, br d, J = 8.5 Hz, HC-7), 3.91-3.85 (1H, m, OH, HC-3), 3.78 (0.75H, ddd, J = 2.5, 
6, 7 Hz, HC-3), 3.67-3.62 (1H, m, HC-5), 3.28 (0.25H, dd, J = 9.5 Hz, HC-7), 3.06 
(0.75H, dq, J = 10.5, 7 Hz, HC-10), 2.90 (0.75H, dq, J = 8.5, 7 Hz, HC-8), 2.86 (0.75H, 
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br s, HO), 2.40 (0.25H, br d, J = 1 Hz, HO), 2.32 (0.25, dq, J = 9.5, 7 Hz, HC-10), 2.10-
2.03 (2.75H, m, HC-4, H2C-16), 2.03 (0.75H, s, H3CCO), 1.93 (2.25H, s, H3CCO), 1.85-
1.80 (0.25H, m, HC-4), 1.74-1.66 (6.75H, m, H3CC-12, H3CC-14, HC-8), 1.65-1.57 
(0.75H, s, HC-2, HC-4, HC-6), 1.54-1.47 (1.5H, s, H2C-2), 1.39-1.32 (0.25H, m, HC-2), 
1.27 (2.25H, d, J = 7 Hz, H3C-8), 1.14 (0.75H, d, J = 7 Hz, H3C-4), 1.04 (2.25H, d, J = 7 
Hz, H3C-6), 1.02- 0.89 (9.75H, m, H3C ×3.25), 0.87 (0.75H, d, J = 7 Hz, H3CC-10), 0.83 
(2.25H, d, J = 7 Hz, H3CC-4). 
13C NMR (125 MHz, CDCl3) δ (* major isomer) 216.0* (s, C-9), 169.8 (s, COO), 169.5* 
(s, COO), 135.9* (d, C-13), 135.1 (d, C-13), 134.0* (d, C-15), 133.7 (d, C-15), 131.3* (s, 
C-12 or C-14), 130.6 (s, C-12 or C-14), 129.1* (s ×2, C-12 or C-14), 100.9 (s, C-9), 
82.8* (d, C-11), 81.7 (d, C-11), 80.1* (d, C-5), 78.9 (d, C-5), 76.9* (d, C-3), 75.8 (d, C-
7), 71.34* (d, C-7), 71.26 (d, C-3), 50.8* (d, C-8), 47.5* (d, C-10), 44.1 (d), 42.4 (d, C-
10), 40.6 (d), 39.4* (d, C-4), 36.3* (d, C-6), 35.4 (d), 27.7 (t, C-2), 25.2* (t, C-2), 21.64* 
(t ×2, C-16), 21.61 (q, CH3CO), 21.3* (q, CH3CO), 16.77* (q, CH3C-14), 16.75 (q, 
CH3C-14), 14.9* (q, CH3C-10), 14..4 (q), 14.3* (q, CH3C-8 or C-17), 14.2* (q, CH3C-8 
or C-17), 13.5 (q ×2), 13.2* (q, CH3C-12), 13.0 (q), 12.4 (q), 12.3* (q, CH3C-4 or CH3C-
6), 12.0* (q, CH3C-4 or CH3C-6), 11.3 (q), 11.2* (q, C-1), 11.1 (q), 10.8 (q). 
LRMS (EI), m/z (relative intensity): 422 ([M-18]+, 0.5), 362 (4), 235 (10), 195 (17), 149 
(62), 138 (68), 121 (121), 109 (46), 69 (42). 
HRMS (ESI), m/z calcd for C25H44O6+Na: 463.3030; found: 463.3043. 
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(4R,5S,6S,8R,10R,11S,12E,14E)-9-Cyano-5-hydroxy-4,6,8,10,12,14-hexamethyl-3,5-
dioxo-9-((trimethylsilyl)oxy)heptadeca-12,14-dien-11-yl Acetate (200).  
 
200 
Oxalyl chloride (140 µL, 201 mg, 1.6 mmol) was added to a stirred solution of 
DMSO (0.23 mL, 25 mg, 3.2 mmol) in CH2Cl2 (1 mL) at -78 °C under argon. After 30 
min, a solution of 197 (44 mg, 0.08 mmol) in CH2Cl2 (0.4 ml) was added dropwise via 
syringe to the above Swern reagent. After 2 h, Et3N (0.66 mL, 480 mg, 4.7 mmol) was 
added to the reaction mixture. After 30 min, the reaction mixture was transferred to a −50 
°C bath. After 30 min, the mixture was diluted with ethyl acetate, washed with saturated 
aq NaHCO3 solution (×2), dried over Na2SO4, concentrated, and fractionated by PTLC 
(40% ethyl acetate in hexane) to give the titled compound as a 1.2:1 mixture of 
diastereomers (27.5 mg, 63%). 
colorless oil, TLC Rf = 0.5 (40% ethyl acetate in hexane). 
IR (DRIFT) νmax 3472, 1741, 1717, 1702 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.90 (1H, s, HC-13), 5.35-5.29 (1H, m, HC-15), 5.14 
(0.5H, d, J = 9 Hz, HC-11), 5.07 (0.5H, d, J = 10 Hz, HC-11), 3.71 (0.5H, ddd, J = 5, 7, 7 
Hz, HC-5), 3.66 (10.5H, ddd, J = 3, 8.5, 9.5 Hz, HC-5), 3.60 (0.5H, d, J = 9.5 Hz, OH), 
3.43 (0.5H, q, J = 7 Hz, HC-8), 3.25 (0.5H, d, J = 7 Hz, OH), 3.17 (0.5H, q, J = 7 Hz, 
HC-8), 2.89-2.80 (1H, m, HC-4 or HC-6), 2.78-2.67 (1H, m, HC-4 or HC-6), 2.66-2.55 
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(1H, m, HC-2), 2.53 (0.5H, dq, J = 10, 7 Hz, HC-10), 2.51-2.40 (1H, m, HC-2), 2.37 
(0.5H, dq, J = 9, 7 Hz, HC-10), 2.16 (s) and 2.06 (s) (3H, , H3CCO), 2.10-2.03 (2H, m, 
H2C-16), 1.73-1.68 (6H, m, H3CC-12, H3CC-14), 1.38 (1.5H, d, J = 7 Hz, H3CC-8), 1.27 
(1.5H, d, J = 7 Hz, H3CC-8), 1.26 (1.5H, d, J = 7 Hz, H3CC-4 or H3CC-6), 1.21 (1.5H, d, 
J = 7 Hz, H3CC-4 or H3CC-6), 1.16 (1.5H, d, J = 7 Hz, H3CC-4 or H3CC-6), 1.08 (1.5H, 
d, J = 7 Hz, H3CC-10), 1.06 (1.5H, t, J = 7 Hz, H3C-1), 1.04 (1.5H, d, J = 7 Hz, H3CC-4 
or H3CC-6), 1.03 (1.5H, t, J = 7 Hz, H3C-1), 0.98 (1.5H, t, J = 7.5 Hz, H3C-17), 0.97 
(1.5H, t, J = 7.5 Hz, H3C-17), 0.80 (1.5H, d, J = 7 Hz, H3CC-10), 0.28 (s) and 0.24 (s) (, , 
H3CSi ×3). 
13C NMR (125 MHz, CDCl3) δ 217.8 (s), 216.5 (s), 213.9 (s), 213.7 (s), 170.6 (s), 169.6 
(s), 135.5 (d), 135.0 (d), 134.0 (d), 133.6 (d), 131.3 (s), 131.2 (s), 130.8 (s), 130.3 (s), 
119.7 (s), 119.4 (s), 80.6 (d), 80.4 (d), 78.1 (d), 77.9 (s), 77.0 (d), 74.7 (s), 55.1 (d), 50.8 
(d), 50.3 (d), 49.3 (d), 47.9 (d), 46.1 (d), 41.7 (d), 41.4 (d), 36.4 (t), 35.9 (t), 21.8 (q), 
21.63 (t), 21.61 (t), 21.57 (q), 16.8 (q ×2), 15.5 (q), 15.0 (q), 14.9 (q), 14.22 (q), 14.20 (q 
×2), 14.16 (q), 13.7 (q), 13.5 (q), 13.4 (q), 12.7 (q), 11.2 (q), 7.7 (q), 7.6 (q), 2.1 (q ×3), 
1.8 (q ×3). 
HRMS (ESI), m/z calcd for C29H53NO6Si+Na: 558.3221; found: 558.3226. 
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(4R,5S,6S,8R,10R,11S,12E,14E)-9-cyano-5-hydroxy-4,6,8,10,12,14-hexamethyl-3,5-
dioxo-9-((trimethylsilyl)oxy)heptadeca-12,14-dien-11-yl Acetate (202).  
 
202 
Pyridine (96 µL, 94 mg, 1.2 mmol), HF·pyridine (70 µL), and water (4 µL) were 
added sequentially to a solution of 200 (27.5 mg, 51.3 µmol) in THF (1.2 mL). After 24 
h, the reaction mixture was diluted with ethyl acetate and washed sequentially with 
saturated aq NaHCO3, saturated aq NH4Cl and brine. The organic layer was dried over 
Na2SO4, and concentrated to give the crude product (29.2 mg) as a 1.2:1 mixture 
cyanohydrin diastereomers. The above crude was taken up in ethyl acetate (1 mL) and 
silica gel 60 (100 mg) was added. The resulting suspension was stirred for 2 h and then 
filtered. The combined filtrate and ethyl acetate washings were concentrated to give the 
titled compound as a mixture of ring-chain and keto-enol tautomers (20.3 mg, 91%). 
1H NMR (500 MHz, CDCl3) δ (partial data) 16.97 (0.16, s, HO-enol), 6.04-5.89 (1H, 
several s, HC-13), 5.34 (1H, bt, HC-15), 5.28-5.15 (1H, several d, J = 5-6 Hz, HC-11), 
4.99 (0.05, s, HO-hemiacetal), 4.04-3.98 (0.7H, q ×2). 
13C NMR (125 MHz, CDCl3) δ (partial data) enols: 199.1 (s, CO), 193.6 (s, CO), 105.0 
(s, C-8); acetate carbonyls: 169.6 (s, CO), 169.5 (s, CO), 169.35 (s, CO); 82.3 (d, C-11), 
82.1 (d, C-11), 81.9 (d, C-11), 61.8 (d, C-8), 59.8 (d, C-8). 
LRMS (CI, NH3), m/z (relative intensity): 454 ([M+18]+, 17), 378 (26), 377 (100), 359 
(54), 263 (58), 195 (37), 149 (30), 115 (13), 109 (11). 
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HRMS (CI, NH3), m/z calcd for C25H40O6+NH4: 454.3169; found: 454.3161. 
11-O-Acetylmuamvatin (203).  
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203 
Pyridine (48 µL, 47 mg, 0.6 mmol), HF·Py (32 µL), and water (2 µL) was added 
sequentially to a solution of 202 (10 mg, 23 µmol) in THF (0.6 mL). After 10 days, the 
reaction mixture was diluted with ethyl acetate and washed sequentially with saturated 
solution of NaHCO3 (×3), saturated aq NH4Cl (×3), and brine (5 ml). The organic layer 
was dried over Na2SO4, concentrated, and fractionated by PTLC (40% ethyl acetate in 
hexane) to give recovered 202 (5.1 mg, 51 %) and the titled compound (4.8 mg, 48%). 
Resubjecting the recovered 202 to a the same reaction conditions gave 202 (2.4 mg, 24%) 
and additional titled compound (2.1 mg, 21%): [α]D +40 (c 0.2, CHCl3). 
IR (DRIFT) νmax: 3435, 1737 cm
-1
.  
1
H NMR (500 MHz, CDCl3) δ 5.94 (1H, s, HC-13), 5.53 (1H, d, J = 8.5 Hz, HC-11), 
5.33 (1H, br dd, J = 7, 7.5 Hz, HC-15), 3.80 (1H, br s, HC-5), 2.56 (1H, br s, HO), 2.21 
(1H, dq, J = 8.5, 7.5 Hz, HC-10), 2.10-2.04 (3H, m, HC-8, H2C-16), 1.97 (3H, s, 
H3CCO), 1.89 (1H, dq, J = 1, 7 Hz, HC-6), 1.72 (6H, br s, H3C-12, H3C-14), 1.63-1.54 
(2H, m, HC-2, HC-4), 1.47 (1H, dq, J = 14, 7.5 Hz, HC-2), 1.12 (3H, d, J = 7 Hz, H3CC-
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6), 1.09 (3H, d, J = 7 Hz, H3CC-4), 1.01 (3H, d, J = 6.5 Hz, H3CC-8), 0.97 (3H, t, J = 7.5 
Hz, H3C-17), 0.93 (3H, t, J = 7.5 Hz, H3C-1), 0.78 (3H, d, J = 7.5 Hz, H3CC-10). 
13
C NMR (125 MHz, CDCl3) δ 169.9 (s, CO), 134.0 (d, C-13), 133.2 (d, C-15), 131.7 (s, 
C-12 or C-14), 131.6 (s, C-12 or C-14), 103.4 (s, C-9), 102.5 (s, C-3), 97.7 (s, C-7), 79.6 
(d, C-11), 78.9 (d, C-5), 43.4 (d, C-6), 39.9 (d, C-10), 38.0 (d, C-4), 35.0 (d, C-8), 30.0 (t, 
C-2), 21.8 (q, CH3CO), 21.6 (t, C-16), 16.9 (q, CH3C-14), 14.3 (q, C-17), 14.0 (q, CH3C-
12), 13.6 (q, CH3C-4 or CH3C-6), 13.4 (q, CH3C-4 or CH3C-6), 10.5 (q, CH3C-10), 7.2 
(q, CH3C-8), 6.1 (q, C-1). 
LRMS (EI), m/z (relative intensity): 436 ([M]+, 4), 419 (3), 376 (10), 195 (29), 176 (20), 
153 (18), 149 (100), 139 (50), 121 (87), 57 (55). 
HRMS (EI), m/z calcd for C25H40O6: 436.2825; found: 436.2816. 
Muamvatin (30).  
 
30 
DIBAL-H (1 M in toluene; 50 µL, 50 µmol) was added to a stirred solution of 
203 (6.8 mg, 15 µmol) in Et2O (2 mL) at –78 °C under argon. After 2 h, the reaction 
mixture was diluted with CH2Cl2 (20 ml) and washed with aq Rochelle’s salt (1.4 M). 
The aqueous layer was back extracted with CH2Cl2. The combined organic layers were 
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dried over Na2SO4, concentrated, and fractionated by PTLC (40% ethyl acetate in 
hexane) to give the titled compound (5.6 mg, 91%): [α]D +60 (c 0.13, CH2Cl2). 
1
H NMR (500 MHz, CDCl3) δ 5.87 (1H, br s, HC-13), 5.31 (1H, br dd, J = 7, 7 Hz, HC-
15), 4.40 (1H, d, J = 9 Hz, HC-11), 4.38 (1H, br s, HOC-11), 3.88 (1H, br s, HC-5), 2.59 
(1H, br s, HOC-7), 2.13-2.05 (3H, m, HC-8, H2C-16), 2.00-1.92 (2H, m, HC-6, HC-10), 
1.76 (3H, br s, H3CC-12), 1.72 (3H, br s, H3C-14), 1.70-1.65 (2H, m, HC-4, HC-2), 1.59-
1.51 (1H, m, HC-2), 1.18 (3H, d, J = 7 Hz, H3CC-4), 1.14 (3H, d, J = 7 Hz, H3CC-6), 
1.03 (3H, d, J = 7 Hz, H3CC-8), 0.98 (3H, t, J = 7.5 Hz, H3C-17), 0.95 (3H, t, J = 7.5 Hz, 
H3C-1), 0.72 (3H, t, J = 7 Hz, H3CC-10). 
13C NMR (125 MHz, CDCl3) δ 134.7 (s, C-12), 132.9 (d, C-13), 132.3 (d, C-15), 131.7 
(s, C-14), 105.4 (s, C-9), 103.2 (s, C-3), 97.7 (s, C-7), 79.6 (d, C-11), 78.8 (d, C-5), 43.1 
(d, C-6), 40.9 (d, C-10), 37.8 (d, C-4), 35.2 (d, C-8), 30.1 (t, C-2), 21.6 (t, C-16), 16.9 (q, 
CH3C-14), 14.4 (q, C-17), 13.45 (q, CH3C-4 or CH3C-6), 13.41 (q, CH3C-4 or CH3C-6), 
12.5 (q, CH3C-12), 10.6 (q, CH3C-10), 6.9 (q, CH3C-8), 6.1 (q, C-1). 
LRMS (EI), m/z (relative intensity): 394 ([M]+, 4), 376 (10), 294 (11), 256 (31), 238 
(29), 183 (39), 153 (41), 109 (48), 86 (28), 57 (100). 
HRMS (EI), m/z calcd for C23H38O5: 394.2719; found: 394.2715. 
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